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Summary 
Specific delivery of drugs to diseased sites in the body is a major topic in the development of drug 
delivery system today. Especially, the field of cancer treatment needs improved drug delivery 
systems as the strong dose-limiting side effects of chemotherapy today often present a barrier for 
an effective cure.  
Liposomes have attracted much attention since they were first proposed as potential drug 
carrier agents in the 1970s. Chapter one gives an introduction to the strategies used in liposomal 
drug delivery today. The important issues as enhanced specific uptake in diseased tissue and 
effective unloading of the encapsulated drug have been tried optimized in a variety of ways. Many 
propose the use of small molecules, such as vitamins and peptides, for active targeting of the 
liposomes to overexpressed receptors on the cancerous tissue. Once located close to the diseased 
site a trigger mechanism for releasing the drug from the liposome interior is often needed. Several 
approaches have been suggested to work as release mechanisms such a pH changes, the presence 
of enzymes or external applied stimulus as heat or light. 
Chapter two deals with the synthesis of the functionalized phospholipids, which function as 
the targeting moiety on the surface of the liposomes. Several examples of synthetic procedures 
known from the literature are presented. The chapter is completed with a study covering the 
conjugation efficiencies of a variety of chemical functionalities. Large differences are revealed 
between the conjugation efficiency in solution and directly on the surface of the pre-formed 
liposomes. 
In chapter three the efficiency of the targeted liposomes is investigated. In vitro 
experiments using fluorescent phospholipids and in vivo experiments using radiolabeled 
liposomes and a PET imaging technique. The results were encouraging and proved the large 
potential of radiolabeled liposomes as candidates for revealing the biodistribution of drug delivery 
systems. 
Chapter four deals with one of the large dilemmas, when using liposomes as drug delivery 
agents. The presence of a shielding polymer layer on the surface of the liposome is important in 
order for it to circulate in the blood stream. However, the presence of the polymer obstructs the 
uptake pattern of the liposomes, limiting the therapeutic efficacy of the liposomes. We developed 
liposomal formulations which present a targeting moiety on the surface to guide the uptake, in 
addition to an enzymatically cleavable peptide sequence, whose cleavage would result in removal 
of the polymer layer as well as uncovering cationic charges on the liposomal surface. These 
systems were shown to have superior drug efficacy in vitro.  
 
 
 IV 
 
 
 
 
  
 V 
 
Dansk resumé 
Specifik levering af lægemidler til sygdomsramte steder i kroppen spiller en stor rolle i udvikling 
af nye drug delivery systemer i dag. Især indenfor kræft behandlingen er der brug for 
forbedringer, da de dosis-afhængige bivirkningerne i kemoterapien i dag ofte forhindrer en 
effektiv helbredelse.  
Liposomer har tiltrukket sig meget opmærksomhed, siden det i 1970’erne blev foreslået, at 
de havde potentiale som drug delivery system. Kapitel et giver en introduktion til de strategier, 
der anvendes i liposomal drug delivery i dag. De vigtige emner, som øget specifikt optag i 
sygdomsramt væv og den effektive frigivelse af det indkapslede lægemiddel, har været forsøgt 
optimeret på utallige måder. Mange foreslår anvendelsen af små molekyler, såsom vitaminer og 
peptider, som en aktiv metode til at styre liposomerne hen imod overudtrykte receptorer på 
kræftvæv. Når liposomet er fremme ved det sygdomsramte sted er der ofte brug for en trigger 
mekanisme for at frigive lægemidlet. Utallige fremgangsmåder er blevet foreslået som 
frigivelsesmekanisme såsom ændringer i pH, tilstedeværelsen af enzymer eller udfrakomne 
stimulus såsom varme eller lys. 
Kapitel to omhandler fremstillingen af funktionelle phospholipider, der sidder på 
overfladen af liposomet og leder det hen til de sygdomsramte celler. Adskellige eksempler på 
syntese procedurer kendt fra litteraturen præsenteres. Dette kapitel er afsluttet med et studie som 
omhandler effektiviteten af konjugeringsreaktioner mellem forskelige kemiske funktionaliteter. 
Det viste sig, at der var store forskelle mellem effektiviteten for konjugeringer udført i opløsning 
og konjugeringer udført direkte på liposomets overflade. 
I kapitel tre undersøges effektiviteten af de targeterede liposomer. In vitro eksperimenter, 
hvor der blev anvendt fluoriserende phospholipider samt in vivo eksperimenter, hvor der blev 
anvendt radioaktiv mærket liposomer og PET billeddannelse. Resultaterne var opløftende og 
beviste de radioaktiv mærkede liposomes’ store potentiale til at afdække biodistributionen af drug 
delivery systemer. 
Kapitel fire omhandler ét af de store dilemmaer, når det kommer til brugen af liposomer 
som drug delivery agenter. Tilstedeværelsen af en skærmende polymer på overfladen af liposomet 
er vigtigt for, at den kan cirkulere i blodbanen. Men tilstedeværelsen forstyrer optagelsesmønstret 
af liposomerne og begrænser derved deres terapeutiske effect. Vi har udviklet liposome 
formuleringer, som præsenterer en targetering del på overfladen af liposomet for at guide dets 
optag, samt en enzymatisk spaltbar peptide sekvens, hvis spaltning vil resultere i fjernelse af 
polymer laget såvel som afdække kationiske ladninger på liposomets overflade. Disse systemer 
viste sig at have give en høj effektivitet af lægemidlet in vitro. 
 
 VI 
 
  
 VII 
 
Abbreviations 
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine  
(sPLA2) Secretory phospholipase A2 
% ID Percent injected dose 
AcOH Acetic acid 
ADC Antibody-drug conjugate 
Bq Becquerel 
CPP Cell-penetrating peptide 
cryoTEM Cryogenic transmission electron microscopy  
CT Computed tomography 
CuAAC Copper-catalyzed azide-alkyne cycloaddition 
DLS Dynamic light scattering 
DMF N,N-dimethylformamide 
DOPE Diacylphosphatidylethanolamine 
DOTA 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid 
DP-MCP-PEG Dipalmitoyl-metalloproteinase cleavable peptide-PEGylated 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSPE-NBD 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-
 benzoxadiazol-4-yl) 
DSPE-PEG2000 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
 glycol)-2000]  
DTT Dithiothreitol 
ECM Extracellular matrix 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ELAM Endothelial-leukocyte adhersion molecule-1 
EPR Enhanced permeability and retention 
Fab´ Antigen-binding fragment 
Fc Fragment crystallizable 
Fmoc 9-fluorenylmethyloxycarbonyl 
FR Folate receptor 
GRD Glycine-arginine-aspartic acid 
GPCR G protein-coupled receptor 
HA2 Influenza hemagglutinin 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HER2 Human epidermal growth factor 2  
HPLC High-performance liquid chromatography 
ICAM Intercellular adhersion molecule-1 
ICP-AES Inductively coupled plasma atomic emission spectroscopy 
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i.v. Intravenous 
LUV Large unilamellar vesicle 
mAb Monoclonal antibody 
MALDI TOF MS Matrix assisted laser desorption/ionization time-of-flight mass 
 spectroscopy 
MFI Mean fluorescence intensity 
MLV Multi-lamellar vesicle  
MMP Matrix metalloproteinase 
MRI Magnetic resonance imaging 
MSC Mesenchymal stem cell 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) 
 2H-tetrazolium salt 
NGR Asparagine-glycine-arginine 
OA Oleic acid 
PBS Phosphate-buffered saline 
PC Phosphatidylcholine 
PDP N-[3-(2-pyridyldithio)propionate] 
PE Phosphatidylethanolamine 
PEG Poly(ethyleneglycol) 
PET Positron emission tomography 
p.i. Post injection 
PMS Phenazine methosulfate  
RES Reticuloendothelial system 
RGD Arginine-glycine-aspartic acid 
SAR Structure-activity relationship 
scFv Single chain variable fragment 
SEC Size exclusion chromatography  
SPECT Single-photon emission computed tomography 
SST Somatostatin 
SSTR Somatostatin receptor 
T½ Half-life 
TATE [Tyr3,Thr8]-octreotate 
TFA Trifluoroacetic acid 
TFE 2,2,2-trifluoroethanol 
TIS Triisopropylsilane 
VCAM Vascular cell adhersion molecule-1 
VH Variable region heavy chain 
VL Variable region light chain 
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Chapter 1  
 
Liposomes as drug delivery agents 
Despite a major effort in the search for more effective cancer treatments this devastating 
disease still causes the death of more than 7.5 million people worldwide every year 
(www.iarc.fr). The pharmaceutical industry continues to successfully develop cytotoxic 
drugs which can serve as potential candidates for the treatment of cancers; however upon 
administration these are often broadly distributed within the whole body resulting in 
toxicity to normal tissues, limited tumor accumulation and severe dose-limiting side 
effects, which are reducing their clinical application.  
Cancer originates from the accumulation of numerous critical somatic mutations of 
healthy cells. This results in malignant cancer cells being identical to healthy cells in most 
aspects. Consequently, finding selective drugs; toxic to malignant cells and non-toxic to 
healthy cells can be rather challenging. The use of drug loaded nanocarriers which can 
deliver their payload at specific tumor sites in a clinical relevant dose could prove to be a 
superior strategy in the fight against cancer. In an attempt to improve tumor accumulation 
and specificity of the drug unloading site new methodologies of drug delivery is finding 
its use. 
1.1 Liposomes 
Since their discovery in 1965 by Bangham and co-workers [Bangham, 1965] the 
liposomes have been a subject of increasing interest. These nanoparticles were suggested 
to hold potential as drug carriers in 1974 by Gregoriadis [Gregoriadis, 1971; Gregoriadis, 
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1974] as their composition of natural phospholipids makes them highly biocompatible 
and biodegradable with low intrinsic toxicity as well as low immunogenicity. They can 
encapsulate drugs of different lipophilicities in either their hydrophilic lumen or 
hydrophobic bilayer [Gulati, 1998]. 
Broad biodistribution to non-diseased tissue and low inefficient accumulation of 
drug at the actual tumor site, are two key problems, which liposomes can help overcome. 
When cytotoxic drugs are loaded into liposomes these are no longer dictated by their own 
pharmacokinetic and pharmacodynamic profile, but instead controlled by the properties 
of the liposome. Liposomes protect the encapsulated drug while assisting it in reaching its 
target site by passive accumulation (vide infra). 
In general three basic requirements are needed for the liposomes to be considered as 
a successful drug delivery agent in chemotherapy: (I) long, stable blood circulation, (II) 
high tumor accumulation and (III) effective release of the encapsulated drug once at 
tumor site. 
Intensive research during the last decade has generated liposomes optimized for in 
vivo use and a few have entered the clinic such as Doxil®, Myocet® and DaunoXome®. 
1.1.1 Stealth liposomes 
Early formulations of liposomes were challenged by their fast blood clearance by the 
phagocytic cells of the reticuloendothelial system (RES). It was discovered that their 
physiochemical properties such as size, surface charge [Juliano, 1975] and lipid 
composition [Gabizon 1988] correlated with the types of proteins binding to them and 
thereby their clearance. In general, large liposomes are cleared faster than small ones, and 
those composed of unsaturated lipid are cleared faster than those composed of saturated 
lipid [Senior, 1982]. The incorporation of cholesterol further stabilizes the liposomes in 
vivo [Damen, 1981]. Negatively charged liposomes are cleared faster than neutral charged 
ones, while a positive surface charge leads to toxic liposomes which are quickly removed 
from the blood circulation. Despite combining this knowledge when formulating the 
liposomes, they could not fully avoid binding with serum proteins and the uptake by RES 
was too significant for them to be efficient drug carriers. 
This issue was solved by coating the liposomes with polymers which would 
suppress protein absorption and opsonisation, especially the hydrophilic polymer 
poly(ethyleneglycol) (PEG) is now used for this purpose [Woddle, 1992; Klibanov, 
1990]. The polymer provides steric hindrance by occupying the space just adjacent to the 
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liposome surface with its flexible chain, which tend to limit the binding of serum 
opsonins and reduce the RES uptake rate [Drummond, 1999].  
The incorporation of PEG results in long-circulating stabilized liposomes, also 
known as sterically stabilized liposomes or Stealth. This longer circulation lifetime 
provides the liposomes a greater chance for accumulation in the tumor tissue. 
1.2 Passive accumulation in tumors 
The longer blood circulation of the liposomes also lead to an improvement in the second 
requirement for this drug delivery system since long circulating liposomes were found to 
have increased accumulation in tumor tissue over healthy tissue [Gabizon, 1994]. A 
phenomenon later described as the enhanced permeability and retention (EPR) effect.  
Characteristic of many malignant tumors are their fast growth and need to form new 
blood vessels (angiogenesis). These newly formed blood vessels are often abnormal in 
their form and architecture with large fenestrations varying from 100-1200 nm [Yuan, 
1995; Hobbs, 1998; Jang, 2003], a pore size much larger than the ones found in normal 
vessels (around 6 nm [Drummond, 1999]). This leakiness combined with an ineffective 
lymphatic drainage make liposomes passively accumulate in tumor tissue [Maeda, 2000]. 
A large distribution of liposomes in the interstitium surrounding the tumor cells is 
hindered due to a high interstitial pressure and a large interstitial space compared with 
healthy tissue [Jain, 1990]. Consequently, not all solid tumors are suitable for treatment 
with passive accumulating liposomes, as the tumor vasculature is highly heterogeneous in 
terms of density and distribution of vessels, depending on the size of the tumor as well as 
their location inside the tumor [Rubin, 1966]. Generally, peripheral regions have a higher 
vessel density than central parts, and the central parts have a higher interstitial pressure 
than the periphery. This leads to an irregular drug distribution throughout the solid tumor, 
resulting in larger tumors being more difficult to treat than smaller ones. 
1.3 Active tumor targeting 
A way to maintain the liposomes in the interstitial space of the tumor is to take advantage 
of specific surface receptors and antigens that are overexpressed on cancer cells 
[Ruoslahti, 2002; Peer, 2007] or on endothelial cells in the angiogenic blood vessels  
[Folkman, 1995; Ruoslahti, 2010]. The targeted liposomes concentrate in the tumor site 
by the EPR effect like for the non-targeted liposomes, but once there, they can actively be 
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taken up by the tumor cells after binding to their target receptor or antigen [Allen, 2002]. 
This is commonly referred to as active targeting (Figure 1). 
 
Figure 1: Schematic presentation showing passive and active targeting strategies of liposomes. Liposomes 
are concentrated in the tumor interstitium by extravasation of the fenestrated tumor vessels and are retained 
due to ineffective lymphatic drainage (EPR effect). The passive accumulation of liposomes results in a local 
release of the drug near the cancer cells, while the active targeted liposomes can release their drug load 
extracellular before or after binding to the surface of the cells, or the liposomes can be endocytosed and 
drug released intracellular [Peer, 2007]. 
 
Targeting of endothelial cells in angiogenic blood vessels is generally considered to be 
advantageous over tumor cell targeting as endothelial cells are generitically stable and the 
risk of developing drug resistance is reduced [Lila, 2009]. They are highly accessible for 
circulating liposomes, and damage to a few tumor blood vessels may result in a strong 
growth inhibition of the surrounding tumor cells, which are depending on nutrients and 
oxygen supply from these vessels. The special characteristics of proliferating endothelial 
cells in tumors are shared between a variety of tumor types which can be beneficial when 
trying to develop a wide-ranging chemotherapeutic formulation. Strategies, which target 
both tumor vasculature as well as tumor cells, have proved to be more effective than 
targeting of the two tissues individually [Koning, 2004]. 
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Different approaches have been tested for attachment of the targeting ligand to the 
liposome surface. Targeting ligands have been conjugated directly to the phospholipid 
headgroups of non-PEGylated liposomes. However, these liposomes suffered from rapid 
blood clearance. A similar conjugation approach was used on PEGylated liposomes, 
resulting in longer circulating liposomes, but these liposomes showed reduced targeting 
properties due to steric hindrance from the PEG chains [Torchilin, 1992]. To minimize 
shielding of the targeting ligand by the PEG chains, the targeting ligand was moved to the 
end of the PEG chain, giving it opportunity to extend beyond the PEG coating and 
maximize its exposure to the targeted receptor [Maruyama, 2002]. 
A great number of different targeting ligands have been conjugated to the liposome 
surface including vitamins, peptides and antibodies using a variety of chemical methods 
[Jølck, 2010].  
 
1.3.1 Antibodies as targeting ligands 
Antibodies are proteins used by the immune system to identify foreign objects in the body 
and they represent one of the most versatile ligands that can be attached to liposomes. 
However, the antibody functionalization of liposomes is generally challenging, where 
region specificity and degree and conversions are the main problems. One of the key 
reasons for this is that antibodies can only be attached to liposomes by post-
functionalization, i.e. the liposomes are formed prior to attachment and the conjugation 
chemistry therefore has to work well in aqueous buffer. Antibodies can be attached as 
whole monoclonal antibodies (mAb) or as fragments thereof (Figure 2). 
Full antibodies have stability advantages over small fragments such as Fab´ and 
scFv, but can trigger compliment activation [Moghimi, 2010] and induce antibody-
dependent cytotoxicity [Sapra, 2003]. Furthermore, the Fc fragment is known to 
accelerate clearance of the immunoliposomes by RES and thus decrease the blood 
circulation time of the liposomes [Allen, 1995]. This undesired clearance can be 
minimized by using just Fab´ or scFv [Baxter, 1994]. 
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Figure 2. Schematic representation of various antibody constructs: Monoclonal antibody (mAb); F(ab´)2 
generated by pepsin digestion of the Fc domain of mAb; Fab´ from reduction of the disulfide bond in the 
hinge region of F(ab´)2; scFv of recombinant VL and VH regions linked by a short peptide sequence. 
 
Antibodies against the human epidermal growth factor 2 (HER2) have been widely used 
in combination with liposomal drug delivery systems. This antigen is frequently 
overexpressed on cancer cells and only weakly expressed in normal tissue [Martin, 1982]. 
Another popular targeting site using antibodies is the adhesion molecules expressed in 
endothelial cells such as endothelial-leukocyte adhesion molecule-1 (ELAM), 
intercellular adhesion molecule-1 (ICAM) and vascular cell adhesion molecule-1 
(VCAM) [Gunawan, 2010].  
Generally, immunoliposomes show a superior anticancer efficacy over non-targeted 
liposomes, though several studies have proved this efficacy to be caused by increased 
cancer cell uptake and internalization and not due to a change in biodistribution or 
increased tumor accumulation [Kirpotin, 2006; Hatakeyama, 2007]. 
1.3.2 Peptides as targeting ligands 
The use of peptide-targeted liposomes as therapeutics has become highly interesting with 
the increasing knowledge of specific peptide sequences of proteins involved in cell-cell 
interactions as well as the improvement in synthesis of synthetic peptides that closely 
resemble the human ones. The peptide-targeted liposomes can increase the delivery of 
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drug to cancer cells by targeting overexpressed receptors or by using unspecific cell 
penetrating peptides.  
G protein-coupled receptors (GPCR) are a diverse family of transmembrane 
proteins responsible for interacting with extracellular molecules and thus regulate various 
functions in the cell. A large number of GPCRs with known binding peptides are found to 
be overexpressed on the surface of cancer cells, including the somatostatin receptor 
[Volante, 2008], the neurotensin receptor [Myers, 2009] and cholecystokinin receptor 
[Miyasaka, 2003].  
Cell-penetrating peptides (CPP) are a class of peptides which typically contain a 
large portion of highly charged amino acids such as arginine or lysine. The first one 
identified was transactivator of transcription (TAT) from the HIV-1 TAT peptide 
[Frankel, 1988]. Later a variety of peptides which share TAT’s ability to carry a drug 
across the hydrophobic cell membrane into the cytoplasm of cells have been identified, as 
penetratin [Dupont, 2011] and synthetic polyarginines. When applying these sorts of 
peptide sequences, it is critical to have the right ratio between cell-penetrating peptide and 
a shielding PEG layer on the surface of the liposome. PEG needs to ensure long enough 
blood circulation time for the liposome to accumulate in the target site by the EPR effect 
and hinder that the cell-penetrating peptide has too much unspecific binding to healthy 
cells encountered on its way. However, PEG must not shield the cell-penetrating peptide 
too much, making it unable to interact with the target cell membrane. 
Peptides targeting the endothelial cells and mimic local bioadhesion have attracted 
much attention in the peptide targeting field. The integrins, especially, which are a 
receptor family that mediates the attachment of cells to their surrounding extracellular 
matrix, such as vitronectin, fibronectin and collagen. Integrins play a major role in tumor 
progression and metastasis [Desgrosellier, 2010] and is highly upregulated in both solid 
tumors as well as tumor vasculature. The small tripeptide RGD (Arginine-Glycine-
Aspartic acid) found in many of the extracellular matrix proteins bind strongly to the 
integrin receptors and have been broadly used in liposomal peptide-targeted drug delivery 
[Meerovitch, 2003]. The NGR (Asparagine-Glycine-Arginine) sequence binds to an 
endothelium associated aminopeptidase-N form, found upregulated in angiogenesis and 
tumor growth [Corti, 2008]. Good tumor accumulation and therapeutic efficacy have been 
shown for both these targeting peptides [Murphy, 2008; Pastorino, 2003]. 
 
 8 
 
1.3.3 Folic acid as targeting ligand 
Liposomes functionalized with the vitamin, folic acid, have attracted much attention as 
the folate receptors are highly overexpressed in a number of cancers. The vitamin is 
internalized to a large extent in proliferating cells as folic acid is essential in the 
biosynthesis of nucleotides; consequently fast dividing malignant cells are in great need 
of this nutrient. Normally, the folate receptors are expressed at the apical side of epithelial 
cells and not accessible to drug in the blood circulation. However, when the epithelial cell 
becomes malignant, the membrane loses its polarity and the folate receptor can be located 
at the basal surface of the membrane as well [Lu, 2002].  
An interesting feature of folate-targeted liposomes is that they have shown an 
ability to bypass the P-glycoprotein efflux pump. This is often involved in multi-drug 
resistance mechanisms and considered to be a major complication in cancer therapy. It is 
found that the ability is coupled to folate-liposomes being taken up by receptor-mediated 
endocytosis [Goren, 2000]. 
 
Although the active targeting strategies can seem promising, obstacles still exist. 
Unfortunately, the use of targeted liposomes does not necessary results in increased tumor 
accumulation and even if an increased accumulation is achieved, this does not guarantee 
an improved therapeutic outcome. Attaching a targeting ligand on the surface of a 
liposome naturally decreases its blood circulation time as the ligand will increase 
unspecific binding to healthy cells and may trigger enhanced opsonisation and removal by 
RES. When liposomes with strong binding ligands bind to the first cancerous cells they 
meet, there is a risk that they will block the extravasation of more liposomes to the tumor 
interstitial space [Barenholz, 2001]. Moreover, their fast binding will prevent their 
diffusion through the tumor tissue and they will mainly be located in the blood vessel 
region. This is known as the binding-site barrier. Another challenge of active targeting via 
receptor-mediated uptake is release of the encapsulated drug once the liposomes have 
been internationalized. The harsh environment found in endosomes and especially 
lysosomes can degrade the encapsulated drug, if it does not succeed in escaping these 
vesicles [Sapra, 2003]. 
1.4 Triggered release of drug content 
The third requirement for liposomes to be good drug delivery agents is dependent upon 
their ability to release the encapsulated drug once at target site. Drug release may take 
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place extracellular in close proximity to the cell followed by cell uptake of the drug, or 
the intact drug loaded liposomes can be internalized and release their drug intracellular 
(Figure 1). 
High accumulation of drug loaded liposomes in the tumor site does not necessarily 
result in high therapeutic effect. This limited therapeutic effect can partly be due to 
degradation of the drug in the endosomes/lysosomes, before it has a chance to carry out 
its effect. Several specific drug release mechanisms have been investigated in order to 
optimize the therapeutic efficacy of the delivered liposomes. The strategies involve 
exploiting tumor microenvironment such as pH changes or the presence of enzymes 
[Andresen, 2010], applying external stimulus such as heat [Manzoor, 2012], light [Leung, 
2012], ultrasound [Barenholz, 2009] or simple physio-chemical characteristics of the 
encapsulated drug [Barenholz, 2001]. 
1.4.1 pH sensitive liposomes 
The pH of the tumor microenvironment is lower than in healthy tissues, though often not 
much lower than 6.5. This small difference from normal tissue pH makes it very 
challenging to design liposomes which are stable through circulation, but becomes 
ruptured in the tumor. A better strategy is to utilize the low pH in the endosomes and 
lysosomes, where pH can be lower than 5 [Benjaminsen, 2011].  
Four classes of pH sensitive liposomes have been describers [Drummond, 2000]. 
The first class applies liposomes formulated with a combination of an unsaturated 
phospholipid as diacylphosphatidylethanolamine (DOPE) and an acidic amphiphile as 
oleic acid (OA). As DOPE cannot form a stable bilayer structure on its own the OA is 
added as a stabilizer. Once the OA becomes protonated in the acidic endosome/lysosome 
the membrane will be destabilized and non-bilayer structures important for fusiogenic 
events are created [Chernomordik, 1996]. 
The second class of liposomes includes specially engineered phospholipid 
components that contain chemical bonds which can be hydrolyzed in an acidic 
environment and thus increase the presence of membrane destabilizing phospholipid. This 
has been done with a head-modified DOPE-maleyl that would release the stabilizing 
group at low pH leaving the unmodified DOPE [Drummond, 1995]. Another example is 
removal of the stabilizing PEG chains by using an acid-labile vinyl ether PEG lipid, 
resulting in unmodified DOPE and destabilization of the liposomal membrane [Shin, 
2003].  
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The third class involves the incorporation of pH-sensitive peptides into the 
liposomal membrane to promote fusion between the liposomes and the 
endosomal/lysosomal membrane [Etzerodt, 2012]. The most studied pH-sensitive 
peptides are GALA and the influenza hemagglutinin-derived (HA2) peptides, which have 
both shown increased contents leakage from liposomes [Parente, 1990; Ishiguro, 1996]. 
The final class of pH sensitive liposome formulations contains pH-titratable 
polymers. An advantage with the use of synthetic polymers is their large structure 
flexibility, large-scale synthesis and low immunogenicity. The polymer is normally a 
polycation (weak base) or a polyanion (weak acid) and its mechanism of destabilization 
of the membrane depends on these properties [Uster, 1985; Zignani, 2000].  
1.4.2 Heat and light sensitive liposomes 
Liposomes sensitive to light and heat are interesting strategies for triggered release. 
However, a shortcoming for these two methods is that the tumor localization needs to be 
known [Kong, 1999]. Unfortunately, patients often die from metastatic cancer and not the 
primary tumor itself. 
One rational behind using hyperthermia and liposomes together is that the local 
elevation of temperature can increase extravasation of the liposomes into the tumor site 
due to vasodilation, while at the same time the heating can trigger the liposomes to 
release their content [Gaber, 1996].  
Liposomes sensitive to heat are formulated with phospholipids showing a narrow 
main phase transition temperature just above body temperature. This has been achieved 
by using a blend of the saturated phospholipids DPPC and DSPC which released their 
content at 42 °C [Gaber, 1996]. By formulating the liposomes from DPPC, DSPE-
PEG2000 and a lysolipid instead the content was released at 39-40 °C [Needham, 2013]. 
Strategies using a light source to trigger release from liposomes can broadly be 
categorized as photochemical or photophysical strategies. Photochemical strategies 
include photopolymerization, photoisomerization and photocleavage, while strategies 
including the use of molecular dyes and gold nanoparticles belong in the photophysical 
field [Leung, 2012]. 
Applications of the photochemical methods often require synthesis of a molecule 
which contains the desired light-responsive properties as well as a moiety that can be 
stably incorporated into the liposomal membrane. Release using photoisomerization often 
depend upon the molecule changing its conformational shape by illumination and hence 
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destabilizes the membrane. The photocleavable strategy involves amphiphiles molecules 
which upon illumination triggers separation of the polar and nonpolar moieties and causes 
destabilization of the membrane [Anderson, 1992], while the photopolymerization 
strategy utilizes the formation of phospholipid domains and hence destabilization of the 
membrane by cross-linking polymerizable phospholipids in the presence of non-
polymerizable phospholipids [O’Brien, 1998]. However, since the need for relatively high 
energies is involved in photochemistry, UV light is often used, which leads to concerns 
regarding UV radiation toxicity and the formation of reactive oxygen species. 
Liposomes can be sensitized to light using dyes or gold nanoparticles embedded in 
their lumen, their membrane or surrounding them. This photophysical strategy takes 
advantage of the photothermal heating via molecular absorbers or metallic nanoparticles 
which can lead to controlled release from liposomes [Khoobene, 1990]. Especially the use 
of plasmon resonance from metallic nanoparticles is interesting, as their optical properties 
can be tuned from the visible to the near-infrared range just by varying their shape and 
size [Troutman, 2008]. This tunability makes it possible to apply wavelengths that are 
safe and still able to penetrate the tissue to a relevant depth. 
1.4.3 Enzymatic sensitive liposomes 
Enzymes of particular interest in the tumor tissue are those that catalyze the degradation 
of phospholipids such as secretory phospholipase A2 (sPLA2) or enzymes that are 
secreted in high concentrations into the tumor interstitium as the matrix 
metalloproteinases (MMP), where the liposomes accumulate. 
The sPLA2 catalyzes the hydrolysis of phospholipids in their sn-2 position yielding 
free fatty acids and lysolipids which acts as detergents and destabilizes the membrane 
[Henriksen, 2010]. The enzyme is found overexpressed in the environment surrounding 
malignant tumors and has been linked to increased aggressiveness of the cancer [Dong, 
2010]. sPLA2 demonstrates an enhanced activity towards aggregated phospholipids such 
as liposomes over monomeric phospholipids. This enhanced activity is found to be 
influenced by the surface charge of the liposome and phospholipid composition. Healthy 
mammalian cells are characterized by a neutral phospholipid composition in their outer 
leaflet and are poor substrates for the sPLA2 in order to keep them safe, when the enzyme 
is upregulated. Experimentally, it has been confirmed that sPLA2 is more active towards 
PEGylated phospholipids and other negatively charged membranes [Jørgensen, 2002; 
Leidy, 2006]. The steric barrier induced by PEGylation of the liposomes does not hinder 
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the sPLA2 enzyme from reaching the liposomal surface where hydrolysis takes place. 
However, the practical application of using sPLA2 as a trigger system in chemotherapy 
with encapsulated drugs is limited, as sPLA2 is inactive towards membranes containing 
significant amounts of cholesterol. Cholesterol increases the ability of liposomes to retain 
their drug load and is an important component in e.g. Stealth formulations [Drummond, 
1999]. 
The matrix metalloproteinase family consists of multiple subtypes, all being zinc-
containing endopeptidase, where MMP-2 and MMP-9 are the most studied ones, as they 
are found highly upregulated in cancers. Their function in breaking down the extracellular 
matrix (ECM), assist cancerous cells in their invasion, angiogenesis and metastatic spread 
[Rundhaug, 2003]. The MMPs have been applied in triggered drug release aspects; 
although the strategy is less straightforward as for utilizing the sPLA2 strategies. A 
synthetic lipid component has to be constructed, showing a specific cleavage site for the 
enzyme in mind. Despite this synthetic need, several strategies have been applied using 
MMP enzymes. MMP-9 degradable lipopeptides have been incorporated into liposomes, 
resulting in destabilization of the membrane and drug release [Sarkar, 2004]; MMP-2 
unmasking of the PEG layer on a liposome surface resulting in the exposure of a 
galactosylated liposome for macrophage targeting [Terada, 2006]; and lipid-peptide-PEG 
conjugates incorporated in liposomes showed an enhanced transfection efficiency of a 
HT1080 cell line after MMP removal of the PEG layer [Hatakeyama, 2007]. 
Despite being larger than the sPLA2 enzyme (14 kDa) the MMPs (MMP-2 72 kDa; 
MMP-9 92 kDa) have shown no difficulties in reaching the hydrolytic site below the 
shielding PEG layer. 
Though, sPLA2 and MMP are the two most studied enzymes for triggered drug 
release from liposomes, others have been suggested, such as elastase [Meers, 2001], 
alkaline phosphatase [Davis, 1998] and phospholipase C [Villar, 2001]. 
 
These strategies selectively target the cancerous tissue over healthy by using targeting 
ligands on the surface of liposomes. To have the liposomes release their content in a 
location relevant to treatment of the tumor, appear promising in the search for more 
efficacious chemotherapeutic treatments.  
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Chapter 2  
 
Engineering liposomes for biological targeting 
There is an increasing demand for delivery systems that specifically transport drug to 
cancerous tissue and improve the therapeutic index of the encapsulated drug by triggered 
release. In an attempt to fulfil this demand liposomes have been coated with a variety of 
targeting ligands aimed at selectively or overexpressed receptors in cancerous tissues. 
Liposomes with targeting ligands as drug delivery vehicles are superior to e.g. antibody-
drug conjugates (ADC) as only few targeting ligands are required for the liposomes to 
deliver thousands of drug molecules.  
However, surface functionalization of liposomes with targeting ligands is not a 
trivial process and care has to be taken in evaluating the degree of functionalization. 
Often the conjugation of a ligand to a pre-formed liposome does not proceed as well on 
the liposome surface as it does in solution. Many times this evaluation is not performed 
which can pose a problem, as many of the utilized chemistries are far from quantitative. 
This has resulted in a strong motivation for improving the synthetic approaches towards 
these promising functionalized nanomaterials. 
2.1 Functionalized liposomes 
Generally three different methods are used for the surface functionalization of liposomes.  
The first one is often applied for small ligands, such as peptides [Elegbede, 2008; 
Espuelas, 2005], vitamins [Lee, 1995; Saul, 2003] and saccharides [Shimada, 1997; Zhu, 
2007] which are conjugated to a lipid (e.g. DSPE-PEG, cholesterol or fatty acids) in an 
 14 
 
organic solvent and purified afterwards. This results in a functionalized lipid which can 
be mixed with natural phospholipids and thus incorporated into the liposomal membrane 
in the hydration step. A disadvantage of this process is that a significant amount of the 
ligand is need, and roughly half of the functionalized lipid will be facing the lumen of the 
liposome and being unable to interact with target receptors. However, a major advantage 
of this strategy is that the amount of functionalized lipid added can be accurately 
controlled. 
The second approach to functionalize liposomes is the post-insertion approach 
[Ishida, 1999]. This is usually used for ligands which are expensive such as antibodies 
[Pan, 2007; ElBayoumi, 2009] and proteins [Chiu, 2006]. Lipids with a reactive 
functional group on the distal end of e.g. DSPE-PEG are formed in a micelle and the 
ligand reacted onto the surface. Alternative the lipid-ligand conjugate can be prepared as 
above and self-assembled in a micelle. The micelles are mixed with pre-formed 
liposomes and in a time and temperature dependent manner the functionalized lipids from 
the micelle will transfer to the outer membrane of the liposomes. The advantage with this 
method is that no functionality is lost to the inside of the liposomes, while a disadvantage 
is that a quantification of the amount of functionality on the final liposome preparation 
will have to be carried out. 
The third strategy is the post-functionalization. Pre-formed liposomes displaying a 
reactive group in their headgroup can be conjugated with the desired targeting ligand. 
This method is usually applied for large ligands like antibodies and proteins. A challenge 
using this method is that the reaction has to perform well in aqueous buffer and the degree 
of functionalization will have to be quantified. The advantage is that no ligand is lost to 
the interior of the liposome and that the pre-formed liposomes can be loaded with drug 
under stronger conditions (e.g. heat) without having to protect the ligand. 
A wide variety of coupling methods have been developed and to ensure correct 
orientation of the targeting ligand, bioorthogonal and site-specific reactions are required. 
Preferably, the conjugation method chosen should be able to proceed under mild 
conditions; it should be fast, reproducible and result in non-toxic and non-immunogenic 
chemical bonds. A few of these conjugation strategies are presented below. 
2.1.1 Conjugation of ligands to amino-functionalized liposomes 
This functionalization approach is based on naturally occurring phospholipids and can be 
used without prior functionalization of these. Torchilin was one of the first ones to 
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describe the use of this method by conjugating an antigen to the surface of the liposome 
using a homobifunctional amine-amine crosslinker [Torchilin, 1978]. However, the use of 
crosslinkers can result in uncontrolled polymerization and liposome aggregation. 
Furthermore, an antibody or peptide often contains more than one amine functionality and 
specificity of the reaction can be lost. 
2.1.2 Conjugation of ligands to carboxylic acid functionalized liposomes 
Conjugation to carboxylic acids on the surface of liposomes [Yagi, 2000; Bendas, 2003] 
can be achieved by either reacting phosphatidylethanolamine (PE lipids) with an 
anhydride [Kung, 1986] or by using commercial available phospholipids and activating 
them with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). This activated ester 
can react with amines with efficiencies depending on the spacer length between the 
liposome surface and carboxylic acid functionality. If the carboxylic acid is attached to 
the distal end of a PEG chain instead of directly on the liposome surface, no real effect of 
spacer length is seen [Maruyama, 1995]. Often many amine functionalities are present in 
antibodies and peptides; hence a random attachment and altered binding affinity towards 
the receptor can be the consequence. 
2.1.3 Conjugation of ligands to thiol-functionalized liposomes 
Often the thiol functionality is introduced on the liposome surface as disulfide protected 
in the form of N-[3-(2-pyridyldithio) propionate] (PDP). This group is removed by 
reduction in situ with dithiothreitol (DTT) [Allen, 1995] and the free thiol can be reacted 
with a thiol or maleimide functionalized ligand [Muñoz, 1998; Mercadal, 1999]. The 
shortcoming of this method is the risk of forming intermolecular disulfide bonds leading 
to crosslinking of the reactive ligands or liposomes. 
2.1.4 Conjugation of ligands to maleimide-functionalized liposomes 
A very frequently used approach to functionalize liposomes is by the Michael Addition. A 
thioether bond is formed between a maleimide-functionalized phospholipid and a thiol-
containing ligand [Fleiner, 2001; Park, 2001; Gradauer, 2012]. Often the maleimide 
moiety is attached to the distal end of PEG, but a direct surface functionalization can be 
obtained by using N-(4-(p-Maleimidophenyl)butyryl)-phosphatidylethanolamine. The 
Michael Addition has been used for attaching proteins like Annexin-A5 [Garnier, 2009], 
antibodies [Béduneau, 2007] and small peptides as cRGD [Janssen, 2003].  This method 
is straightforward without any need for prior activation or catalysts to support the 
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reaction, it takes place close to neutral pH and for smaller ligands it can be expected to be 
quantitative. However, the maleimide derivatives have been shown to be immunogenic 
[Peeters, 1989; Boeckler, 1996]. 
2.1.5 Conjugation of ligands to alkyne-functionalized liposomes 
Meldal and Sharpless were the first to show the application of Cu(I) to catalyze the azide-
alkyne Huisgen 1,3-dipolar cycloaddition (CuAAC) [Tornøe 2001; Tornøe 2002; 
Sharpless, 2002], generally referred to as the Click Reaction. Based on this work 
liposomes have been functionalized with a variety of ligands; e.g. an azido-modified 
mannose ligand [Hassane, 2006] and an azido-NBD ligand [Cavalli, 2006]. The reaction 
is highly orthogonal to other chemical functionalities and site-specific conjugation is 
possible as azides and alkynes are not naturally found in biomolecules. One limiting 
factor is the mandatory use of catalytic copper. As the reaction requires a catalytic 
amount of copper(II)sulphate and sodium ascorbate to generate Cu(I) in situ, this will 
need to be completely removed before the liposomes can be used for in vitro or in vivo 
applications, as copper is considered toxic. Furthermore, the copper catalyzed reaction is 
only applicable for saturated liposomes as unsaturated phospholipids are prone to 
oxidation by the copper ions [Gal, 2003]. 
Copper-free Click Reactions are reported, which relies on the use of strain-
promoted cycloalkynes [Bostic, 2012]. Their use decreases the activation energy of the 
reaction, enabling it to be carried out without the presence of a copper catalyst [Shea, 
1992]. The reaction is fast and results often in almost quantitative yields of the triazole 
formation. No toxicity has been observed from the use of cyclooctynes [Chang, 2010]. 
 
2.1.6 Conjugation of ligands to aldehyde-functionalized liposomes 
The conjugation between an aldehyde and a hydrazide occur spontaneously without the 
need of a catalyst. The aldehyde functionality can be anchored into the liposome 
membrane as described by Bonnet et al. using the ether lipid di-O-hexadecyl-rac-
glyceraldehyde [Bourel-Bonnet, 2005]. For the coupling of peptides to the liposome 
surface a hydrazide moiety can easily be introduced to the peptide during its on resin 
synthesis, in the form of N,N,N-(tri(tert-butyloxycarbonyl)hydrazinoacetic acid, which is 
fully compatible with solid-phase peptide synthesis (SPPS) [Bonnet, 2003].  
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2.1.7 Conjugation of ligands to hydrazide-functionalized liposomes 
For the conjugation of antibodies to the liposome surface the inverted position of the 
functional groups is widely applied [Hansen, 1995; Lopes de Menezes, 1998]. The 
hydrazide group can be introduced to the liposome membrane in the form of lauric acid 
hydrazide [Chua, 1984] or by attaching it to the distal end of DSPE-PEG [Zalipsky, 
1993]. The carbohydrate groups on the constant region of the antibody’s heavy chain can 
be mildly oxidized by e.g. sodium periodate resulting in the formation of an aldehyde 
[Koning, 1999; Harding, 1997], which can be coupled to the hydrazide liposomes. 
2.2 Objective 
In order to address the problems touched upon in the introduction to this chapter such as 
non-quantitative conjugation reactions on the surface of liposomes, low reproducibility 
and highly varying yields compared to reactions performed in solution, a systematic study 
was done. This study investigated PEGylated liposomes functionalized with a 
neuroendocrine tumor targeting peptide, Octreotate; synthesized with several 
functionalities that have been used for surface conjugation of nanoparticles. The reaction 
kinetics and overall yield was quantified by high-performance liquid chromatography 
(HPLC). Reactions were conducted in solution as well as by post-functionalization of 
liposomes in order to study the effects of steric hindrance and possible affinity between 
the peptide and liposome surface. 
Furthermore, we present a new highly efficient and chemoselective liposome 
functionalization method based on oxime bond formation between a hydroxylamine and 
an aldehyde modified phospholipid component. 
2.2.1 Octreotate as model peptide 
Targeted liposomes that recognize overexpressed receptors or antigens on diseased cells 
have great potential in therapeutic and diagnostic applications; hence an analogue of the 
Somatostatin peptide was applied as model peptide in this study. 
The regulatory hormone Somatostatin (SST) was discovered in 1973 by Brazeau et 
al. [Brazeau, 1973]. They discovered the SST-14 member from the Somatostatin family, 
while the other important member of this family, the SST-28, was discovered by 
Pradayrol in 1980 [Pradayrol, 1980].  Somatostatin is secreted in the form of a precursor 
molecule which enzymatically is processed to yield the active forms. In the case of 
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Somatostatin the processing of the 92-amino acid long promolecule results in the two 
active segments SST-14 and SST-28 (Figure 3) [Shen, 1982]. 
 
SST-28:  Ser1-Ala2-Asn3-Ser4-Asn5-Pro6-Ala7-Met8-Ala9-Pro10-Arg11-Glu12-Arg13-Lys14-Ala15-Gly16-Cys17-
  
 Lys18-Asn19-Phe20-Phe21-Trp22-Lys23-Thr24-Phe25-Thr26-Ser27-Cys28. 
 
SST-14: Ala1-Gly2-Cys3-Lys4-Asn5-Phe6-Phe7-Trp8-Lys9-Thr10-Phe11-Thr12-Ser13-Cys14. 
 
Figure 3: SST-28 has 28 amino acids and SST-14 has 14 amino acids. As can be seem from the sequences 
the SST-14 is derived from SST-28 by cleavage between Lys14 and Ala15.   
 
 
These two peptides bind to five different forms of the G protein-coupled receptors 
(SSTR1-5) expressed in various tissues, and often in more than one form in a single cell. 
The SST-14 and SST-28 are somewhat selective for the receptors, where SSTR1-4 bind 
SST-14 with higher affinity than SST-28, and SSTR5 predominantly binds SST-28 [Patel, 
1995]. 
The biological role of the hormone Somatostatin is to regulate the endocrine 
system. The peptide is naturally produced by neurons in the hypothalamus - and other 
parts of the brain - and is transported through the median eminence to the anterior 
pituitary where it inhibits the synthesis and secretion of growth hormone and thyroid-
stimulating-hormone. Somatostatin is classified as an inhibitory hormone, and in addition 
to these two hormone regulations it has a regulating effect on the secretion of insulin, 
glucagon, gastrointestinal hormones; it can reduce gastric emptying as well as blood flow 
in the intestine, and smooth muscle contraction [Widmaier, 2004]. By Somatostatin’s 
inhibition of growth hormone the protein synthesis as well as carbohydrate and lipid 
metabolism are effected throughout the body. 
The secretion of Somatostatin is controlled by a negative feedback mechanism 
which can be exploited in a number of diseases, where the amount of secretion of 
Somatostatin has gone wrong. Many tumor cell lines have been found to overexpress 
Somatostatin receptors; hence Somatostatin analogues can be administrated, affecting 
mainly cancerous cells over healthy cells.  
Many hormones have a minimum sequence that fulfils the requirements for a 
complete biological function. Hence, peptide analogues for these hormone receptors have 
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often been modified extensively and it can be difficult to find the relation to the natural 
occurring hormone. To determine which sequence that is important for a full biological 
activity one can systematically modify each amino acid, either deleting it or substituting it 
for an alanine or glycine residue - called an ala or gly scan [Morrison, 2001]. Once these 
single modifications have been carried out and a minimum bioactive sequence 
determined, it can be convenient to search for a certain required secondary structure. This 
is mainly done by substituting D-amino acids for the natural found L-amino acid. Adding a 
D-amino acid in a hormone analogue can be advantageous as peptides containing these, 
generally are found to have a longer half-live in vivo due to reduced susceptibility to 
enzymatic degradation. For cyclic peptides, as Somatostatin, an optimization of the ring 
size can be utilized as well. 
Mainly the SST-14 has been inspiration to many Somatostatin analogues. These 
have been developed by systematic studies and have resulted in analogues with a reduced 
ring size as well. Structure-activity relationship (SAR) studies done on a large number of 
Somatostatin analogues have shown that the sequence Phe7-Trp8-Lys9-Thr10 is critical for 
biological recognition [Melacini, 1997]. These amino acids will form a β turn which is 
necessary for biological activity. Trp8 and Lys9 are essential, while Phe7 and Thr10 can 
undergo minor substitutions such as from Phe7 to Tyr7, or Thr10 to Ser10 or Val10 [Veber, 
1984]. 
One analogue which has received much attention is Octreotate (Figure 4). It 
consists of only eight amino acids compared to the 14 amino acids in SST-14 and 
consequently, the ring size of this analogue is smaller than the natural hormone. This 
analogue binds primarily to the SSTR2 subtype, which most Somatostatin receptor-
positive tumors express [Reubi, 2000]. 
 
 
Figure 4. The cyclic Somatostatin analogue Octreotate (TATE): NH2-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-
Thr-OH used as a model peptide for surface functionalization of liposomes. 
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This Somatostatin analogue was used as a model peptide for the surface functionalization 
of liposomes testing the conjugation competence of matching chemical functionalities. 
2.3 Materials and methods 
Full experimental details and characterizations are available in Appendix II. 
2.3.1 Synthesis of functionalized TATE peptides 
The model peptides 1a-e for somatostatin receptor targeting, were prepared using a SPPS 
strategy as shown in Figure 5. The N-terminal functionalized TATE peptides 1a-e were 
synthesized by SPPS on H-Thr(tBu)-OH preloaded Wang Resin by standard Fmoc 
methodology. Each coupling was performed by activating the Fmoc protected amino acid 
with O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
(HATU) in the presence of 2,4,6-collidine in DMF. Cleavage of the Fmoc group was 
carried out using piperidine in DMF (Figure 5). Completion of each coupling and 
deprotection step was monitored by the Kaiser test. HATU was used to ensure high 
conversion with minimum epimerization.  
After assembly of the resin immobilized octapeptide, NH2-D-Phe-Cys(Acm)-
Tyr(tBu)-D-Trp-(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu)-resin, the linear peptide 
was treated with Tl(CF3COO)3, which in a single step removed the two Acm-protection 
groups present on the cysteine residues and formed the intramolecular disulfide bond. The 
reaction was followed by cleavage of a small amount of peptide from the resin with TFA 
and analyzing the crude peptide by MALDI-TOF MS. Complete Acm-removal and 
disulfide formation were observed after 75 min with no sign of dimerization.  
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Figure 5. Synthesis of TATE derivatives 1a-e using solid phase peptide synthesis. 
 
After extensive washing of the resin, the N-terminal of the resin bound peptide was 
acylated with either 4-maleimidobutyric acid (1a), 3-(tritylthio)-propionic acid (1b), 5-
azidopentanoic acid (1c), 4-pentynoic acid (1d) or bis-Boc-amino-oxyacetic acid (1e), 
before being cleaved from the solid support by treatment with a mixture of TFA/H2O/TIS 
(95:2.5:2.5) to give the maleimide-, thiol-, azide-, alkyne- or hydroxylamine-modified 
TATE peptides (Table 1).  
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Table 1. Chemical structure of R-COOH used for synthesis of TATE derivatives 1a-e and corresponding 
characterization by MALDI TOF MS. 
 
 
 
Final purification of the peptides was accomplished by HPLC. 
 
2.3.2 Synthesis of DSPE-PEG2000 functionalized phospholipids 
In order to formulate liposomes exposing the appropriate chemical functionalities at the 
distal end of the PEG-corona, PEGylated phospholipids with the desired functionalities 
were synthesized in a single step from DSPE-PEG2000-NH2 by acylation of the amino 
group with the desired functionality in the presence of either HATU or EDC·HCl (Figure 
6) or by reduction of the DSPE-PEG2000-PDP to yield the free thiol moiety (Figure 7).  
PEGylated phospholipids exposing a terminal alkyne, a cyclic alkyne, an aldehyde, 
or an azide functionality at the distal end of the polymer (2a-d) were synthesized by 
acylating DSPE-PEG2000-NH2 with 4-pentynoic acid (2a), 1-fluorocyclooct-2-
ynecarboxylic acid (2b), 4-carboxybenzaldehyde (2c), or 5-azidopentanoic acid (2d), 
respectively. 1-Fluorocyclooct-2-ynecarboxylic acid was synthesized as described 
elsewhere [Schultz, 2010]. DSPE-PEG2000-SH (3) was synthesized in a single step from 
DSPE-PEG2000-PDP by reduction of the pyridyldithiopropionate (PDP) group by DTT 
applying standard conditions [Cleland, 1964] which resulted in the desired free thiol (3). 
The DSPE-PEG2000-maleimide (4) functionalized phospholipid was purchased from 
Avanti Polar Lipids, Inc., Alabama. 
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Figure 6. Synthesis of functionalized DSPE-PEG2000-NH2 phospholipid conjugates 2a-d and their 
corresponding reaction conditions. 
 
 
 
 
Figure 7. Synthesis of DSPE-PEG2000-SH phospholipid conjugate 3. 
2.3.3 Liposome formulation 
In order to evaluate the efficiency of the different coupling strategies and make a valid 
comparison, a standardized protocol was used to minimize the influence of other 
parameters.  
Functionalized liposomes composed of DSPC/DSPE-PEG2000/DSPE-PEG2000-R 
(95:4:1) (R = alkyne (2a), cycloalkyne (2b), aldehyde (2c), azide (2d), thiol (3), or 
maleimide (4)) were prepared by the method described by Bangham et al. [Bangham, 
1964]. Lipids were dissolved in CH3Cl/MeOH (9:1) and mixed in the ratio (95:4:1) 
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DSPC/DSPE-PEG2000/DSPE-PEG2000-R. The solvent was removed under a stream of 
nitrogen to form a lipid film. The lipid films were placed under vacuum overnight to 
remove remaining traces of organic solvent. The obtained lipid films were hydrated in a 
HEPES buffer, (10 mM HEPES, pH 6.5, 145 mM NaCl) at 65 °C for 1 h; followed by 10 
freeze-thaw cycles and extrusion at 65 °C through a 100 nm polycarbonate filter using an 
Avanti Polar Lipids mini-extruder.  
The size distribution of the liposomes was analyzed using dynamic light scattering 
(DLS), as well as their zeta potential using a Brookhaven Zeta PALS analyzer. All 
liposomes had a diameter of approximately 100 nm and slightly negative ζ-potential due 
to the presence of the DSPE-PEG2000 lipids (approximately -5 mV). 
 
Figure 8. Schematic presentation of a liposome presenting functional moieties and their matching reactive 
counterparts, as well as final product. Figure kindly provided by Rasmus I. Jølck. 
2.3.4 Conjugation in solution 
For the conjugation reactions in solution DSPE-PEG2000 functionalized lipid (0.2 mM, 
0.55 mL, 1.1 equiv.) was dissolved in MeOH and mixed with the corresponding 
functionalized TATE in MeOH (0.2 mM, 0.50 mL, 1.0 equiv.). The reaction was stirred 
at room temperature and aliquots (50 μL) were removed at the indicated times and 
analyzed by analytical HPLC. A linear gradient was used from 100% A (aqueous solution 
containing 5% MeCN and 0.1% TFA) to 100% B (MeCN containing 0.1% TFA) over 15 
min with a flow rate of 1 mL/min and AUC for the free TATE was measured relative to 
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AUC for the coupled product at 280 nm. For the reaction between the maleimide and thiol 
functionalities Et3N (50 mM, 6.0 μL, 3.0 equiv.) was added to facilitate the coupling, 
while for the copper catalyzed click reactions CuSO4·5H2O (1.0 M, 2.5 μL, 25 equiv.) 
and sodium ascorbate (1.0 M, 5.0 μL, 50 equiv.) were added.  
Before injecting the aliquots from the copper catalyzed click reactions onto the 
analytical HPLC column 20 μL of a 10% NH4OH solution was added to ensure the 
copper ions were in solution and not interfering with the HPLC signals [Sharpless, 2005]. 
2.3.5 Conjugation by post-functionalization of liposomes. 
Pre-formed functionalized liposomes ((25 mM, 0.50 mL, 1.1 equiv.) - normalized 
according to a 45:55 distribution ratio between the inner- and outer liposomal membrane) 
were mixed with the corresponding TATE peptide (4.2 mM, 15 μL, 1.0 equiv.) dissolved 
in MeOH. The reactions were shaken (not stirred; to avoid foaming) at room temperature 
and aliquots (40 μL) removed for analysis by analytical HPLC. A linear gradient was 
used from 100% A (aqueous solution containing 5% MeCN and 0.1% TFA) to 100% B 
(MeCN containing 0.1% TFA) over 15 min with a flow rate of 1 mL/min. The AUC for 
the free TATE was calculated relative to the AUC of the phospholipid coupled product at 
280 nm to monitor the conjugation efficiency. For the copper catalyzed click reactions 
CuSO4·5H2O (1.0 M, 1.6 μL, 25 equiv.) and sodium ascorbate (1.0 M, 3.1 μL, 50 equiv.) 
were added. As for the conjugations done in solution 20 μL of a 10% NH4OH solution 
was added to the copper catalyzed click aliquots prior to HPLC analysis. 
 
Triplicates of all reactions were carried out to ensure reproducibility and elucidate the 
heterogeneity of liposomal post-functionalization. The amount of functionalized TATE 
added in the two conjugation approaches was carefully controlled by measuring the 
concentration of the peptide stock solution by UV-vis, thus ensuring exactly the same 
peptide concentration in all reactions. 
To ensure the same total concentration of phospholipids in all reactions, phosphorus 
content measurement was carried out by inductive coupled plasma atomic emission 
spectroscopy (ICP-AES). All reactions were monitored for 24 hours by HPLC using UV-
detection (λ = 280 nm), and up to 72 hours in selected cases, by removing small aliquots 
from the reaction vial, and the conjugation efficiency was calculated based on the area 
under the curve (AUC) for the free peptide and the DSPE-PEG2000-TATE conjugate, 
respectively (Figure 9). MALDI-TOF MS was used to verify that an excess of the 
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functionalized phospholipids reagent existed in all reactions that did not go to completion 
within 72 hours. 
 
Figure 9. Example of monitoring a conjugation reaction by HPLC over time at 280 nm. The decreasing 
peak at 8.5 min belongs to the free TATE-maleimide (1a), while the peak increasing at 15.6 min is the 
product from the Michael Addition between TATE-maleimide (1a) and DSPE-PEG2000-SH (3). 
2.4 Results and discussion 
2.4.1 Conjugation of TATE and DSPE-PEG2000 by oxime formation 
This method, which has not previously been reported for the surface functionalization of 
liposomes, is chemoselective and bioorthogonal to functional groups in most natural 
occurring ligands and could serve as an excellent alternative to existing liposome post-
functionalization methods [Richard, 2005]. TATE-hydroxylamine (1e) and DSPE-
PEG2000-benzaldehyde (2c) were conjugated, both in solution and on the liposome 
surface, by simply mixing the two components without any additives.  
Oxime bond formation in solution was found to be quantitative within one hour, 
whereas eight hours of incubation was needed once performed directly on the liposome 
surface (Figure 10). Both procedures resulted in complete conversion to the phospholipid 
coupled TATE within 24 hours under mild conditions.  
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Figure 10. Conjugation of DSPE-PEG2000 and TATE by oxime bond formation. Reactions carried out in 
solution and directly on the liposome surface. TATE-hydroxylamine (1e) + DSPE-PEG2000-benzaldehyde 
(2c) in solution (○), TATE-hydroxylamine (1e) +DSPE-PEG2000-benzaldehyde (2c) on liposomes (□). All 
values are means ± SEM (n = 3). 
 
Oxime bond formation is known to be accelerated by the presence of aniline [Dirksen, 
2008], acetic acid [Gustafsson, 2001] or Lewis acids [Sridhar, 2011]. In order to verify 
this, acetic acid (0.1% v/v) was added to a liposome batch containing TATE-
hydroxylamine (1e). Under these conditions, the conjugation yield reached 78% within 5 
minutes. Without the presence of the catalyst, 30% conversion was observed within the 
same time frame. The oxime bond formation is a reversible process; however, HPLC and 
MALDI TOF MS did not show any reversible formation of the starting materials within 
one week in aqueous medium, which supports the reporting of oxime bonds to be more 
hydrolytically stable than, e.g., its analogous hydrazine bond at physiologically relevant 
pH [Rose, 1996]. 
The position of these two functional groups is not interchangeable, as placing the 
aldehyde functionality on TATE will induce the risk of intramolecular imine formation. 
2.4.2 Conjugation of TATE and DSPE-PEG2000 by CuAAC 
Conjugation of TATE and DSPE-PEG2000 by the CuAAC reaction was carried out using 
sodium ascorbate to generate Cu(I) from CuSO4·5H2O in situ [Tornøe, 2002; Rostovtsev 
2002]. Reactions were carried out with the azide present on the TATE peptide, the alkyne 
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at the PEG terminal of DSPE-PEG2000, and vice versa. The relative position of the 
functional moieties was found to have no significant effect on the reaction efficacy under 
the solution conditions, as both orientations result in approximately 98% yield after 12 
hours (Figure 11). A different result was obtained when monitoring the post-
functionalization reaction on the liposome surface. 
The cycloaddition between the azide-functionalized TATE (1c) and the alkyne-
modified phospholipid (2a) resulted in about 75% yield after 2 hours, while the opposite 
position having the azide functionality present on the liposomes and the alkyne at the N-
terminal of the peptides levelled out at 43%. 
 
Figure 11. Conjugation of DSPE-PEG2000 and TATE by the CuAAC reaction. Reactions carried out in 
solution and directly on the liposome surface. TATE-azide (1c) + DSPE-PEG2000-alkyne (2a) in solution 
(○), TATE-azide (1c) + DSPE-PEG2000-alkyne (2a) on liposomes (□), TATE-alkyne (1d) + DSPE-PEG2000-
azide (2d) in solution (◊), TATE-alkyne (1d) + DSPE-PEG2000-azide (2d) on liposomes (Δ). All values are 
means ± SEM (n = 3). 
 
Functionalization of azide-modified liposomes by the CuAAC reaction has not previously 
been reported elsewhere to our knowledge. Functionalization of liposomes by the CuAAC 
reaction has consistently been carried out with alkyne-modified liposomes and azide-
functionalized ligands; thus, these reports have not observed the clear negative trend 
observed here with the azide-functionalized liposomes. Furthermore, removing the copper 
fully from the final product to avoid copper induced cytotoxicity can be challenging, 
which to some degree reduces the usability of this reaction for biological purposes. 
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2.4.3 Conjugation of TATE and DSPE-PEG2000 by Cu-free click chemistry 
A method to avoid addition of toxic copper salts as catalyst in the triazole formation is to 
use strained or electron-deficient alkynes [Agard, 2004; Li, 2004]. This strategy was 
studied using the DSPE-PEG2000-cyclooctyne (2b) and azide-functionalized TATE (1c). 
In solution, the conjugation was remarkably slow, yet highly reliable and reproducible 
with no form of decomposition or side product formation. As the reaction was terminated 
after 50 days, a product yield of 86% was obtained without reaching a plateau. Applying 
the post-functionalization protocol resulted in a remarkably faster initial reaction (Figure 
12), and a level of 84% yield was reached after 72 hours. 
 
Figure 12. Conjugation of DSPE-PEG2000 and TATE by strain-promoted Click reaction. Reactions were 
carried out in solution and directly on the liposome surface. TATE-azide (1c) + DSPE-PEG2000- 
cyclooctyne (2b) in solution (○), TATE-azide (1c) + DSPE-PEG2000-cyclooctyne (2b) on liposomes (□). All 
values are means ± SEM (n = 3). 
 
Interestingly, triazole formation was significantly faster when performed on liposome 
surfaces compared to the reaction in solution. This is presumably due to favourable 
interactions between the liposome surface and TATE-azide (1c). As TATE-azide (1c) is 
not highly soluble in the buffer, it prefers to bind to the PEG layer, bringing it closer to 
the reaction sites on the surface, which leads to a faster reaction. 
Choosing a more reactive cyclooctyne could not only increase the reaction rate in 
solution, but also increase the risk of side product formation [Chenoweth, 2009; Codelli, 
2008]. However, a relatively long synthetic procedure to obtain the cyclooctyne moiety 
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limits the use of this type of copper-free click reaction. Furthermore, it has been shown 
that thiols can add spontaneously to cyclooctynes limiting the bioorthogonality, as some 
degree of nonspecific reactions can occur [Fairbanks, 2010]. 
2.4.4 Conjugation of TATE and DSPE-PEG2000 by Michael Addition 
The final approach tested to conjugate TATE and DSPE-PEG2000 was using the Michael 
Addition procedure. In general, the Michael Addition proceeded rapidly within the first 
four hours until reaching a plateau, and reactions carried out in solution were slightly 
faster compared to the liposomal counterpart. The orientation of the maleimide and the 
thiol was found to have a decisive impact on the conjugation efficiency. Michael addition 
in solution between DSPE-PEG2000-SH (3) and TATE-maleimide (1a) resulted in 97% 
conversion, whereas when performed on the liposome surface, 92% conversion was 
observed. The opposite orientation of functionalities expressed in the form of DSPE-
PEG2000-maleimide (4) and TATE-thiol (1b) only resulted in 53% product formation 
when performed in solution and 40% for the postfunctionalization of liposomes (Figure 
13), which was surprising. 
 
Figure 13. Conjugation of DSPE-PEG2000 and TATE by Michael addition. Reactions carried out in solution 
and directly on the liposome surface. TATE-maleimide (1a) + DSPE-PEG2000-SH (3) in solution (○), 
TATE-maleimide (1a) + DSPE-PEG2000-SH (3) on liposomes (□), TATE-thiol (1b) + DSPE-PEG2000-
maleimide (4) in solution (◊), TATE-thiol (1b) + DSPE-PEG2000-maleimide (4) on liposomes (Δ). All 
values are means ± SEM (n = 3). 
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The origin for this observation is not clear, however; multiple factors could have caused 
this drop in conversion. Hydrolysis of the maleimide moiety to the nonreactive maleamic 
acid at pH > 8.5 has been reported in the literature [Gregory, 1955], but at pH 6.5 where 
our reactions are carried out, this should be minimized [Barradas, 1976; Matsui, 1978]. 
This was confirmed by MALDI-TOF MS where intact DSPE-PEG2000-maleimide as well 
as unreacted TATE-SH was observed. However, a minor amount of methoxysubstituted 
maleimide was also observed by MALDI-TOF MS indicating that the oxa-Michael 
Addition is a competing side reaction [Finnegan, 1965]. 
As poor conversion was observed for the reaction carried out in solution as well as 
on the surface, we speculated that the TATE-thiol (1b) peptide was the limiting factor in 
this reaction. TATE-thiol (1b) is highly prone to oxidation resulting in nonreactive 
TATE-dimers; however, dimerization was not observed by HPLC or by MALDI-TOF 
MS. 
As a positive control of the reactivity of the commercial DSPE-PEG2000-maleimide 
(4), a test reaction using 2-mercaptoethanol was conducted. Using this small and highly 
reactive thiol, complete product formation was observed within two hours as confirmed 
by MALDI-TOF MS, confirming excellent reactivity of DSPE-PEG2000-maleimide (4). 
Hence, the reason for the low coupling efficiency between DSPE-PEG2000-maleimide (4) 
and TATE-SH (1b) is not clear. 
2.5 Concluding remarks 
These studies demonstrate the importance of choosing the correct chemistry in order to 
obtain a quantitative surface functionalization of liposomes. 
A novel highly effective method to functionalize liposomes by post-
functionalization as well as under solution conditions has been introduced in the form of 
an oxime bond formation between an aldehyde and a hydroxylamine. This conjugation is 
chemoselective and bioorthogonal to functional groups in most naturally occurring 
relevant ligands, and based on our investigations, it could serve as an excellent alternative 
to existing liposome post-functionalization methods.  
In addition, a systematic study has been conducted to elucidate the optimal 
postfunctionalization chemistry with focus on the relative position of the reactive 
functionalities. In general, the reactions carried out directly on the surface of the 
functionalized liposomes were slower than the solution phase counterpart, except for the 
strain-promoted click reaction, which surprisingly showed the opposite trend. Despite of 
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possible heterogeneities of liposomal formulations, surface conjugation reactions were, in 
general, highly reproducible.  
The relative position of the reactive functionalities was found to have a significant 
impact on the degree of conversion for the Michael Addition and the CuAAC reaction. 
The Michael Addition was found to be most effective when the nucleophilic thiol was 
present at the distal end of the PEG polymer compared to the N-terminal of TATE. A 
similar observation was observed for the CuAAC reaction. The relative positions of the 
azide and the alkyne did not influence the degree of conversion in solution; however, 
once performed on the liposome surface it had a decisive impact. Having the alkyne 
functionality present at the liposome surface resulted in 75% conversion, whereas the 
azide functionalized liposomes only resulted in 43% product formation. 
The findings described above will be useful for future postfunctionalization designs 
and clearly illustrate that care should be taken to select the most appropriate chemistry for 
the desired chemical manipulation. Furthermore, it is also evident that post-functionalized 
nanoparticles in general should always be analyzed in order to ensure the desired 
composition of the nanoparticle constructs. 
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Chapter 3  
 
Targeted liposomes as radiopharmaceuticals 
Cancer management requires reliable diagnosis and fast identification of the primary 
tumor as well as metastases, as the cure rate in cancer patients is strongly dependent on 
the stage of the cancer, when it is diagnosed. Early detection remains a key issue and 
radiopharmaceuticals have played a major role in this aspect. Imaging by the use of 
radiopharmaceuticals is usually one of the first steps in cancer diagnostics. 
Positron emission tomography (PET) is one of the fastest growing imaging 
techniques as it allows for the tracking of organ function at the molecular level, unlike 
other imaging modalities such as magnetic resonance imaging (MRI), computed 
tomography (CT) and x-ray. The combination of PET and CT or MRI imaging - called 
hybrid imaging techniques - complements each other by combining the metabolic 
sensitivity of PET with the spatial resolution of CT or MRI. This provides quantitative 
and accurate pictures of abnormalities characteristic in cancer [Fass, 2008]. 
Nuclear imaging techniques such as PET and single photon emission computed 
tomography (SPECT) involve the injection of a radionuclide, followed by imaging after a 
suitable time giving the radionuclide time to reach its target. Several approaches have 
been investigated using liposomes as nanocarriers of the radionuclide, either by utilizing 
the EPR effect or by using targeted liposomes [Phillips, 2008]. 
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3.1 PET as imaging technique 
In the early 1970s the first PET camera for clinical studies was build and 11C-glucose, 
15O-water and 13N-ammonia were applied as radiotracers to demonstrate its potential 
clinical application [Phelps, 1975]. Compared to SPECT, PET has a higher detection 
sensitivity, which makes it possible to visualize radiotracer concentrations as low as 10-12 
M [Gambhir, 2000; Gambhir, 2002; Phelps, 1975]. 
PET imaging utilizes positron-emitting radionuclides such as 18F, 11C, 64Cu, 15O and 
124Y. When a positron is released, it will travel a few millimetres (1-3 mm) before 
collision and annihilation with an electron, emitting a pair of γ-rays with the energy of 
511 keV each at almost 180 degrees [Bailey, 2005] (Figure 14). 
 
Figure 14. A positron is being ejected from the unstable atomic nuclei and travels a finite distance, before 
annihilation with an electron giving rise to two anticolinear high-energy photons [Bailey, 2005]. 
 
Currently, most PET cancer imaging agents are based on [18F]-2-fluoro-D-deoxyglucose 
(18FDG), an analogue of glucose, because of its high uptake in metabolically active 
tumors as the rate of glycolysis is far greater in neoplastic tissue compared to normal 
tissue [Larson, 1999]. However, not all cancers are well imaged with 18FDG e.g. prostatic 
cancer has a limited uptake of 18FDG, while normal brain tissue have a high uptake of 
18FDG giving rise to a high background, when trying to image brain tumors [Salminen, 
2002]. Sensitivity and specificity is compromised as inflamed and infected tissues will 
have a high uptake of this radiotracer as well. 
New radiotracers for PET are attracting much interest as the ability to monitor trace 
amounts of radiolabeled ligands without affecting biochemical processes in vivo are 
important for the staging of cancer and monitoring of chemotherapy efficacy. PET makes 
it possible to determine drug biodistribution and concentration in tumor versus healthy 
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tissue, and a variety of targeting ligands have been attached to radionuclides such as 
antibodies [Collingridge, 2002] and peptide sequences [Kwekkeboom, 2010]. 
3.1.1 Radionuclides used in PET 
The most commonly used radionuclides for PET imaging have relatively short half-lives, 
such as 18F (t½ = 110 min), 11C (t½ = 20 min), 13N (t½ = 10 min), 15O (t½ = 2 min). Since 
the energy for the annihilation process for photons is the same for all positron emitters 
(511 keV) the selection of radionuclide is mainly based on the biochemical event that 
needs imaging. 
Radionuclides with long half-lives, such as 64Cu (t½ = 12.7 hours) and 124I (t½ = 101 
hours) may be preferred for tracking longer circulating formulations as liposomes 
[Phillips, 2008; Petersen 2012]. 
Copper has several positron emitting radioisotopes; 60Cu, 61Cu, 62Cu, 64Cu and 67Cu 
with half-lives ranging from 10 minutes to 62 hours. The most applied copper isotopes 
are 62Cu (t½ = 9.7 min) and 64Cu (t½ = 12.7 hours), which are used for different purposes. 
62Cu has a higher sensitivity than 64Cu, but because of its short half-life it is only suitable 
for studying fast kinetics, whereas the longer imaging time for 64Cu can compensate for 
the lower sensitivity, due to a better spatial resolution [Williams, 2005]. 
3.1.2 The use of liposomes for PET imaging 
Liposomes are one of the more popular systems when it comes to the delivery of 
radionuclides in vivo. Their ability to deliver molecules with a high variety of 
physiochemical properties, in addition to their particular accumulation in tumor and 
metastatic tissue, give them a central position in diagnostics [Maede, 2000]. The 
combination of this specific tissue targeting and the radionuclides encapsulated in the 
liposome aqueous core or conjugated to the liposome surface, makes it possible to obtain 
PET images with lower radionuclide concentrations. 
The first use of radiolabeled liposomes was done in 1970s [Neerunjun, 1977; 
Richardson, 1977]. Tumor bearing rats were injected with 99mTc labeled liposomes for 
SPECT imaging. The radioactivity distribution in the whole rat was visualized by a γ-
camera-computer system, and the radioactivity in each organ was measured quantitatively 
after the rat was sacrificed. Since then much progress have been made; in regard to 
technology as well as in regard to radiolabeling techniques. 
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As the radionuclides typically used for PET imaging are relatively short-lived the 
radiolabeling of liposomes should be carried out just prior to the beginning of an 
experiment. Ideally, pre-manufactured stock liposomes should be utilized together with a 
remote loading technique. This technique has generally been achieved by the use of 
different lipophilic chelators to carry the radionuclide across the phospholipid bilayer 
membrane. Already encapsulated in the liposome core is a hydrophilic agent for which 
the radionuclide has a high affinity. Hence, the radionuclide will bind stronger to the 
agent inside than to the lipophilic chelator and stay inside of the liposome. This method 
typically provides high loading efficiencies (>90%) in addition to good in vivo stability as 
the radionuclide is protected inside the liposome [Phillips, 1999; Petersen 2012]. 
Other radiolabeling methods exist, however these are shown to be less effective and 
not as widely applied. Liposomes can be labeled in their bilayer membrane. This can be 
accomplished by embedding the radionuclide into the bilayer membrane during liposome 
formation [Espinola, 1979], by attaching the radionuclide to the liposome surface via 
basic electrostatic interactions [Phillips, 1999] or by binding the radionuclide to a surface 
anchored chelator [Hnatowich, 1981; Seo, 2011]. These methods are generally less 
applied, as the radionuclide is not covalently bound to the surface or the bilayer, and the 
risk of release of the radionuclide under in vivo conditions is high. 
The aqueous lumen in the liposome can hold radionuclides as well. These can be 
passively loaded into the hydrophilic lumen in the hydration step of the liposomes 
[McDougall, 1974; Oku, 1993]. This passive accumulation is less practical as it is limited 
by the interior volume of the liposome and often provides low encapsulation - liposomes 
of 100 nm give < 10% encapsulation efficiency [Petersen, 2012]. 
For in vivo purposes it is important that the radiolabeled liposomes are stable and 
able to retain their radionuclide as release of the radionuclide during or after injection can 
lead to incorrect interpretation of biodistribution results. From a traditional drug delivery 
point of view a long blood circulation time is considered advantageous, however when 
considering radioactive labeled liposomes a too slow clearance could be a limiting factor, 
as un-accumulated liposomes will add to the background signal, resulting in deteriorating 
the image quality. Hence, a compromise has to be made between desired tumor 
accumulation and blood circulation time. 
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3.2 cRGD as targeting ligand 
As for drug delivery purposes radioactive labeled liposomes can be aimed at specific 
tissues by the use of targeting ligands. A ligand that has attracted much attention since its 
discovery more than 25 years ago is the RGD (Arginine-Glycine-Aspartic acid) peptide 
[Pierschbacher, 1984]. This tripeptide sequence is naturally found in proteins of the 
extracellular matrix (ECM) such as fibronectin, vitronectin and fibrinogen, where 
integrins link the intracellular cytoskeleton of cells to the ECM by recognizing the RGD 
sequence [Ruoslahti, 1996]. Cells that are unable to attach to the extracellular matrix will 
generally undergo apoptosis; consequently, RGD containing conjugates have the ability 
to inhibit cell attachment and accordingly induce apoptosis [Saiki, 1990].  
Cell adhesion molecules such as the integrins play a major role in angiogenesis and 
metastasis. The integrin family includes at least 24 heterodimers assembled from 18 alpha 
and 8 beta subunits. Integrin heterodimers contain binding sites for divalent magnesium 
and calcium ions that facilitate their binding of ligands. Several integrins recognise the 
RGD sequence; all five αv integrins (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8), two β1 integrins 
(α5β1 and α8β1), and αIIbβ3 [Humphries, 2006]. Studies have shown that especially αvβ3 
and αvβ5 integrins are upregulated in endothelial cells of angiogenic blood vessels 
supplying tumor tissues as well as many types of malignant tumor cells. These integrins 
are not widely detected in healthy tissues and can thus serve as a valuable biomarker for 
neovascularisation [Friedlander, 1996]. Clinical studies have correlated the expression of 
αvβ3 integrins with tumor grade and aggressiveness [Schnell, 2008] and the capability to 
detect upregulated αvβ3 integrin expression could lead to better characterization and 
staging of cancers. 
A large variety of RGD analogues which serve as integrin inhibitors have been 
developed, and a few have been evaluated in clinical trials as anti-angiogenic treatments 
[Mas-Moruno, 2010]. Pioneering studies by Pierschbacher and Ruoslahti [Pierschbacher, 
1984] described the tetrapeptide sequence RGDS (Arginine-Glycine-Aspartic acid-
Serine) as the minimal sequence for binding of fibronectin with its surface receptor. 
However, later studies revealed that the serine residue could be replaced with other amino 
acids without loss of biological function, while the first three were essential for activity. 
Linear peptides have a great number of conformations in solution, which can lead to 
poor binding affinity and receptor selectivity. A useful way to reduce this number is by 
cyclization of the linear peptide, and all selective RGD ligands are cyclic. A cyclic 
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conformation has furthermore proved to be less susceptible to degradation 
[Bogdanowich-Knipp, 1999]. One last modification to introduce stability and high 
receptor specificity of the RGD peptide is the introduction of a hydrophobic D-amino acid 
in position 4. Often the amino acid in position 5 is a lysine residue, which makes an ideal 
building block for further chemical conjugation reactions (Figure 15). 
 
 
Figure 15. The Arg in position 1 and Asp in position 3 promote ionic interactions with the receptor. Gly in 
position 2 could enforce steric restrictions, while the amino acid in position 4 should be a hydrophobic D-
amino acid in order to provide optimal interaction with the receptor. Position 5 can be chosen freely without 
significant impact on the biological activity [Mas-Monuro, 2010]. 
 
Crystal structures of integrins complexed with RGD ligands have revealed that the 
peptide binds at an interface between the α and β subunits. The arginine fits into a cleft in 
the α-subunit, while the aspartic acid coordinates to a cation bound in the β-subunit 
[Xiong, 2002].  
Multimeric cRGD analogues have superior biological activity compared to 
monomeric analogues in targeting the integrin receptors [Ye, 2006; Liu, 2007]. When 
attached to a nanocarrier system, such as a liposome, the chance of longer blood 
circulation time as well as increased chances for receptor-mediated internalization is often 
larger than for single peptide constructs [Boturyn, 2004]. 
3.3 Objective 
The integrins αvβ3 and αvβ5 are cell adhesion molecules known to play a critical role in 
tumor angiogenesis and metastasis. The ability to visualize and quantify the uptake of 
liposomes targeted towards αvβ3 and αvβ5 integrins on a whole body basis could provide 
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an excellent tool for the development of targeted liposome drug delivery systems. This 
allows for direct assessment of integrin expression in vivo and efficacy of anti-angiogenic 
treatment. 
This study investigated the in vitro and in vivo characteristics of tumor-targeting 
liposomes presenting a cRGD peptide sequence and liposomes presenting a non-active 
cGRD peptide sequence on the surface. 
In vitro uptake experiments were performed using fluorescent phospholipids in the 
liposomal membrane and flow cytrometry, while in vivo biodistribution was quantified 
using 64Cu-loaded liposomes and a combined PET/CT system. 
 
3.4 Materials and methods 
Full experimental details and characterizations are available in Appendix III. 
 
3.4.1 Synthesis of propargyl functionalized cRGD and cGRD peptides 
The click reaction was chosen as conjugation method for the attachment of cRGD and 
cGRD peptides to DSPE-PEG2000 phospholipids. Consequently, the alkyne functionality 
needed to be introduced to the peptide sequence. This was achieved by the commercial 
available amino acid derivative Fmoc-propargyl-Gly-OH. 
The two peptides were prepared using a SPPS strategy. The linear peptides were 
synthesized on a 2-chlorotrityl chloride resin using standard Fmoc methodology. The 
coupling of each amino acid was carried out by pre-activation of the Fmoc protected 
amino acid with HATU in the presence of 2,4,6-collidine in DMF. Cleavage of the Fmoc 
group was done using piperidine in DMF and the completion of each coupling was 
monitored by the Kaiser test. The 2-chlorotrityl chloride resin is highly acid labile and the 
fully protected linear peptides NH2-Asp(OtBu)-D-Phe-Propargyl-Arg(Pbf)-Gly-OH and 
NH2-Asp(OtBu)-D-Phe-Propargyl-Gly-Arg(Pbf)-OH were cleaved from the solid support 
by use of a mixture of AcOH:TFE:CH2Cl2 (10:20:70). 
Cyclization was performed in solution between the N-terminal of the aspartic acid 
and the free carboxylic acid on either glycine (cRGD) or arginine (cGRD) using diphenyl 
phosphoryl azide to give the desired propargyl functionalized cyclic peptides 5 and 6 
(Figure 16). Final purification of the peptides was accomplished by HPLC. 
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3.4.2 Synthesis of DSPE-PEG2000-cRGD and DSPE-PEG2000-cGRD phospholipids 
Synthesis of the azide functionalized DSPE-PEG2000 (2d) was carried out as described in 
section 2.3.2. 
For the conjugation between DSPE-PEG2000-N3 and the propargyl functionalized 
peptides general CuAAC conditions were applied (Figure 16). Sodium ascorbate was 
used to generate the catalytic amount of Cu(I) from copper(II)sulphate pentahydrate 
resulting in formation of a triazole ring between the azide and alkyne moieties. 
  
Figure 16. CuAAC coupling conditions for DSPE-PEG2000-N3 (2d) and cRGDfPropargyl (5) or 
cGRDfPropargyl (6) resulting in peptide functionalized phospholipids 7 and 8. 
 
The coupled products were purified by HPLC and characterized by MALDI-TOF MS. 
3.4.3 Preparation of liposomes for in vitro studies 
Liposomes composed of DSPC/DSPE-PEG2000/DSPE-NBD/DSPE-PEG2000-cRGD or 
DSPE-PEG2000-cGRD (94.5:4:0.5:1) as well as control liposomes composed of 
DSPC/DSPE-PEG2000/DSPE-NBD (94.5:5:0.5) were prepared by the method described 
by Bangham et al. [Bangham, 1964]. The phospholipids were dissolved in CH3Cl/MeOH 
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(9:1), the solvent was removed under a stream of nitrogen resulting in a lipid film which 
was placed under vacuum overnight to remove trace amounts of organic solvent.  
The obtained lipid films were hydrated in a sterile PBS buffer for 1 hour at 65 °C, 
followed by freeze-thaw cycles and extrusion at 65 °C through 100 nm polycarbonate 
filters using an Avanti Polar Lipids mini-extruder. The formed liposomes were 
characterized by DLS and zeta potential measurements (Zeta PALS, Brookhaven 
Instruments). 
3.4.4 Preparation of 64Cu-liposomes for in vivo studies 
Liposomes composed of DSPC/cholesterol/DSPE-PEG2000/DSPE-PEG2000-cRGD 
(55:40:4:1) or DSPE-PEG2000-cGRD (55:40:4:1) as well as control liposomes composed 
of DSPC/cholesterol/DSPE-PEG2000 (55:40:5) were prepared by the method described by 
Bangham et al. [Bangham, 1964]. The phospholipids were dissolved in CH3Cl/MeOH 
(9:1), the solvent removed under a stream of nitrogen resulting in a lipid film which was 
placed under vacuum overnight to remove trace amounts of organic solvent. 
The obtained lipid films were hydrated in a HEPES buffer containing the 
hydrophilic copper chelating agent DOTA for 1 hour at 65 °C, followed by extrusion at 
65 °C through a 100 nm polycarbonate filer using an Avanti Polar Lipids mini-extruder. 
Un-encapsulated DOTA was removed from the outside of the formed liposomes by 
filtration, exchanging the external DOTA containing buffer with a HEPES buffer. 
The purified DOTA containing liposomes were added to a vial containing 
radioactive 64Cu and incubated 1 hour at 50-55 °C resulting in a loading efficiency of 
<95%.  
3.4.5 Flow cytometry 
To obtain a quantitative picture of the internalization of cRGD-liposomes, cGRD- 
liposomes and control PEG-liposomes flow cytometry was performed. The human 
glioblastoma cell line U87MG has a high expression of integrins and were used to 
evaluate receptor-mediated uptake [Fueyo, 2003]. Cells were incubated with NBD-
fluorescent liposomes for 5 hours, washed with PBS, trypsinated and washed again before 
analysis using by flow cytometry on a Gallios system. The NBD-fluorescent cells were 
measured with a blue laser (488 nm) for excitation and emission passfilter of 525 ± 10 
nm. 10,000 events were collected for each sample and non-treated cells were used as 
reference and the gates adjusted from those. 
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3.4.6 Confocal microscopy 
The uptake of cRGD-liposomes, cGRD-liposomes and control PEG-liposomes were 
visualized using confocal microscopy. U87MG cells were grown on top of glass slides, 
incubated with the NBD-labeled liposomes for 24 hours, washed with PBS as well as 
PBS containing Heparin and two times with PBS again. They were fixated in 4% 
paraformaldehyde in PBS for 3 minutes, followed by washing with PBS. The plates were 
allowed to dry, before being mounted onto a microscopy slide using Vectashield® 
HardSet Mounting Medium. Imaging was performed with a Leica confocal microscope 
using an excitation wavelength of λ = 476 nm and an emission bandwidth range of 485-
600 nm. 
3.4.7 Peptide-targeted 64Cu liposomes in vivo 
For quantification of the biodistribution of 64Cu labeled liposomes, U87MG cells were 
inoculated in the flank of nude female mice and allowed to grow for four weeks. 64Cu 
cRGD-liposomes, cGRD-liposomes and control PEG-liposomes were intravenous 
injected through the tail vein. PET scans were acquired at times 1 hour, 18 hours and 45 
hours, and for the anatomical localization of radioactivity CT images were acquired at the 
same time point. 
At the 45 hours time point the animals were sacrificed and the level of radioactivity 
was measured in selected tissues using a gamma-counter. 
 
3.5 Results and discussion 
3.5.1 In vitro studies 
To visualize internalization of cRGD-liposomes, cGRD-liposomes and control PEG-
liposomes (Table 2) confocal microscopy was used.  
 
Table 2. Mol% composition of liposome formulations used for uptake studies in the human glioblastoma 
U87MG cell line. 
Type of liposome DSPC DSPE-PEG DSPE-NBD 
DSPE-PEG-cRGD 
(7) 
DSPE-PEG-cGRD 
(8) 
a - PEG-liposomes 94.5 5 0.5 0 0 
b - cGRD-liposomes 94.5 4 0.5 0 1 
c - cRGD-liposomes 94.5 4 0.5 1 0 
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The human glioblastoma cell line U87MG commonly known to have a high expression of 
integrins was used for this purpose. Cells were incubated for 24 hours with liposomes, 
washed thoroughly with PBS buffer containing Heparin to release surface-bound 
particles, before being imaged with a confocal microscope (Figure 17). 
 
 
           
 
Figure 17. Representative confocal microscope images showing U87MG cells with internalized NBD-
liposomes. (A) cRGD-liposomes (c). (B) cGRD-liposomes (b). (C) control PEG-liposomes (a). Scale bar 15 
µm. 
 
By the use of flow cytometry a quantitative uptake of cRGD- (c), cGRD- (b), and control 
PEG-liposomes (a) could be determined. Cells were incubated for 5 hours with peptide-
labeled liposomes (b or c) or control PEG-liposomes (a), before their uptake was 
quantified (Figure 18). 
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Figure 18. Uptake in U87MG cells, reported as mean fluorescence intensity (MFI) and percentage of cells 
with internalized NBD-labeled liposomes relative to the total amount of cells measured. All values are 
means ± SEM (n = 2). 
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cRGD-liposomes (c) had by far the highest internalization in U87MG cells compared to 
cGRD-liposomes (b) and control PEG-liposomes (a). cGRD-liposomes (b) as well as 
PEG-liposomes (a) were nearly identical and a small amount of unspecific uptake could 
be observed for these two formulations. To estimate possible background fluorescence, 
values for untreated cells are reported. 
As uptake of positively charged liposomes are often more significant than for 
negative or neutral charged ones [Miller, 1998], the surface charge of the three different 
liposome compositions (Table 2) were measured (Table 3). 
 
Table 3. Size and surface charge of liposomes used for uptake studies in the human glioblastoma U87MG 
cell line. 
Type of liposome DLS (nm) PDI Zeta (mV) Std. error (mV) 
a - PEG-liposomes 72.4 0.040 -   1.28 ±   1.19 
b - cRGD-liposomes 75.4 0.006 -   1.70 ±   1.89 
c - cGRD-liposomes 92.7 0.005 -   0.36 ±   2.74 
 
Since all the liposome formulations evaluated exposed approximately the same surface 
charge, it is believed that their difference in uptake is largely due to specific integrin 
receptor uptake of the cRGD-targeted liposomes. 
In order to further confirm the presence of integrin receptors on the human 
glioblastoma cell line U87MG, we conducted an inhibition study using free peptide. Cells 
were incubated with free cRGD peptide or free cGRD peptide for 15 minutes followed by 
addition of cRGD-liposomes (c) or control PEG-liposomes (a) (Figure 19). 
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Figure 19. Inhibition of liposomal uptake using free cRGD and free cGRD peptide in U87MG cells. (A) 
Incubation with increasing concentrations of free cRGD peptide leads to decrease in the uptake of cRGD-
liposomes (c). (B) Incubation with free scrambled cGRD peptide followed by addition of cRGD-liposomes 
(c), or incubation with free cRGD peptide followed by addition of PEG-liposomes (a). All values are means 
± SEM (n = 2). 
 
The addition of increasing concentrations of free cRGD peptide led to a reduction in the 
uptake of cRGD-liposomes (c) presumably by inhibition of the integrins receptors (Figure 
19 A). To ensure that it was not the sole presence of any peptide that led to decreased 
liposome uptake, cells were incubated with free cGRD peptide in the highest possible 
concentration, before addition of cRGD-liposomes (c). The presence of free cGRD 
peptide had no influence on the uptake of cRGD-liposomes (c) as this was approximately 
equal to conditions with no free peptide added (Figure 19 B). To confirm that the free 
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cRGD peptide would only influence uptake through the integrin receptors, cells were 
incubated with and without free cRGD peptide followed by addition of control PEG-
liposomes (a). The uptake of PEG-liposomes (a) was identical under both conditions 
(Figure 19 B).  
These uptake studies supported the existence of integrin receptors on the U87MG 
cell line and their important function in the superior uptake of cRGD-targeted liposomes 
(c) over scrambled cGRD-liposomes (b) and control PEG-liposomes (a). 
 
3.5.2 In vivo studies 
Existing studies often report inconsistent results, when it comes to the difference between 
active targeted and passive accumulation of drug delivery systems in vivo. Positive results 
are commonly obtained in vitro, while in vivo results are more conflicting [Kirpotin, 
2006; Bartlett, 2007]. In order to compare the in vivo biodistribution of cRGD-liposomes 
and its scrambled analogue cGRD-liposomes to the in vitro results, liposomes were 
loaded with radioactive 64Cu and accumulation in mice xenograft models were measured 
by PET/CT. 
 
Table 4. Mol% composition of liposome formulations used in a tumor-bearing (glioblastoma U87MG) 
mouse xenograft model. 
Type of liposome DSPC DSPE-PEG Cholesterol DSPE-PEG-cRGD DSPE-PEG-cGRD 
d - PEG-liposomes 55 5 40 0 0 
e - cGRD-liposomes 55 4 40 0 1 
f - cRGD-liposomes 55 4 40 1 0 
 
 
Postdoc Anncatrine Luisa Petersen (DTU Nanotech) and Postdoc Tina Binderup 
(University of Copenhagen) prepared and injected 64Cu-liposomes (Table 4) into U87MG 
tumor bearing mice. The mice were scanned in a micro-PET/CT scanner allowing for 
direct determination of organ and tumor distribution (Figure 20). 
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Figure 20. Biodistribution of 64Cu-cRGD-liposomes (f) in a tumor-bearing (glioblastoma U87MG) mouse 
xenograft model. PET/CT images 45 hours post-injection. (A) Axial PET/CT image; tumor marked with 
arrows. (B) Coronal PET/CT image; spleen and liver marked with arrows. (C) Sagittal PET/CT image; liver 
and red bone marrow marked with arrows. Figure kindly provided by Anncatrine Luisa Petersen and Tina 
Binderup. 
 
The biodistribution was visualized and quantified for 64Cu-containing cRGD- (f), cGRD- 
(e), and control PEG-liposomes (d) (Figure 20 and 21). Figure 20 shows 64Cu-cRGD-
liposomes (f) 45 hours post-injection. A high accumulation can be visualized in the spleen 
and liver as expected, while an accumulation within the red bone marrow was 
surprisingly. The satisfactorily accumulation within the tumors was also visualized 
(Figure 20), and measured (Figure 21). 
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Figure 21. In vivo biodistribution of 64Cu-cRGD-liposomes (f), 64Cu-cGRD-liposomes (e), 64Cu-PEG-
liposomes (d). Accumulation in liver, spleen, kidney, muscle and tumor expressed as percent injected dose 
per organ (% ID/g). (A) Full graphic picture of the biodistribution; (B) zoom of graph A. 
 
 
The majority of all three liposome formulations were detected in the spleen and liver, as 
expected, as these organs participate in the extraction of liposomes from the blood 
circulation by the RES (Figure 21). 64Cu-cRGD-liposomes (f) showed a much higher 
accumulation in the spleen and liver, than both 64Cu-cGRD-liposomes (e) and 64Cu-PEG-
liposomes (d), indicating that these organs were responsible for a larger clearance of the 
64Cu-cRGD-liposomes (f). Particularly, the spleen accumulation were significant larger 
than normally observed for liposomes [Petersen, 2012]. This enhanced accumulation 
could probably be explained by the expression of both αvβ1 and α5β1 in especially the red 
pulp, but also the white pulp of the spleen [Liakka, 1994]. 
The tumor accumulation for 64Cu-cRGD-liposomes (f) was 2.49 % ID/g, while 
64Cu-cGRD-liposomes (e) and 64Cu-PEG-liposomes (d) showed a higher value of 3.40 % 
ID/g and 3.87 % ID/g, respectively, at 45 hours post-injection. They all show high tumor-
to-muscle ratios. In order to identify a tumor on a medical image, the tumor needs to 
contain activity sufficiently larger than the background. Often muscle tissue represents 
the background.  Generally, a tumor-to-muscle ratio of at least 1.5 to 2 is required to 
identify a tumor and at the same time provide diagnostically significant images [Philips, 
1999].  The tumor-to-muscle ratios for the three formulations are shown in Table 5. 
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Table 5. Tumor-to-muscle ratio for 64Cu containing liposomes in a tumor-bearing (glioblastoma U87MG) 
mouse xenograft model. 
Type of liposome Tumor-to-muscle ratio Std. dev. 
d - 64Cu-PEG-liposomes 13.7 ±   4.2 
e - 64Cu-cGRD-liposomes 14.6 ±   8.0 
f - 64Cu-cRGD-liposomes 13.3 ±   3.0 
 
The tumor-to-muscle ratios were very similar (Table 5), despite the more pronounced 
clearance of 64Cu-cRGD-liposomes (f) compared to 64Cu-cGRD-liposomes (e) and 64Cu-
PEG-liposomes (d), indicating a targeting effect of the cRGD peptide sequence. 
Interestingly, an accumulation could be detected in the red bone marrow for the 
64Cu-cRGD-liposomes (f) (Figure 20), whereas none were detected for either 64Cu-
cGRD-liposomes (e) or 64Cu-PEG-liposomes (d) (data not shown). The increased 
accumulation of 64Cu-cRGD-liposomes (f) could possibly be explained by the high 
expression of α5β1 on undifferentiated adult mesenchymal stem cells (MSC) from bone 
marrow and adipose tissue [Goessler, 2008]. 
3.6 Concluding remarks 
Hybrid imaging techniques such as PET/CT are used in all phases of cancer management. 
Early detection and correct treatment of cancer can be a major contributor to a reduction 
in mortality and these techniques are able to supply complementary information for 
improved staging and therapy planning. Targeted therapies are developing into being an 
important part of modern cancer treatment and the integrins are interesting targets in this 
aspect. 
This study aimed to visualize and quantify the uptake and biodistribution of integrin 
targeted liposomes opposed to non-targeted formulations in vitro as well as in vivo. In 
vitro results demonstrated the superior uptake of cRGD-liposomes in a human 
glioblastoma cell line (U87MG). This uptake was assigned to receptor-mediated uptake, 
as studies showed inhibition of the uptake, in the presence of free cRGD peptide. The 
presence of free scrambled cGRD had no impact on the uptake, and the unspecific uptake 
of control PEG-liposomes was not affected by the presence of free cRGD peptide. 
Encouraged by these results the biodistribution of the liposomal formulations were 
tested in a xenograft mouse model bearing an integrin expressing tumor cell line 
(U87MG). Three different formulations of 64Cu-liposomes were prepared and their 
 50 
 
accumulation in organs and tumors evaluated. The 64Cu-cRGD-liposomes showed large 
accumulation in spleen, liver and red bone marrow. The accumulation in spleen and liver 
could be attributed to their function in clearance of nanoparticles from the blood 
circulation. However, the extremely high accumulation - even for nanoparticles - in the 
spleen could also be influenced by the presence of integrins in this organ. The 
accumulation in the red bone marrow was unexpected, but can potentially be explained by 
the high expression of integrins on undifferentiated adult mesenchymal stem cells. 
However, the profound uptake of 64Cu-cRGD-liposomes in the spleen and liver may 
hamper the imaging of abdominal tumors and could limit the safely administrated active 
dose. 
The scrambled 64Cu-cGRD-liposomes and control 64Cu-PEG-liposomes showed 
very similar biodistribution indicating the targeting potential of 64Cu-cRGD-liposomes. 
64Cu-cGRD-liposomes and 64Cu-PET-liposomes demonstrated a higher accumulation in 
the tumors than the 64Cu-cRGD-liposomes; however, when looking at their tumor-to-
muscle ratios these were practically identical, despite the extensive clearance of 64Cu-
cRGD-liposomes in the spleen. 
Future studies with targeted 64Cu-liposomes could provide a great insight into the 
actual biodistribution of various targeted drug delivery systems and illustrate their 
potentials. 
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Chapter 4  
 
Cationic liposomes and the PEGylation dilemma 
Cationic liposomes have been applied for drug delivery as the positively charged 
liposomes bind to negatively charged cell membranes as a cause of electrostatic attraction 
and an enhanced uptake can be expected. However, cationic liposomes have been 
reported to bind serum proteins, which can lead to aggregation and rapid clearance from 
the blood circulation. In addition, unspecific binding to healthy cells is difficult to avoid 
under in vivo conditions and the positive charged particles thus leads to higher 
cytotoxicity. Currently, the strategy to avoid unspecific binding and fast blood clearance 
is to use PEG chains to sterically shield the liposomes from blood components [Torchilin, 
1994]. Although the enhanced circulation time of PEGylated liposomes allows for 
enhanced accumulation in tumors, the influence of PEG on cell uptake and intracellular 
trafficking can compromise the drug efficiency [Harvie, 2000; Hyvönen, 2004]. 
To solve this PEG-associated issue, multiple examples are reported, where the PEG 
chains have been attempted removed once at target site. The dissociation of PEG from the 
rest of the liposomes can be accomplished by the use of breakable bonds such thiol 
reducible bonds [McNeeley, 2009; Ishida, 2001], esterase-catalyzed cleavable bonds [Xu, 
2008], or by choosing the correct length of the lipid anchor, which in a time dependent 
manner would exchange out of the membrane [Wheeler, 1999]. The shedding of PEG can 
occur before or after cellular uptake (Figure 22).  
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Figure 22. Schematic representation of dissociation of PEG from the liposome. Top panel shows the 
extracellular removal of PEG. (a) PEG is removed, drug released and taken up by the cell; (b) removal of 
PEG leads to exposure of a targeting moiety and receptor-mediated uptake; (c) removal of PEG leads to 
exposure of a hidden cationic charge.  Lower panel shows the removal of PEG after internalization in the 
cell [Romberg, 2008].  
 
The removal of the hydrophilic PEG coating can lead to destabilization of the liposomal 
membrane resulting in release of encapsulated content [Ishida, 2001; Shin, 2003], 
exposure of a hidden targeting ligand [McNeeley, 2009; Hatakeyama, 2009] or exposure 
of a positive charge leading to stronger interaction with the cell membrane [Miller, 1998]. 
4.1 Removal of PEG using matrix metalloproteinase enzymes 
An applied method to remove PEG from the surface of liposomes once accumulated at 
target site has been to take advantage of the high secretion of MMPs from tumors into the 
extracellular space. MMP is involved in many aspects of the tumor growth and spread 
such as angiogenesis, invasion and metastasis by its ability to degrade extracellular 
matrix. MMPs are secreted as inactive zymogens (proMMPs) and they need to be 
activated to carry out their function. Their expression is low in normal cells [Coussens, 
2002]; hence they can potentially be used for site specific removal of PEG chains. 
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Terada et al. have developed a functionalized liposomal system consisting of PEG-
peptide-DOPE in combination with galactose moieties as targeting ligands. The special 
synthesized peptide contained a MMP-2 cleavable sequence which is degraded in 
proximity to the tumor cells due to their enhanced excretion of MMPs. The removal of 
PEG would uncover the galactose ligands on the surface of the liposomes, resulting in 
enhanced specific uptake in HepG2 cells [Terada, 2006]. A similar approach was used by 
Harakeyama et al. were MMP-2 cleavage of a PEG-peptide-DOPE led to removal of 
PEG. They observed a higher interaction with the MMP secreting cell lines (HT1080, 
MG-63 and HOS) and enhanced transfection efficiency within these [Harakeyama, 2007]. 
 
 
Inspired by the work above, a special lipo-peptide was designed for embedding into 
positive charged liposomal membranes. It consisted of two dipalmitoyl acyl chains 
connected to a cleavable peptide sequence followed by a PEG2000. The peptide would be 
sensitive towards MMP-2 and MMP-9 enzymatic cleavage and by this process release the 
shielding PEG layer as well as four negatively charged amino acid residues. This results 
in liposomes exposing a positive surface charge due to the lipids formulated in the 
liposome, allowing for high interaction with the cell membrane. In addition, the PEG 
layer could also be removed after internalization into the endosomes, where MMP 
enzymes can be found; e.g. MMP-14 which function as a potent activator of proMMP-2 
[Messarltou, 2009] (Figure 23).  
By additional targeting of the cancer tissue by the use of a targeting moiety the 
intracellular MMP activation in the endosomes could be particular useful. 
Whether the liposomal membrane would be destabilized by the removal of PEG and 
release its content outside the cells or it would be internalized in the endosome before 
release remains to be revealed. 
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Figure 23. Negatively charged liposome exposed to secreted MMP-2 and MMP-9 in the extracellular space 
of tumor cells. Enzymatic cleavage removes the shielding PEG layer along with four negative charged 
amino acid residues. The positive charged liposome can release its content before internalization in the cell 
or after uptake in the endosomes, where the PEG layer can also be removed. Figure kindly provide by Jonas 
R. Henriksen. 
4.2 Objective 
The positive charged liposomes are important potential candidates in drug delivery. 
However, their unspecificity is a major challenge which needs to be addressed. 
The goal of these studies was to elucidate, if the combination of a targeting ligand 
and a cleavable PEG lipo-peptide could enhance uptake and cytotoxicity of oxaliplatin 
loaded liposomes in vitro. The liposomes were formulated with the cationic lipid DOTAP 
that should stay hidden underneath the shielding PEG layer until the encounter with 
MMPs. The removal of PEG will expose the cationic charge which should facilitate 
interactions with cell membranes as well as the release of cytotoxic oxaliplatin. The 
results will be validated using flow cytometry methods and cytotoxic colorimetric assays. 
The ability to both tune the release of encapsulated drug in addition to an 
improvement in the specific delivery in one single formulation would be a great 
advantage in future drug delivery systems. 
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4.3 Materials and methods 
Full experimental is available in Appendix IV. 
4.3.1 Synthesis of dipalmitoyl-metalloproteinase cleavable peptide-PEGylated 
A special lipo-peptide needed to be synthesized in order to address the PEG dilemma. 
This peptide contained a recognition site for MMP-2 and MMP-9, flanked by two 
palmitoyl chains for insertion into the liposomal membrane on one side, and four 
glutamic acid residues connected to a PEG2000 chain on the other site (Figure 24). 
 
  
Figure 24. Chemical structure of dipalmitoyl-metalloproteinase cleavable peptide-PEGylated (DP-MCP-
PEG) (9). 
 
The linear peptide was synthesized using a SPPS strategy on a TentaGEL PAP2000 resin 
with standard Fmoc methodology. The coupling of each amino acid was carried out by 
pre-activation of the Fmoc protected amino acid with HATU in the presence of 2,4,6-
collidine in DMF. Cleavage of the Fmoc group was done using piperidine in DMF and 
the completion of each coupling was monitored by the Kaiser test. The fully deprotected 
peptide dipalmitoyl-Dap-Trp-Ile-Pro-Val-Ser-Leu-Arg-Ser-Gly-Glu-Glu-Glu-Glu-
PEG2000 was cleaved from the resin using a mixture of TFA: H2O:TIS (95:2.5:2.5). The 
lipo-peptide was purified by HPLC and characterized by MALDI-TOF MS. 
4.3.2 Synthesis of DSPE-PEG2000-cRGD phospholipid 
This phospholipid conjugate was prepared as described in section 3.4.2 
4.3.3 Synthesis of DSPE-PEG2000-Folate phospholipid 
The commercial available DSPE-PEG2000-NH2 was functionalized with folic acid. The 
folic acid was pre-activated with HATU in the presence of triethylamine and product 
formation was followed and characterized by MALDI-TOF MS (Figure 25). The folate 
modified phospholipid was purified before use by HPLC. 
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Figure 25. Coupling conditions for DSPE-PEG2000-NH2 and folic acid resulting in the γ-folate 
functionalized phospholipid (10). 
 
4.3.4 Synthesis of DSPE-PEG2000-Octaarginine phospholipid 
The highly positively charged octaarginine sequence was synthesized on a TentaGEL 
resin using SPPS strategy and a standard Fmoc methodology. The coupling of each amino 
acid was carried out by pre-activation of the Fmoc protected amino acid with HATU in 
the presence of 2,4,6-collidine in DMF. Cleavage of the Fmoc group was done using 
piperidine in DMF and the completion of each coupling was monitored by the Kaiser test. 
The peptide hydroxylamine-(Arg)8-NH2 (11) was cleaved from the resin and 
simultaneously deprotected using a mixture of TFA:H2O:TIS (95:2.5:2.5). The crude 
peptide was purified by HPLC. 
DSPE-PEG2000 aldehyde functionalized phospholipid (2c) was prepared as 
described in section 2.3.2. 
The hydroxylamine-octaarginine (11) and DSPE-PEG2000-aldehyde (2c) were 
dissolved in a solvent mixture of methanol and water, and the conjugation reaction took 
place without further addition of additives (Figure 26). The octaarginine modified 
phospholipid was purified by HPLC. 
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Figure 26. Coupling conditions for DSPE-PEG2000-aldehyde (2c) and hydroxylamine-octaarginine (11) 
resulting in the octaarginine functionalized phospholipid (12). 
 
4.3.5 Preparation of liposomes for uptake studies 
Liposomes were in general composed of DSPC/DOPE-RhoB/cholesterol and total of 5% 
DSPE-PEG2000 lipid - either as pure DSPE-PEG2000 phospholipid or as a mixture with 
functionalized DSPE-PEG2000 phospholipids. The functionalized DSPE-PEG2000 
phospholipids used were DSPE-PEG2000-Octaarginine, DSPE-PEG2000-cRGD and DSPE-
PEG2000-Folate as well as the lipo-peptide DP-MCP-PEG.  DOTAP was excluded or used 
in an amount of 7.5%. Hence, liposomes formulated without DOTAP had the 
composition DSPC/DOPE-RhoB/cholesterol/DSPE-PEG2000 (54.5:0.5:40:5), while 
liposomes containing DOTAP had the composition DSPC/DOPE-
RhoB/cholesterol/DSPE-PEG2000/DOTAP (47:0.5:40:5:7.5). In a few studies the DSPC 
phospholipid was replaced with a POPC phospholipid; however the use of matrix 
phospholipid will be pointed out. 
The phospholipids were dissolved in CH3Cl/MeOH (9:1), the solvent removed 
under a stream of nitrogen and the lipid film placed under vacuum overnight to remove 
trace amounts of organic solvent. The obtained lipid films were hydrated in a 
HEPES/sucrose buffer for 1 hour at 65 °C, followed by freeze-thaw cycles and extrusion 
at 65 °C through 100 nm polycarbonate filters using an Avanti Polar Lipids mini-
extruder. The formed liposomes were characterized by DLS and zeta potential 
measurements (Zeta PALS, Brookhaven Instruments). 
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4.3.6 Preparation of oxaliplatin loaded liposomes for cytotoxicity studies 
Liposomes had identical compositions as described above only excluding the fluorescent 
DOPE-RhoB phospholipid.  
As described above, the phospholipids were dissolved in CH3Cl/MeOH (9:1), the 
solvent removed under a stream of nitrogen and the lipid film placed under vacuum 
overnight to remove trace amounts of organic solvent. The obtained lipid films were 
hydrated in a HEPES/sucrose buffer containing oxaliplatin (~15 mg/mL) for 1 hour at 70 
°C, followed by extrusion at 70 °C through 100 nm polycarbonate filters using an Avanti 
Polar Lipids mini-extruder. To remove un-encapsulated oxaliplatin from the outside of 
the liposomes, they were transferred to dialysis cassettes and dialyzed 3 days, exchanging 
the external oxaliplatin containing buffer with a HEPES/sucrose buffer.  
Encapsulation efficiency of oxaliplatin and leakiness of the liposomes were 
measured by ICP-AES. 
4.3.7 Cell lines 
HT1080, a human fibrosarcoma cell line was used in most of the experiments. This cell 
line has a high secretion of MMP-2 and MMP-9 enzymes [Roomi, 2009], which 
corresponds well with the idea of the DP-MCP-PEG peptide. Two other cell lines used 
were expressing receptors to cRGD and folate, respectively. The human glioblastoma cell 
line U87MG [Fueyo, 2003] for cRGD targeted experiments, and the human 
nasopharyngeal epidermal carcinoma cell line KB [Weitman, 1992] for folate targeted 
experiments. 
4.3.8 Flow cytometry 
To obtain a quantitative measure of the internalization of mono- and dual-functionalized 
liposomes as well as control PEG-liposomes flow cytometry was performed. Cells were 
incubated with RhoB-fluorescent liposomes for 2 hours (KB and HT1080 cell lines) or 5 
hours (U87MG and HT1080 cell lines), washed with PBS, trypsinated and washed again 
before analysis by flow cytometry on a Gallios system using a blue laser (488 nm) for 
excitation and a filter of 575 ± 10 nm for emission. 10,000 events were collected for each 
sample and non-treated cells were used as reference and the gates adjusted from those. 
4.3.9 Confocal microscopy 
The uptake of mono-functionalized, dual-functionalized and control PEG-liposomes were 
visualized using confocal microscopy. Cells were grown on top of glass slides, incubated 
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with the RhoB-labeled liposomes for 24 hours, washed with PBS as well as PBS 
containing Heparin and two times with PBS again. They were fixated in 4% 
paraformaldehyde in PBS for 3 minutes, followed by washing with PBS. The plates were 
allowed to dry, before being mounted onto a microscopy slide using Vectashield® 
HardSet Mounting Medium. Imaging was performed with a Leica confocal microscope 
using an excitation wavelength of λ = 561 nm and an emission bandwidth range of 568-
711 nm. 
4.3.10 Cytotoxicity assay 
The cytotoxicity of oxaliplatin loaded liposomes was evaluated using a colorimetric 
method for determining the number of viable cells. This assay uses the tetrazolium 
compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium salt (MTS) and phenazine methosulphate (PMS). MTS is reduced by 
metabolically active cells into a formazan product. The quantity of formazan product 
measured at 490 nm absorbance is directly proportional to the number of living cells.  
Cells were seed in 96-well plates and incubated overnight, before the addition of 
oxaliplatin liposomes in concentrations from 0.3 µM to 50 µM oxaliplatin. After 
incubation for 24 hours, the liposome containing medium was replaced with fresh, and 
the plates incubated for another three days. Medium was replaced with MTS/PMS 
containing medium and the plates incubated 2 hours before the absorbance was measured 
using a micro plate reader (Perkin Elmer). 
4.3.11 Cryogenic transmission electron microscopy 
Specimens for cryoTEM were prepared on freshly glow-discharged carbon copper grids 
covered with formvar (300 mesh). The concentrations of phospholipids were in the range 
of 10 mM and 4 µl were applied to each grid surface. The grids were blotted for excess 
liquid and plunge-frozen in liquid ethane using a Vitrobot (FEI Company). Frozen grids 
were transferred to a cryoholder and visualized in a Tecnai G20 electron microscope (FEI 
Company) at 200 kV accelerating voltage. 
4.4 Results and discussion 
4.4.1 Cationic liposomes 
Liposomes were formulated with octaarginine and their internalization was compared to 
control PEG-liposomes (Table 6) in HT1080 cells. 
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Table 6. Mol% composition of liposome formulations used for uptake studies in the human fibrosarcoma 
HT1080 cell line. 
Type of liposome POPC DSPE-PEG DOPE-RhoB Cholesterol DOTAP 
DSPE-PEG- 
Octaarginine(12) 
g - PEG-liposomes 47 5 0.5 40 7.5 0 
h - Octaarginine- 
      liposomes 
47 4 0.5 40 7.5 1 
 
 
When liposomes were formulated with 1% octaarginine functionalized DSPE-PEG2000 
phospholipid (h) the zeta potential would become highly positive (Table 7). 
 
 
Table 7. Size and surface charge of liposomes used for uptake studies in the human fibrosarcoma HT1080 
cell line. 
Type of liposome DLS (nm) PDI Zeta (mV) Std. error (mV) 
g - PEG-liposomes 143.0 0.026 7.30 ±   0.84 
h - Octaarginine-liposomes 126.4 0.069 16.89 ±   1.60 
Human fibrosarcoma HT1080 were treated for 5 hours with octaarginine-liposomes (h) or 
control PEG-liposomes (g), before their internalization were measured by flow cytometry 
(Figure 27). 
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Figure 27. Uptake in HT1080 cells, reported as mean fluorescence intensity (MFI) and percentage of cells 
with internalized RhoB-labeled liposomes relative to the total amount of cells measured. All values are 
means ± SEM (n = 2). 
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The liposomes functionalized with octaarginine (h) showed increased uptake compared to 
control PEG-liposomes (g). It could be seen from the high MFI value that numerous cells 
had taken up a large amount of liposomes. To validate if this high internalization had any 
enhanced cytotoxic effect, liposomes containing oxaliplatin were made. 
Oxaliplatin is a platinum-based anticancer drug approved for colorectal cancer 
treatment. The precise mechanism by which oxaliplatin kills cancer cells are not clear, but 
broadly speaking the platinum-based drugs reacts with DNA bases and disrupt essential 
processes such as DNA replication and transcription, leading to apoptosis [Di Francesco, 
2002]. In order for oxaliplatin to reach the DNA it has to escape the liposome. To 
investigate if this escape was possible with the described liposomes formulations, cells 
were incubated with oxaliplatin containing liposomes (Figure 28). 
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Figure 28. HT1080 cells treated with oxaliplatin loaded liposomes as well as free oxaliplatin. ▲ PEG-
liposomes; ■ Octaarginine-liposomes; ○ free oxaliplatin. The liposome formulations were as described in 
Table 6 only substituting DOPE-RhoB with POPC. All values are means ± SEM (n = 2). 
 
Control PEG-liposomes showed very low cytotoxic effect on the HT1080 cells, while 
octaarginine-liposomes were more toxic than free oxaliplatin. The enhanced 
internalization of octaarginine liposomes compared to control PEG-liposomes is likely to 
be caused by the high interaction between the negatively charged cell surface and the 
positive charged liposomes [Zabner, 1995]. The enhanced cytotoxic effect seen for only 
octaarginine-liposomes could be due to the ability of the cationic liposomes to fuse with 
the anionic endosomal/lysosomal membranes and release the encapsulated oxaliplatin 
into the cytoplasm [Dominska, 2010]. If the liposomes stay too long in the 
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endosomes/lysosomes the risk is that they and their encapsulated content will be degraded 
of the harsh environment existing in these vesicles. Another explanation to the difference 
observed in cytotoxicity between the two formulations could be a higher exocytosis 
degree of the PEG-control liposomes compared to octaarginine-liposomes. However, 
initial studies have shown that longer incubation times leads to higher internalization of 
the liposomes. Indicating that no significant exocytosis of the liposomes are taken place 
within a 24 hour timeframe (data not shown). 
It could seem like the octaarginine-liposomes would serve as great drug delivery 
agents, however an in vivo use of these particles would be completely unacceptable as 
they would not interact specifically with cancerous cells, but with all cell membranes, 
likely to result in large side effects. 
If the charge could be shielded beneath a PEG layer and a targeting moiety could 
direct the way to diseased cells, this could provide an opportunity of creating an effective 
and specific drug delivery system. Promising uptake results from cRGD-liposomes were 
illustrated in Chapter Three; hence the efficiency of this targeting moiety was tested with 
and without positive surface charge in vitro (Table 8). 
 
Table 8. Mol% composition of liposome formulations used for uptake studies in the human fibrosarcoma 
HT1080 cell line and human glioblastoma U87MG cell line. 
Type of liposome DSPC DSPE-PEG DOPE-RhoB Cholesterol DOTAP 
DSPE-PEG- 
cRGD(7) 
i - cRGD- 
     liposomes 
54.5 4 0.5 40 0 0.5 
j - cRGD/ DOTAP- 
     liposomes 
47 4 0.5 40 7.5 0.5 
 
cRGD-liposomes were formulated with or without the presence of the cationic 
phospholipid DOTAP (Table 8) and characterized (Table 9). 
 
Table 9. Size and surface charge of liposomes used for uptake studies in the human fibrosarcoma HT1080 
cell line and human glioblastoma U87MG cell line. 
Type of liposome DLS (nm) PDI Zeta (mV) Std. error (mV) 
i - cRGD-liposomes 176.8 0.122 -   12.57 ±   1.44 
j - cRGD / DOTAP-liposomes 174.7 0.119      4.89 ±   1.30 
 
The internalization of these formulations was tested in two different cell lines HT1080 
and U87MG (Figure 29). 
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Figure 29. Uptake in HT1080 cells (A) and U87MG cells (B) reported as mean fluorescence intensity 
(MFI) and percentage of cells with internalized RhoB-labeled liposomes relative to the total amount of cells 
measured. All values are means ± SEM (n = 2). 
 
 
Since both cell lines express integrin receptors [Conforti, 1994; Fueyo, 2003] the 
receptor-mediated internalization is not widely affected by the presence of DOTAP. They 
both (i and j) show a high degree of uptake compared to control PEG-liposomes (g) 
(Figure 27), however the uptake in either of the two cell lines do not compare to the high 
uptake of octaarginine liposomes, when examining the MFI values (Figure 27). This is 
expected, as the surface charge of octaarginine-liposomes (h) is significant more positive 
than for cRGD-liposomes (i, j). Eventhough the surface charge of PEG-liposomes (g) is 
slightly more positive, than for cRGD-liposomes with DOTAP (j) (Table 7 and Table 9), 
the uptake is still higher for the latter. This indicates that receptor-mediated uptake is 
playing a role as well, and not sole surface-surface charge interactions are responsible for 
the uptake. 
The cytotoxic effect of oxaliplatin liposomes - targeted, and with and without the 
presence of DOTAP - was evaluated (Figure 30). 
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Figure 30. HT1080 (A) and U87MG (B) cells treated with oxaliplatin loaded liposomes as well as free 
oxaliplatin. □ cRGD-liposomes; ■ cRGD/DOTAP-liposomes; ○ free oxaliplatin. The liposome formulations 
were as described in Table 8 only substituting DOPE-RhoB with DSPC. All values are means ± SEM (n = 
2). 
 
None of the two targeted formulations showed any cytotoxic effect. This confirms that the 
positive charge coming from DOTAP has limited influence on the fate of the liposomes. 
The positive charge on the liposomes is not large enough to interact with the 
endosomal/lysosomal membranes and they do not escape or release their content before 
degradation, hence the toxic effect of oxaliplatin is lacking. Receptor-mediated uptake 
seem to be the major cause for increased uptake and not surface charge interactions, as 
also concluded from Figure 29. From the curve ascribed to free oxaliplatin is can be seen 
that the HT1080 cells are more sensitive to oxaliplatin than U87MG. For the HT1080 
cells ~10 % are alive after treatment with 50 µM oxaliplatin, while for the U87MG cells 
this number is ~40%. 
The positive charge from DOTAP is situated directly on the surface of the liposome 
likely to be fully covered by the surrounding PEG layer, while the charge coming from 
the octaarginine peptide is extending beyond the PEG layer of the liposome, being free to 
interact with the cell membranes. The DP-MCP-PEG peptide was designed to overcome 
this limitation by removing the PEG layer and allowing for more direct interaction 
between DOTAP and the cell membranes. 
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4.4.2 cRGD and DP-MCP-PEG functionalized liposomes 
As the DP-MCP-PEG contains four negatively charged residues (glutamic acid) exposed 
just beneath the PEG layer these should preferably keep the liposomes negatively charged 
while in circulation, despite the presence of DOTAP. When the PEG layer along with the 
four negative charges are removed by the MMPs, the DOTAP charge is exposed, being 
able to interact strongly with the cell membrane. The combination with the targeting 
cRGD peptide should give the liposomes a possibility to undergo receptor-mediated 
endocytosis once accumulated in the ECM by the EPR effect. 
The zinc-dependent endopeptidase thermolysin was selected as a convenient model 
enzyme for the MMP enzymes, since their catalytic domains as well as their substrate 
selectivity are similar [Pelmenschikov, 2002]. The MMP enzymes have a tendency to 
undergo self-hydrolysis which can be problematic, when performing an experimental 
setup [Sakar, 2008]. 
Liposomes were formulated with the targeting peptide cRGD and DP-MCP-PEG 
with and without the presence of DOTAP (Table 10). Their size (Table 11) and zeta 
potential (Table 12) were characterized.  
 
 
Table 10. Mol% composition of liposome formulations used for uptake studies in the human fibrosarcoma 
HT1080 cell line and human glioblastoma U87MG cell line as well as for MALDI-TOF MS analysis. 
Type of liposome DSPC 
DSPE 
-PEG 
DOPE 
-RhoB 
Cholesterol DOTAP 
DSPE-PEG- 
cRGD(7) 
DP-MCP-
PEG(9) 
 
k - DP-MCP- 
      PEG-lipo. 
 
54.5 0.5 0.5 40 0 0 4.5 
l - DP-MCP-PEG 
    / DOTAP-lipo. 
 
47 0.5 0.5 40 7.5 0 4.5 
m - cRGD /  
       DP-MCP- 
       PEG-lipo. 
 
54.5 0 0.5 40 0 0.5 4.5 
n - cRGD / DP- 
      MCP-PEG /  
      DOTAP-lipo. 
 
47 0 0.5 40 7.5 0.5 4.5 
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Table 11. Size of liposomes used for uptake studies in the human fibrosarcoma HT1080 cell line and 
glioblastoma U87MG cell line. 
Type of liposome Without DOTAP With DOTAP 
 DLS (nm) PDI DLS (nm) PDI 
cRGD / DP-MCP-PEG-liposome (m, n) 179.9 0.037 177.2 0.146 
DP-MCP-PEG-liposome (k, l) 140.2 0.109 167.0 0.080 
 
 
Table 12. Surface charge of liposomes used for uptake studies in the human fibrosarcoma HT1080 cell line 
and glioblastoma U87MG cell line. 
Type of liposome Without DOTAP With DOTAP 
 Zeta (mV) Std. error (mV) Zeta (mV) Std. error (mV) 
cRGD / DP-MCP-PEG- liposome (m, n) -   9.98 ±   1.15 -   8.28 ±   1.54 
DP-MCP-PEG-liposome (k, l) -   23.42 ±   2.42 -   7.51 ±   1.03 
 
 
The surface charge of the liposomes changed, when DOTAP was incorporated in the 
formulation. Especially, the mono-functionalized DP-MCP-PEG-liposomes (k versus l) 
had a large change, while the dual-functionalized were more moderate (m versus n). 
However, they did not show positive charges as observed for the cRGD-liposomes (j) 
(Table 9) due to shielding of the positive DOTAP by the negative charges carried by DP-
MCP-PEG.  
As a proof-of-concept, liposomes containing DP-MCP-PEG and DOTAP were 
incubated in the presence of thermolysin (Table 13 and Figure 31). The negative surface 
charge of the DP-MCP-PEG/DOTAP liposomes (l) changed to positive, when exposed to 
thermolysin. 
 
 
Table 13. Surface charge of liposomes incubated with or without thermolysin. 
Type of liposome Without thermolysin With thermolysin 
 Zeta (mV) Std. error (mV) Zeta (mV) Std. error (mV) 
l - DP-MCP-PEG / DOTAP-liposomes -   8.85 ±   1.17 2.86 ±   0.968 
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Figure 31. MALDI-TOF MS showing the DP-MCP-PEG liposomes (l) after exposure to thermolysin. (A) 
not fully cleaved DP-MCP-PEG; (B) fully cleaved DP-MCP-PEG. 
 
MALDI-TOF MS analysis confirmed that the DP-MCP-PEG peptide was cleaved by 
thermolysin. 
 
In order to evaluate if the presence of the MMP cleavable lipo-peptide would 
change the uptake pattern of the liposomes, their uptake was investigated in the MMP 
secreting cell line HT1080, as well as the integrin presenting cell U87MG (Figure 32). 
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Figure 32. Uptake in HT1080 cells (A) and U87MG cells (B) reported as mean fluorescence intensity 
(MFI) and percentage of cells with internalized RhoB-labeled liposomes relative to the total amount of cells 
measured. All values are means ± SEM (n = 2). 
 
 
 68 
 
For the internalization in the HT1080 cell line the DOTAP containing liposomes (l, n) 
were superior (Figure 32 A). The combination of the targeting cRGD moiety and the 
MMP cleavable DP-MCP-PEG part (n) showed enhance uptake over the both the mono-
functionalized cRGD/DOTAP-liposomes (j) (Figure 29) and the DP-MCP-PEG/DOTAP-
liposomes (l) (Figure 32). More or less the same picture is seen in the uptake pattern for 
the U87MG cell line (Figure 32 B). However, in this cell line the cRGD-targeting has a 
higher effect on the uptake. The uptake of dual-functionalized cRGD/DP-MCP-PEG-
liposomes (m) is comparable with mono-functionalized DP-MCP-PEG/DOTAP-
liposomes (l). 
The quantitative flow cytometry measurements were supported by confocal imaging 
using the human glioblastoma cell line U87MG (Figure 33). 
 
            
           
 
Figure 33. Representative confocal microscope images showing U87MG cells with internalized RhoB-
liposomes. (A) cRGD/DOTAP-liposomes (j). (B) cRGD/DP-MCP-PEG/DOTAP-liposomes (n). (C) DP-
MCP-PEG/DOTAP-liposomes (l). Scale bar 15 µm. 
 
From the confocal images it is difficult to distinguish any real difference in the 
internalization of fluorescent liposomes between the three formulations (Figure 33). 
However, the images proved that internalization was indeed occurring and indicated that 
different uptake mechanisms could be taking place. For the mono-functionalized 
cRGD/DOTAP-liposomes (j) it seemed like most of the cytoplasma was fluorescent, 
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while for the mono-functionalized DP-MCP-PEG/DOTAP-liposomes (l) the fluorescence 
showed up in spots. However, due to time constrains this was not investigated further. 
To decide which strategy - dual-functionalization or mono-functionalization 
combined with a positive charge - would give a greater therapeutic efficacy the uptake 
pattern was compared to the cytotoxic profile of the liposomes containing encapsulated 
oxaliplatin (Figure 34). 
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Figure 34. HT1080 (A) and U87MG (B) cells treated with oxaliplatin loaded liposomes as well as free 
oxaliplatin. □ cRGD/DP-MCP-PEG-liposomes; Δ DP-MCP-PEG-liposomes; ▲ cRGD/DP-MCP-
PEG/DOTAP-liposomes; ■ DP-MCP-PEG/DOTAP-liposomes; ○ free oxaliplatin. The liposome 
formulations were as described in Table 10 only substituting DOPE-RhoB with DSPC. All values are 
means ± SEM (n = 2). 
 
In both cell lines; HT1080 (Figure 34 A) and U87MG (Figure 34 B), the dual-
functionalized DOTAP liposomes (n) turned out to be the most toxic ones. A minor 
cytotoxic effect was seen at the highest concentrations for liposomes without DOTAP (k, 
m) compared to the cRGD-liposomes (i, j) (Figure 30). Free oxaliplatin and the two 
DOTAP containing liposomes (l, n) showed similar cytotoxic profiles in the HT1080 cell 
line (Figure 34 A). In the U87MG cell line an increased cytotoxic effect was seen from 
the DOTAP containing liposomes (l, n), with the mono-functionalized DP-MCP-
PEG/DOTAP-liposomes (l) showing the highest cytotoxicity, while the dual-
functionalized cRGD/DP-MCP-PEG/DOTAP-liposomes (n) would lie in the range of free 
oxaliplatin (Figure 34 B). 
From the cytotoxic effect on especially the U87MG cells, it can be concluded that a 
high uptake not necessarily leads to a high toxicity. In Figure 32 B the dual-
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functionalized-cRGD/DP-MCP-PEG-liposomes (m) and mono-functionalized DP-MCP-
PEG/DOTAP-liposomes (l) showed almost identical uptake, but only the DOTAP 
formulation showed significant cytotoxicity. This emphasizes the importance of the 
liposomes to be able to escape the endosomes/lysosomes in order to release their content 
and provide a cytotoxic response [Dominska, 2010].  
From these cytotoxic profiles it did not seem like the extracellular secretory MMP 
enzymes from HT1080 had a large effect on the cytotoxicity pattern. This is likely to be 
caused by the relative short incubation time, where the HT1080 have a chance to secrete 
the MMP enzymes. The situation would possibly look different in an in vivo situation, 
due to the difference in MMP enzyme concentration. Typically 5 x 104 cells were 
cultured in 1 mL of medium; comparing this to an in vivo situation where 1 g of tissue 
consist of 1 x 109 cells surrounded by approximately 200 µl of extracellular space, the 
MMP enzymes would be largely diluted in the in vitro situation [Tsuji, 1983].  
 
 
The outcome of dual-functionalization together with a hidden cationic charge had proved 
to be rather effective and to examine, if this effect was a general trend, a different 
targeting ligand was investigated. 
 
 
4.4.3 Folate and DP-MCP-PEG functionalized liposomes 
The folate receptor has been found overexpressed in a variety of cancers such as cervical, 
ovarian, breast and colorectal carcinomas [Mathias, 1998], while being limited in most 
normal tissues [Weitman, 1992]. The high affinity of folic acid for folate receptors 
provides a unique opportunity to use folic acid as a targeting ligand on the surface of 
liposomes to delivery therapeutic agents to cancer cells. 
To validate the expression of folate receptors on the human nasopharyngeal 
epidermal carcinoma cell line KB an inhibition study was carried out (Table 14 and 
Figure 35). 
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Table 14. Mol% composition of liposome formulations used for uptake studies in the human fibrosarcoma 
HT1080 cell line and human nasopharyngeal epidermal carcinoma KB cell line. 
Type of liposome DSPC 
DSPE 
-PEG 
DOPE 
-RhoB 
Cholesterol DOTAP 
DSPE-PEG- 
Folate(10) 
DP-MCP-
PEG(9) 
 
o - Folate-lipo. 
 
47 4.5 0.5 40 7.5 0.5 0 
p - Folate / DP- 
     MCP-PEG- 
     liposome 
 
47 0 0.5 40 7.5 0.5 4.5 
q - DP-MCP- 
     PEG-liposome 
 
47 0.5 0.5 40 7.5 0 4.5 
r - PEG-liposome 47 5 0.5 40 7.5 0 0 
        
 
 
All formulations used contained DOTAP. 
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Figure 35. Inhibition of liposomal uptake using free folic acid. (A) Incubation with increasing 
concentrations of free folic acid leads to a decrease in the uptake of folate-liposomes (o). (B) Incubation 
with free folic acid followed by addition of control PEG-liposomes (r) or folate-liposomes (o). All values 
are means ± SEM (n = 2). 
 
 
Increasing amounts of free folic acid inhibited the uptake of folate-liposomes (o) (Figure 
35 A), indicating the presence of folate receptors. In order to test that the free folic acid 
would not inhibit all uptake, the KB cells were treated with free folic acid followed by 
addition of control PEG-liposomes (r). The uptake of control PEG-liposomes (r) were 
unaffected by the presence of free folic acid. As a comparison, data are shown for KB 
cells with or without treatment with free folic acid followed by addition of folate-
liposomes (o) (Figure 35 B). 
The HT1080 cell line are known as folate receptor negative [Moon, 2003]; however 
they were used along with the KB cell line in order to validate, if their MMP secretion 
would have an impact on the fate of the liposomes (Figure 36). 
 
Table 15. Size and surface charge of liposomes used for uptake studies in the human fibrosarcoma HT1080 
cell line and human nasopharyngeal epidermal carcinoma KB cell line. 
Type of liposome DLS (nm) PDI Zeta (mV) Std. error (mV) 
o - folate-liposomes 95.0 0.199 -   6.26 ±   1.05 
p - folate / DP-MCP-PEG-liposomes 93.0 0.005 -   10.91 ±   0.82 
q - DP-MCP-PEG-liposomes 97.0 0.005 -   11.26 ±   0.94 
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Figure 36. Uptake in HT1080 cells (A) and KB cells (B) reported as mean fluorescence intensity (MFI) and 
percentage of cells with internalized RhoB-labeled liposomes relative to the total amount of cells measured. 
All values are means ± SEM (n = 2). 
 
 
Even though the HT1080 cell line should be folate receptor negative [Moon, 2003], the 
highest uptake in this cell line was the folate-functionalized liposomes. However, the 
internalization was not very high as can be seen from the low MFI values for all the 
liposome formulations (Figure 36 A). For the folate expressing cell line KB both 
liposome formulations containing folate (o, p) gave rise to roughly 100 percent positive 
cells within the 2 hours incubation time. Nevertheless, the mono-functionalized folate-
liposomes (o) had the highest internalization degree seen from the MFI point of view. 
This internalization degree was confirmed by confocal microscopy using the human 
nasopharyngeal epidermal carcinoma KB cell line (Figure 37). 
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Figure 37. Representative confocal microscope images showing KB cells with internalized RhoB-
liposomes. (A) folate-liposomes (o). (B) folate/DP-MCP-PEG-liposomes (p). (C) DP-MCP-PEG-liposomes 
(q). Scale bar 15 µm. 
 
 
The confocal images clearly show higher amount of fluorophore internalized in the mono-
functionalized folate-liposomes (o) compared to both dual-functionalized folate/DP-
MCP-PEG-liposomes (p) and mono-functionalized DP-MCP-PEG-liposomes (q); as 
indicated by the MFI values (Figure 36 B). For the mono-functionalized folate-liposomes 
(o) the fluorescence seemed to be located in all cytoplasm as visualized in the case of 
mono-functionalized cRGD-liposomes (j) too (Figure 33 A).  
 
To validate if the different degrees of internalization would affect the cytotoxicity of the 
liposomes, identical formulated oxaliplatin liposomes were made and their cytotoxic 
potential was evaluated (Figure 38). 
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Figure 38. HT1080 (A) and KB (B) cells treated with oxaliplatin loaded liposomes as well as free 
oxaliplatin. ▲ folate-liposomes; Δ DP-MCP-PEG-liposomes; ■ folate/DP-MCP-PEG-liposomes; ○ free 
oxaliplatin. The liposome formulations were as described in Table 14 only substituting DOPE-RhoB with 
DSPC. All values are means ± SEM (n = 2). 
 
Again it is interesting to notice that the high uptake of liposomes not necessary leads to a 
high cytotoxicity. For the mono-functionalized DP-MCP-PEG-liposomes that hardly had 
any uptake in either of the two cell lines tested, a minor cytotoxic effect can be seen, 
while for the mono-functionalized folate-liposomes that showed a major uptake no 
cytotoxicity is observed. The combination of the targeting folate ligand and the cleavable 
lipo-peptide demonstrated the highest cytotoxic effect on both cell lines of the liposomes 
tested (Figure 38), demonstrating that escape from the endosomes/lysosomes is a vital 
process in order to obtain any effect of the encapsulated drug. 
 
4.4.4 Saturated and unsaturated phospholipids 
The matrix phospholipid mainly used in these experiments was the saturated DSPC. It 
was demonstrated by Senior and Gregoriadis [Senior, 1982] that liposomes composed of 
phosphatidylcholine (PC) with saturated fatty acyl chains - as DSPC - were more stable in 
blood than liposomes composed of PC with unsaturated fatty acyl chains - as POPC. In 
addition the saturated DSPC liposomes were less permeable than their unsaturated 
counterparts and retain their drug load more efficient. Nevertheless, they have also shown 
to be rapid cleared from the bloodstream, as their inflexible membranes can result in 
packing defects [Kirby, 1980]. The incorporation of cholesterol was found to be the 
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solution to this problem, as cholesterol increases the fluidity of the membrane as well as 
the packing of phospholipid molecules [Demel, 1976]. 
Hence, for all encapsulation experiments the saturated DSPC system was utilized. 
However, unsaturated POPC formulations (Table 16) were characterized (Table 17) and 
tested as well, showing comparable encapsulation efficiency of oxaliplatin as DSPC (data 
not shown). 
 
Table 16. Mol% composition of liposome formulations used for uptake studies in the human glioblastoma 
U87MG cell line and human nasopharyngeal epidermal carcinoma KB cell line. 
Type of liposome POPC 
DSPE 
-PEG 
cholesterol DOTAP 
DSPE-PEG 
-cRGD(7) 
DSPE-PEG 
-Folate(10) 
DP-MCP 
-PEG(9) 
s - cRGD- 
     liposome 
 
47.5 4.5 40 7.5 0.5 0 0 
t - cRGD / DP- 
     MCP-PEG- 
     liposome 
47.5 0 40 7.5 0.5 0 4.5 
 
u - DP-MCP- 
      PEG- 
      liposome 
 
47.5 0.5 40 7.5 0 0 4.5 
v - folate- 
     liposome 
47.5 4.5 40 7.5 0 0.5 0 
 
w - folate / DP- 
      MCP-PEG- 
      liposome 
47.5 0 40 7.5 0 0.5 4.5 
 
 
Table 17. Size and surface charge of oxaliplatin containing liposomes used for uptake studies in the human 
glioblastoma U87MG cell line and human nasopharyngeal epidermal carcinoma KB cell line. The matrix 
phospholipid was POPC. 
Type of liposome DLS (nm) PDI Zeta (mV) Std. error (mV) 
s - cRGD-liposomes 135.5 0.005 9.31 ±   1.67 
t - cRGD / DP-MCP-PEG-liposomes 156.2 0.191 1.28 ±   1.52 
u - DP-MCP-PEG-liposomes 161.3 0.144 0.49 ±   1.71 
v - folate-liposomes 135.4 0.015 11.75 ±   1.49 
w - folate / DP-MCP-PEG-liposomes 168.7 0.161 0.10 ±   1.49 
 
When performing cytotoxicity experiments with the POPC matrix phospholipid systems 
similar cytotoxic profiles were obtained (Figure 39). 
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Figure 39. (A) U87MG cells treated with oxaliplatin loaded liposomes as well as free oxaliplatin. ▲ 
cRGD-liposomes (s); Δ DP-MCP-PEG-liposomes (u); ■ cRGD/DP-MCP-PEG-liposomes (t); ○ free 
oxaliplatin. (B) KB cells treated with oxaliplatin loaded liposomes as well as free oxaliplatin. ▲ folate-
liposomes (v); Δ DP-MCP-PEG-liposomes (u); ■ folate/DP-MCP-PEG-liposomes (w); ○ free oxaliplatin. 
The liposome formulations were as described in Table 16. All values are means ± SEM (n = 2). 
 
The cytotoxicity of the POPC based liposomal formulations was comparable to the DSPC 
formulations (Figure 30B, 34B and 38B). 
When studying the morphology of the liposomes using cryogenic transmission 
electron microscopy (cryoTEM) a difference was observed between the DSPC and POPC 
liposomal systems (Figure 40). 
 
  
Figure 40. Representative cryoTEM images of DP-MCP-PEG containing liposomes with different matrix 
phospholipids. (A) DSPC-liposomes (l / q); (B) POPC-liposomes (u). 
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The cryoTEM image of DSPC-liposomes (Figure 40 A) shows a striped morphology of 
the liposomes most possibly caused by the presence of the lipo-peptide DP-MCP-PEG. 
Striped domains have been reported as indicating a proximity to a miscibility critical 
point [Keller, 1999]. It was first reported in lipid monolayers [McConnell, 1989], but has 
later been observed in multicomponent lipid bilayers [Honerkamp-Smith, 2008] and 
lipid/protein mixtures [Lipp, 1997]. The direction of the stripes seems to direct the form 
of the liposomes and consequently they are less spherical than usually observed for 
liposomes. The POPC-liposomes are without stripes and shows a much more spherical 
form (Figure 40 B). Outside the liposomes small stripes can be observed, which can be 
assigned to free lipo-peptide not embedded in the phospholipid membrane. We have 
previously observed this trend, when using lipo-peptides (Andersen, 2011). A cryoTEM 
image gives an idea of the morphology of the studied systems; however, more 
quantitative methods should be applied to determine the amount of lipo-peptide 
embedded in the membrane relative to free lipo-peptide. 
4.5 Concluding remarks 
The aim of this study was to investigate, if the combination of a tumor targeting ligand 
and a special designed cleavable PEG peptide could enhance the uptake and cytotoxicity 
of liposomes. 
We showed by the use of a highly positive liposome formulation expressing 
octaarginine on the surface, that this charge resulted in high uptake by cells in vitro and a 
high degree of cytotoxicity. As this kind of formulation is not relevant for in vivo 
purposes we investigated other means of achieving the enhanced uptake and cytotoxicity 
observed in the octaarginine formulation.  
Liposomes with the targeting ligand cRGD was produced and tested in human 
glioblastoma and human fibrosarcoma cell lines. A large uptake was observed after just 
five hours of incubation with the liposomes as characterized by flow cytometry. However, 
the high uptake did not correlate to cytotoxicity as these liposomes showed no cytotoxic 
effect on either cell lines; despite the presence of the positive charged lipid DOTAP. 
Dual-functionalized liposomes were made expressing both the targeting moiety 
cRGD in addition to a special designed lipo-peptide with an enzyme sensitive part. By the 
use of thermolysin as model enzyme, we showed enzymatic cleavage of the peptide 
would result in removal of PEG chains and negatively charged amino residues, resulting 
in exposure of the positive charged lipids below the PEG layer. These formulations 
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showed high uptake as for the mono-functionalized cRGD-liposomes. Additionally they 
also showed high cytotoxic effect on the cells. This led us to believe that the dual-
functionalized liposomes could circumvent the PEG dilemma. The liposomal 
encapsulated content would escape the endosomes/lysosomes before degradation; by 
interacting strongly with the endosomal/lysosomal membranes after removal of the PEG 
chains and negatively charged residues. 
In addition to these studies we tested if the cleavable lipo-peptide would provide 
similar results with a different targeting ligand than cRGD or, when embedded into a 
mono-unsaturated phospholipid membrane. The folate receptor targeting ligand was 
utilized as targeting agent and tested with and without the lipo-peptide present in the 
liposomes, on a human fibrosarcoma cell line and a human nasopharyngeal epidermal 
carcinoma cell line. Both the mono- and dual-functionalized liposomes showed a high 
uptake, but as in the previous experiments only the dual-functionalized formulation 
resulted in cytotoxicity. 
The mono- and dual-functionalized liposomes formulated from the unsaturated 
phospholipid POPC showed cytotoxic curves very alike to the ones observed when using 
a saturated phospholipid as matrix phospholipid. However, their morphology visualized 
in cryoTEM was quite different and emphasized the importance of utilizing multiple 
characterizations methods. 
These studies have shown that by removing the protective PEG layer from the 
liposome surface, uncovering positively charged lipids an enhanced effect of 
encapsulated drugs can be achieved. The targeting moieties have proved to be important 
in order to improve cytotoxicity, but their real potential can not be established, before 
going in vivo, where their ability to increase specific drug delivery to cancerous tissue can 
be elucidated. 
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Chapter 5  
Concluding remarks and perspective 
An immense amount of research is invested in the drug delivery field today. Especially, 
the cancer research field is attracting much attention, as this devastating disease is the 
second leading cause of death every year. Since the liposomes were suggested as drug 
carrier candidates, these have been intensively investigated and many attempts have been 
made to optimize the use of these for chemotherapeutic treatments. Their ability to hold 
cytotoxic drugs in their lumen in addition to their potential to passively accumulate in 
diseased tissues makes them highly interesting. With some degree of success active 
targeting of liposomes has been investigated as a route to improve specificity and 
accumulation in selective tissues. 
 
This thesis covered three different aspects of the use of liposomes as targeted drug 
delivery systems. 
 
The first part included the actual synthetic approaches to obtain targeted liposomes. Many 
methods have been applied over the years. Several important things need to be 
considered, when designing a targeted liposomal system for in vivo use. Preferably, the 
synthetic approach chosen should be able to proceed under mild conditions; it should be 
fast, reproducible and result in non-toxic and non-immunogenic chemical bonds. It should 
be considered how to determine the degree of functionalization as not all reported 
methods are quantitative. We introduced in this section a new conjugation method which 
utilized the binding forming ability between a hydroxylamine and an aldehyde. This 
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resulted in fast and quantitative reactions when performed in solution as well as on the 
surface of pre-formed liposomes.  
It is important to continue the development of new synthetic procedures, which 
perform well in aqueous buffers without toxic additives, as for instance metallic catalysts. 
 
The second part of this thesis aimed to elucidate the in vitro and in vivo efficiency of 
active targeting. In vitro, this was done by the use of fluorescent liposomes, whose uptake 
in cells could be monitored visually by confocal microscopy and quantitatively by flow 
cytometry. Targeted liposomes showed a clear superior uptake compared to two different 
formulations of control liposomes. For in vivo studies a remote loading technique was 
applied to manufacture radioactive labeled liposomes, which could be tracked in vivo by 
the use of positron emission tomography. These results were greatly interesting as a 
different profile could clearly be visualized for the targeted liposomes compared to the 
two formulations of control liposomes; both in regard to accumulation profile and 
clearance profile. Despite, higher clearance of the targeted liposomes by the spleen and 
liver, an equivalent uptake in tumor tissue was observed.  
We believe that the radiolabeled liposomes will be a valuable tool for investigating 
the biodistribution of targeted drug delivery, as this technique can provide a quantitative 
image of the actual effect of the targeting moiety. 
 
The third and last part of this thesis covered the combination of two functionalities on the 
surface of liposomes. One functionality should target the liposomes to diseased tissue, 
while the other functionality should function as a combined enhancer of internalization 
and drug escape. It became clear in this section that a high uptake is not enough to obtain 
efficacy of the drug containing liposomal system. Despite the presence of cationic 
charges on the surface of the applied liposomes, these did not show sufficient interaction 
with the endosomal/lysosomal membranes to induce any drug release and cytotoxic 
effect. To obtain sufficient interaction the shielding PEG layer needed to be removed; 
which was facilitated by a special synthesized lipo-peptide. Greater cytotoxicity was 
observed for two different targeting moieties, each in combination with the removable 
PEG moiety, than for mono-functionalized systems expressing targeting moieties or 
removable PEG lipo-peptide on their own. 
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Future studies in this field should investigate the in vivo biodistribution and 
cytotoxic effect of this dual-functionalized system; e.g. by application of the radiolabeled 
technique described above. 
 
Overall the work presented in this thesis emphasize the importance of acquiring 
knowledge at more than one level - synthetic and biological - before being able to design 
novel efficient targeted drug delivery systems. 
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ABSTRACT: We present here a highly eﬃcient and chemoselective liposome functionalization method based on oxime bond
formation between a hydroxylamine and an aldehyde-modiﬁed lipid component. We have conducted a systematic and
quantitative comparison of this new approach with other state-of-the-art conjugation reactions in the ﬁeld. Targeted liposomes
that recognize overexpressed receptors or antigens on diseased cells have great potential in therapeutic and diagnostic
applications. However, chemical modiﬁcations of nanoparticle surfaces by postfunctionalization approaches are less eﬀective than
in solution and often not high-yielding. In addition, the conjugation eﬃciency is often challenging to characterize and therefore
not addressed in many reports. We present here an investigation of PEGylated liposomes functionalized with a neuroendocrine
tumor targeting peptide (TATE), synthesized with a variety of functionalities that have been used for surface conjugation of
nanoparticles. The reaction kinetics and overall yield were quantiﬁed by HPLC. Reactions were conducted in solution as well as
by postfunctionalization of liposomes in order to study the eﬀects of steric hindrance and possible aﬃnity between the peptide
and the liposome surface. These studies demonstrate the importance of choosing the correct chemistry in order to obtain a
quantitative surface functionalization of liposomes.
■ INTRODUCTION
Functional nanomaterials have attracted considerable attention
due to their highly interesting properties in relation to
diagnostic,1−3 sensor,4,5 imaging,6,7 vaccine,8 and drug delivery
applications.9,10 Within the drug delivery ﬁeld, liposomes have
particularly advantageous properties.11 However, despite
positive results obtained by exploiting the EPR-eﬀect,12
numerous methods to improve drug bioavailability in the
diseased tissue, while maintaining stable liposomes during
circulation, is currently being investigated. By coating the
liposome surfaces with targeting ligands such as antibodies,13,14
peptides,15 proteins,16 polysaccharides,17 lectins,18 and vitamin
analogues,19,20 which are recognized by antigens or receptors
selectively, or overexpressed in, e.g., tumor tissue, increased
drug accumulation in tumors can be achieved. Numerous
bioconjugation methods have been established to surface-
modify liposomes with targeting ligands to enhance tissue
speciﬁcity. To ensure correct orientation of the targeting ligand,
bioorthogonal and site-speciﬁc surface reactions are required.
By the incorporation of unnatural amino acids in peptide or
protein sequences,21 introduction of unnatural functional
groups such as maleimides for Michael addition, azides for
copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition22−24
(CuAAC) or Staudinger ligation using triphosphines,25,26
controlled display of surface ligands can be obtained.
Unfortunately, ligand conjugation to the surface of nano-
particles can suﬀer from low reproducibility and highly varying
yields; e.g., we have previously found that it can be very diﬃcult
to control the Michael addition of a somatostatin receptor
targeting peptide (TATE) to a lipid moiety, even though the
maleimide-based Michael addition is one of the most utilized
conjugation chemistries for peptides and proteins.27,28 As a
consequence hereof, we have conducted a systematic study on a
variety of generally applied conjugation reactions using HPLC
as a method to follow and quantify the reactions both in
solution and by direct conjugation to the liposomal surface.
Reactions conducted directly on liposome surfaces are likely
not to show the same reaction kinetics as ones preformed in
Received: September 8, 2012
Revised: October 24, 2012
Published: November 16, 2012
Article
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solution, and the yield of functionalization will not necessarily
be quantitative and has to be determined case by case.
In this study, we furthermore introduce a novel highly
selective and bioorthogonal conjugation reaction relevant for
the surface functionalization of liposomes. We show a fast and
quantitative coupling of a hydroxylamine functionalized peptide
to an aldehyde-modiﬁed liposome, a strategy for coating
liposomes, which to our knowledge has not previously been
reported. In addition, we show a large dependency on the
relative position of the conjugation functionalities. A knowledge
which we believe is highly useful when designing new
functionalized liposomal systems or other functional nanoma-
terials.
■ EXPERIMENTAL PROCEDURES
Synthesis of Functionalized TATE Peptides. The
functionalized TATE peptides 1a−e were synthesized manually
by using a Wang Resin preloaded with NH2-Thr(tBu)-OH by
standard Fmoc methodology. Each coupling was performed by
activating the Fmoc protected amino acid with O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuor-
ophosphate (HATU) in the presence of 2,4,6-collidine in
DMF. Cleavage of the Fmoc group was carried out using
piperidine in DMF. Completion of each coupling and
deprotection step was monitored by the Kaiser test. Removal
of the acetamidomethyl (Acm) protection groups on the two
cysteines and simultaneous disulﬁde bond formation was
achieved by addition of Tl(CF3COO)3 in DMF. The resin
containing the cyclized peptide was extensively washed with
DMF and subsequently divided into ﬁve solid-phase peptide
synthesis (SPPS) reaction vials in which the N-terminal was
acylated with the desired functionality, cleaved from the solid
support, and puriﬁed by HPLC. Full experimental details and
peptide characterization are available as Supporting Informa-
tion.
Synthesis of Functionalized DSPE-PEG2000 Phospholi-
pids. Functionalized DSPE-PEG2000 phospholipids 2a−d were
synthesized in a single step from DSPE-PEG2000-NH2 by
acylation of the amino group with the desired functionality in
the presence of either HATU or EDC·HCl. Phospholipid 3 was
synthesized in a single step from DSPE-PEG2000-PDP by
reduction by dithiothreitol (DTT). Full experimental details
and lipid characterization are available as Supporting
Information.
Liposome Formulation. Lipids were dissolved in CH3Cl/
MeOH (9:1) and mixed in the ratio 95:4:1 DSPC/DSPE-
PEG2000/DSPE-PEG2000-R (R being the diﬀerent functional
groups illustrated in Schemes 2 and 3). The solvent was
removed under a stream of nitrogen and the ﬁlms placed under
vacuum overnight to remove remaining traces of organic
solvent. The obtained ﬁlms were hydrated in a Hepes buﬀer,
(10 mM Hepes, pH 6.5, 145 mM NaCl) at 65 °C for 1 h;
followed by 10 freeze−thaw cycles and extrusion at 65 °C
through a 100 nm polycarbonate ﬁlter using an Avanti Polar
Lipids mini-extruder. The size distribution of the liposomes was
analyzed using dynamic light scattering, as well as their zeta
potential using a Brookhaven Zeta PALS analyzer. All sizes
were 100−120 nm and all zeta potentials were slightly negative
(approximately −5 mV).
Conjugation in Solution. DSPE-PEG2000 functionalized
lipid (0.2 mM, 0.55 mL, 1.1 equiv.) was dissolved in MeOH
and mixed with the corresponding functionalized TATE in
MeOH (0.2 mM, 0.50 mL, 1.0 equiv.). The reaction was stirred
at room temperature and aliquots (50 μL) were removed at the
indicated times and analyzed by analytical HPLC. A linear
gradient was used from 100% A (aqueous solution containing
5% MeCN and 0.1% TFA) to 100% B (MeCN containing 0.1%
TFA) over 15 min with a ﬂow rate of 1 mL/min and AUC for
the free TATE was measured relative to AUC for the coupled
product at 280 nm. For the reaction between the maleimide
and thiol functionalities Et3N (50 mM, 6.0 μL, 3.0 equiv.) was
added to facilitate the coupling, while for the copper catalyzed
click reactions CuSO4·5H2O (1.0 M, 2.5 μL, 25 equiv.) and
sodium ascorbate (1.0 M, 5.0 μL, 50 equiv.) were added. Before
injecting the aliquots from the copper catalyzed click reactions
onto the analytical HPLC column 20 μL of a 10% NH4OH
solution was added to ensure the copper ions were in solution
and not interfering with the HPLC signals.29
Conjugation by Post-Functionalization of Liposomes.
Preformed functionalized liposomes ((25 mM, 0.50 mL, 1.1
equiv.) - normalized according to a 45:55 distribution ratio
between the inner- and outer liposomal membrane) were
mixed with the corresponding TATE peptide (4.2 mM, 15 μL,
1.0 equiv.) dissolved in MeOH. The reactions were shaken (not
stirred; to avoid foaming) at room temperature and aliquots
(40 μL) removed for analysis by analytical HPLC. A linear
gradient was used from 100% A (aqueous solution containing
5% MeCN and 0.1% TFA) to 100% B (MeCN containing 0.1%
TFA) over 15 min with a ﬂow rate of 1 mL/min. The AUC for
the free TATE was calculated relative to the AUC of the
phospholipid coupled product at 280 nm to monitor the
conjugation eﬃciency. For t e copper catalyzed click rea tio s
CuSO4·5H2O (1.0 M, 1.6 μL, 25 equiv.) and sodium ascorbate
(1.0 M, 3.1 μL, 50 equiv.) were added. As for the conju ations
done in solutio 20 μL of a 10% NH4OH solution was added
t the copper catalyzed click aliquots prior to HPLC analysis.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. The model peptides
1a−1e for somatostatin receptor targeting30 were prepared
using a SPPS strategy as shown in Scheme 1.31 The N-terminal
functionalized TATE peptides 1a−e were synthesized by SPPS
on H-Thr(tBu)-OH preloaded Wang Resin. Acylation of the N-
terminal of the peptide was achieved by activating the Fmoc-
protected amino acid with HATU to ensure high conversion
with minimum epimerization. After assembly of the resin
immobilized octapeptide, H-D-Phe-Cys(Acm)-Tyr(tBu)-D-Trp-
(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu)-resin, the pep-
tide was treated with Tl(CF3COO)3, whic in a single step
removed the two Acm-pr tection groups present on the
cysteine r sidues and fo med the intramolecular disulﬁde bond.
The reaction was follow d by cleavage of a small mount of
peptid from the resin with TFA and anal zing the crude
peptid by MALDI-TOF MS. Complete Acm-re oval and
disulﬁde formation were observed after 75 min wi h o sign of
dimerization. Aft extensive washing of the resin, the N-
terminal was acy ated with the desired carboxylic acid
functionalized linker derivatives and cleaved from the s lid
support by treatment with a mixture of TFA/H2O/TIS
(95:2.5:2.5) to give the esired fu ctionalized TATE peptides
1a−e. Final puriﬁcation of the peptides was accomplished by
HPLC and the obtained products 1a−e characterized by
MALDI-TOF MS (Table 1). In order to formulate liposomes
exposing the appropriate chemical functionalities at the distal
end of the PEG-corona, PEGylated phospholipids with the
desired functionalities were synthesized from either DSPE-
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■ INTRODUCTION
Functional nanomaterials have attracted considerable attention
due to their highly interesting properties in relation to
diagnostic,1−3 sensor,4,5 imaging,6,7 vaccine,8 and drug delivery
applications.9,10 Within the drug delivery ﬁeld, liposomes have
particularly advantageous properties.11 However, despite
positive results obtained by exploiting the EPR-eﬀect,12
numerous methods to improve drug bioavailability in the
diseased tissue, while maintaining stable liposomes during
circulation, is currently being investigated. By coating the
liposome surfaces with targeting ligands such as antibodies,13,14
peptides,15 proteins,16 polysaccharides,17 lectins,18 and vitamin
analogues,19,20 which are recognized by antigens or receptors
selectively, or overexpressed in, e.g., tumor tissue, increased
drug accumulation in tumors can be achieved. Numerous
bioconjugation methods have been established to surface-
modify liposomes with targeting ligands to enhance tissue
speciﬁcity. To ensure correct orientation of the targeting ligand,
bioorthogonal and site-speciﬁc surface reactions are required.
By the incorporation of unnatural amino acids in peptide or
protein sequences,21 introduction of unnatural functional
groups such as maleimides for Michael addition, azides for
copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition22−24
(CuAAC) or Staudinger ligation using triphosphines,25,26
controlled display of surface ligands can be obtained.
Unfortunately, ligand conjugation to the surface of nano-
particles can suﬀer from low reproducibility and highly varying
yields; e.g., we have previously found that it can be very diﬃcult
to control the Michael addition of a somatostatin receptor
targeting peptide (TATE) to a lipid moiety, even though the
maleimide-based Michael addition is one of the most utilized
conjugation chemistries for peptides and proteins.27,28 As a
consequence hereof, we have conducted a systematic study on a
variety of generally applied conjugation reactions using HPLC
as a method to follow and quantify the reactions both in
solution and by direct conjugation to the liposomal surface.
Reactions conducted directly on liposome surfaces are likely
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solution, and the yield of functionalization will not necessarily
be quantitative and has to be determined case by case.
In this study, we furthermore introduce a novel highly
selective and bioorthogonal conjugation reaction relevant for
the surface functionalization of liposomes. We show a fast and
quantitative coupling of a hydroxylamine functionalized peptide
to an aldehyde-modiﬁed liposome, a strategy for coating
liposomes, which to our knowledge has not previously been
reported. In addition, we show a large dependency on the
relative position of the conjugation functionalities. A knowledge
which we believe is highly useful when designing new
functionalized liposomal systems or other functional nanoma-
terials.
■ EXPERIMENTAL PROCEDURES
Synthesis of Functionalized TATE Peptides. The
functionalized TATE peptides 1a−e were synthesized manually
by using a Wang Resin preloaded with NH2-Thr(tBu)-OH by
standard Fmoc methodology. Each coupling was performed by
activating the Fmoc protected amino acid with O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuor-
ophosphate (HATU) in the presence of 2,4,6-collidine in
DMF. Cleavage of the Fmoc group was carried out using
piperidine in DMF. Completion of each coupling and
deprotection step was monitored by the Kaiser test. Removal
of the acetamidomethyl (Acm) protection groups on the two
cysteines and simultaneous disulﬁde bond formation was
achieved by addition of Tl(CF3COO)3 in DMF. The resin
containing the cyclized peptide was extensively washed with
DMF and subsequently divided into ﬁve solid-phase peptide
synthesis (SPPS) reaction vials in which the N-terminal was
acylated with the desired functionality, cleaved from the solid
support, and puriﬁed by HPLC. Full experimental details and
peptide characterization are available as Supporting Informa-
tion.
Synthesis of Functionalized DSPE-PEG2000 Phospholi-
pids. Functionalized DSPE-PEG2000 phospholipids 2a−d were
synthesized in a single step from DSPE-PEG2000-NH2 by
acylation of the amino group with the desired functionality in
the presence of either HATU or EDC·HCl. Phospholipid 3 was
synthesized in a single step from DSPE-PEG2000-PDP by
reduction by dithiothreitol (DTT). Full experimental details
and lipid characterization are available as Supporting
Information.
Liposome Formulation. Lipids were dissolved in CH3Cl/
MeOH (9:1) and mixed in the ratio 95:4:1 DSPC/DSPE-
PEG2000/DSPE-PEG2000-R (R being the diﬀerent functional
groups illustrated in Schemes 2 and 3). The solvent was
removed under a stream of nitrogen and the ﬁlms placed under
vacuum overnight to remove remaining traces of organic
solvent. The obtained ﬁlms were hydrated in a Hepes buﬀer,
(10 mM Hepes, pH 6.5, 145 mM NaCl) at 65 °C for 1 h;
followed by 10 freeze−thaw cycles and extrusion at 65 °C
through a 100 nm polycarbonate ﬁlter using an Avanti Polar
Lipids mini-extruder. The size distribution of the liposomes was
analyzed using dynamic light scattering, as well as their zeta
potential using a Brookhaven Zeta PALS analyzer. All sizes
were 100−120 nm and all zeta potentials were slightly negative
(approximately −5 mV).
Conjugation in Solution. DSPE-PEG2000 functionalized
lipid (0.2 mM, 0.55 mL, 1.1 equiv.) was dissolved in MeOH
and mixed with the corresponding functionalized TATE in
MeOH (0.2 mM, 0.50 mL, 1.0 equiv.). The reaction was stirred
at room temperature and aliquots (50 μL) were removed at the
indicated times and analyzed by analytical HPLC. A linear
gradient was used from 100% A (aqueous solution containing
5% MeCN and 0.1% TFA) to 100% B (MeCN containing 0.1%
TFA) over 15 min with a ﬂow rate of 1 mL/min and AUC for
the free TATE was measured relative to AUC for the coupled
product at 280 nm. For the reaction between the maleimide
and thiol functionalities Et3N (50 mM, 6.0 μL, 3.0 equiv.) was
added to facilitate the coupling, while for the copper catalyzed
click reactions CuSO4·5H2O (1.0 M, 2.5 μL, 25 equiv.) and
sodium ascorbate (1.0 M, 5.0 μL, 50 equiv.) were added. Before
injecting the aliquots from the copper catalyzed click reactions
onto the analytical HPLC column 20 μL of a 10% NH4OH
solution was added to ensure the copper ions were in solution
and not interfering with the HPLC signals.29
Conjugation by Post-Functionalization of Liposomes.
Preformed functionalized liposomes ((25 mM, 0.50 mL, 1.1
equiv.) - normalized according to a 45:55 distribution ratio
between the inner- and outer liposomal membrane) were
mixed with the corresponding TATE peptide (4.2 mM, 15 μL,
1.0 equiv.) dissolved in MeOH. The reactions were shaken (not
stirred; to avoid foaming) at room temperature and aliquots
(40 μL) removed for analysis by analytical HPLC. A linear
gradient was used from 100% A (aqueous solution containing
5% MeCN and 0.1% TFA) to 100% B (MeCN containing 0.1%
TFA) over 15 min with a ﬂow rate of 1 mL/min. The AUC for
the free TATE was calculated relative to the AUC of the
phospholipid coupled product at 280 nm to monitor the
conjugation eﬃciency. For the copper catalyzed click reactions
CuSO4·5H2O (1.0 M, 1.6 μL, 25 equiv.) and sodium ascorbate
(1.0 M, 3.1 μL, 50 equiv.) were added. As for the conjugations
done in solution 20 μL of a 10% NH4OH solution was added
to the copper catalyzed click aliquots prior to HPLC analysis.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. The model peptides
1a−1e for somatostatin receptor targeting30 were prepared
using a SPPS strategy as shown in Scheme 1.31 The N-terminal
functionalized TATE peptides 1a−e were synthesized by SPPS
on H-Thr(tBu)-OH preloaded Wang Resin. Acylation of the N-
terminal of the peptide was achieved by activating the Fmoc-
protected amino acid with HATU to ensure high conversion
with minimum epimerization. After assembly of the resin
immobilized octapeptide, H-D-Phe-Cys(Acm)-Tyr(tBu)-D-Trp-
(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu)-resin, the pep-
tide was treated with Tl(CF3COO)3, which in a single step
removed the two Acm-protection groups present on the
cysteine residues and formed the intramolecular disulﬁde bond.
The reaction was followed by cleavage of a small amount of
peptide from the resin with TFA and analyzing the crude
peptide by MALDI-TOF MS. Complete Acm-removal and
disulﬁde formation were observed after 75 min with no sign of
dimerization. After extensive washing of the resin, the N-
terminal was acylated with the desired carboxylic acid
functionalized linker derivatives and cleaved from the solid
support by treatment with a mixture of TFA/H2O/TIS
(95:2.5:2.5) to give the desired functionalized TATE peptides
1a−e. Final puriﬁcation of the peptides was accomplished by
HPLC and the obtained products 1a−e characterized by
MALDI-TOF MS (Table 1). In order to formulate liposomes
exposing the appropriate chemical functionalities at the distal
end of the PEG-corona, PEGylated phospholipids with the
desired functionalities were synthesized from either DSPE-
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PEG2000-NH2 or DSPE-PEG2000-PDP as illustrated in Schemes
2 and 3. PEGylated phospholipids exposing a terminal alkyne, a
cyclic alkyne, an aldehyde, or an azide functionality at the distal
end of the polymer (2a−d) were synthesized by acylating
DSPE-PEG2000-NH2 with 4-pentynoic acid, 1-ﬂuorocyclooct-2-
ynecarboxylic acid, 4-carboxybenzaldehyde, or 5-azidopentanoic
acid, respectively. 1-Fluorocyclooct-2-ynecarboxylic acid was
synthesized as described elsewhere.32 DSPE-PEG2000-SH (3)
was synthesized in a single step from DSPE-PEG2000-PDP by
reduction of the pyridyldithiopropionate (PDP) group by DTT
applying standard conditions33 which resulted in the desired
free thiol (Scheme 3). The DSPE-PEG2000-maleimide (4)
functionalized phospholipid was purchased from Avanti Polar
Lipids, Inc., Alabama.
In order to evaluate the eﬃciency of the diﬀerent coupling
strategies and make a valid comparison, a standardized protocol
was used to minimize the inﬂuence of other parameters.
Functionalized liposomes composed of DSPC/DSPE-PEG2000/
DSPE-PEG2000-R (95:4:1) (R = alkyne (2a), cycloalkyne (2b),
aldehyde (2c), azide (2d), thiol (3), or maleimide (4)) were
prepared by the method described by Bangham and co-
workers.34 The lipid components were dissolved in a mixture of
CHCl3/MeOH (9:1), and the solvent was removed to form a
transparent lipid ﬁlm. The lipid ﬁlm was hydrated in HEPES-
buﬀer (pH 6.5) at 65 °C and extruded through 100 nm
polycarbonate ﬁlters to form liposomes in the 100 nm range.
The liposomes were characterized by dynamic light scattering
(DLS), and the ζ-potentials were measured to ensure that
liposomes were formed. All liposomes had a diameter of
approximately 100 nm and slightly negative ζ-potential due to
the presence of the DSPE-PEG2000 lipids. Postfunctionalization
was carried out by adding the required components for the
individual reactions (e.g., CuSO4·5H2O and sodium ascorbate
for the CuAAC reaction), followed by addition of the required
functionalized TATE peptide 1a−e (1 equiv peptide to 1.1
equiv of the functionalized lipid component) in MeOH.
Postfunctionalization reactions were carried out at room
temperature and carefully mixed using a plate shaker.
Scheme 1. Synthesis of the TATE-Derivatives 1a−1e
Table 1. Chemical Structure of R-COOH Used for Synthesis
of TATE Derivatives 1a−1e and Corresponding
Characterization by MALDI TOF MS
Scheme 2. Synthesis of the DSPE-PEG2000-NH2 Modiﬁed
Phospholipids 2a−d
Scheme 3. Synthesis of the DSPE-PEG2000-SH (3)
Functionalized Phospholipid
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For the conjugation reactions in solution, functionalized
phospholipids (1.1 equiv) and functionalized TATE peptides
(1 equiv) were dissolved in methanol, mixed with the required
additives to facilitate reaction, as described in the Experimental
Procedures, and stirred at room temperature. Triplicates of all
reactions were carried out to ensure reproducibility and
elucidate the heterogeneity of liposomal postfunctionalization.
The amount of functionalized TATE added in the two
conjugation approaches was carefully controlled by measuring
the concentration of the peptide stock solution by UV−vis, thus
ensuring exactly the same peptide concentration in all reactions.
To ensure the same total concentration of phospholipids in all
reactions, phosphorus content measurement was carried out by
ICP-AES. All reactions were monitored for 24 h by HPLC
using UV-detection (λ = 280 nm), and up to 72 h in selected
cases, by removing small aliquots from the reaction vial, and the
conjugation eﬃciency was calculated based on the area under
the curve (AUC) for the free peptide and the DSPE-PEG2000-
TATE conjugate, respectively (Figure 1). MALDI-TOF MS
was used to verify that an excess of the functionalized
phospholipids reagent existed in all reactions that did not go
to completion within 72 h.
Conjugation of TATE and DSPE-PEG2000 by Oxime
Formation. This method, which has not previously been
reported for the surface functionalization of liposomes, is
chemoselective and bioorthogonal to functional groups in most
natural occurring ligands and could serve as an excellent
alternative to existing liposome postfunctionalization meth-
ods.35 TATE-hydroxylamine (1e) and DSPE-PEG2000-benzal-
dehyde (2c) were conjugated, both in solution and on the
liposome surface, by simply mixing the two components
without any additives. Oxime bond formation in solution was
found to be quantitative within one hour, whereas eight hours
of incubation was needed once performed directly on the
liposome surface (Figure 2). Both procedures resulted in
complete conversion to the phospholipid coupled TATE within
24 h under mild conditions.
Oxime bond formation is known to be accelerated by the
presence of aniline,36 acetic acid,37 or Lewis acids.38 In order to
verify this, acetic acid (0.1% v/v) was added to a liposome
batch containing TATE-hydroxylamine (1e). Under these
conditions, the conjugation yield reached 78% within 5 min.
Without the presence of the catalyst, 30% conversion was
observed within the same time frame. The oxime bond
formation is a reversible process; however, HPLC and
MALDI TOF MS did not show any reversible formation of
the starting materials within one week in aqueous medium,
which supports the reporting of oxime bonds to be more
hydrolytically stable than, e.g., its analogous hydrazine bond at
physiologically relevant pH.39 The position of these two
functional groups is not interchangeable, as placing the
aldehyde functionality on TATE will induce the risk of
intramolecular imine formation.
Conjugation of TATE and DSPE-PEG2000 by CuAAC. An
often applied procedure for nanoparticle functionalization is the
CuAAC reactioncommonly referred to as the Click
Reaction.22−24 Conjugation of TATE and DSPE-PEG2000 by
the CuAAC reaction was carried out using sodium ascorbate to
generate CuI from CuSO4·5H2O in situ. Reactions were carried
out with the azide present on the TATE peptide, the alkyne at
the PEG terminal of DSPE-PEG2000, and vice versa. The relative
position of the functional moieties was found to have no
signiﬁcant eﬀect on the reaction eﬃcacy under the solution
conditions, as both orientations result in approximately 98%
yield after 12 h (Figure 3). A diﬀerent result was obtained when
monitoring the postfunctionalization reaction on the liposome
surface. The cycloaddition between the azide-functionalized
TATE (1c) and the alkyne-modiﬁed phospholipid (2a)
resulted in about 75% yield after 2 h, while the opposite
position having the azide functionality present on the liposomes
and the alkyne at the N-terminal of the peptides leveled out at
43% (Figure 3).
Functionalization of azide-modiﬁed liposomes by the
CuAAC reaction has not previously been reported elsewhere
to our knowledge. Functionalization of liposomes by the
CuAAC reaction has consistently been carried out with alkyne-
modiﬁed liposomes and azide-functionalized ligands; thus,
these reports have not observed the clear negative trend
observed here with the azide-functionalized liposomes.
Furthermore, removing the copper fully from the ﬁnal product
to avoid copper induced cytotoxicity can be challenging, which
Figure 1. Example of the monitoring of a conjugation reaction by
HPLC over time at 280 nm. The decreasing peak at 8.5 min belongs to
the free TATE-maleimide (1a), while the peak increasing at 15.6 min
is the product from the Michael addition between TATE-maleimide
(1a) and DSPE-PEG2000-SH (3).
Figure 2. Conjugation of DSPE-PEG2000 and TATE by oxime bond
formation. Reactions carried out in solution and directly on the
liposome surface. TATE-hydroxylamine (1e) + DSPE-PEG2000-
benzaldehyde (2c) in solution (○), TATE-hydroxylamine (1e) +
DSPE-PEG2000-benzaldehyde (2c) on liposomes (□). All values are
means ± SEM (n = 3).
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to some degree reduces the usability of this reaction for
biological purposes.
Conjugation of TATE and DSPE-PEG2000 by Cu-Free
Click Chemistry. A method to avoid addition of toxic copper
salts as catalyst in the triazole formation is to use strained or
electron-deﬁcient alkynes.40,41 This strategy was studied using
the DSPE-PEG2000-cyclooctyne (2b) and azide-functionalized
TATE (1c). In solution, the conjugation was remarkably slow,
yet highly reliable and reproducible with no form of
decomposition or side product formation. As the reaction
was terminated after 50 days, a product yield of 86% was
obtained without reaching a plateau. Applying the post-
functionalization protocol resulted in a remarkably faster initial
reaction (Figure 4), and a level of 84% yield was reached after
72 h.
Interestingly, triazole formation was signiﬁcantly faster when
performed on liposome surfaces compared to the reaction in
solution. This is presumably due to favorable interactions
between the liposome surface and TATE-azide (1c). As TATE-
azide (1c) is not highly soluble in the buﬀer, it prefers to bind
to the PEG layer, bringing it closer to the reaction sites on the
surface, which leads to a faster reaction. Choosing a more
reactive cyclooctyne could not only increase the reaction rate in
solution, but also increase the risk of side product
formation.42,43 However, a relatively long synthetic procedure
to obtain the cyclooctyne moiety limits the use of this type of
copper-free click reaction. Furthermore, it has been shown that
thiols can add spontaneously to cyclooctynes limiting the
bioorthogonality, as some degree of nonspeciﬁc reactions can
occur.44
Conjugation of TATE and DSPE-PEG2000 by Michael
Addition. The ﬁnal approach tested to conjugate TATE and
DSPE-PEG2000 was using the Michael addition procedure. In
general, the Michael addition proceeded rapidly within the ﬁrst
four hours until reaching a plateau, and reactions carried out in
solution were slightly faster compared to the liposomal
counterpart. The orientation of the maleimide and the thiol
was found to have a decisive impact on the conjugation
eﬃciency. Michael addition in solution between DSPE-
PEG2000-SH (3) and TATE-maleimide (1a) resulted in 97%
conversion, whereas when performed on the liposome surface,
92% conversion was observed. The opposite orientation of
functionalities expressed in the form of DSPE-PEG2000-
maleimide (4) and TATE-thiol (1b) only resulted in 53%
product formation when performed in solution and 40% for the
postfunctionalization of liposomes (Figure 5), which was
surprising. The origin for this observation is not clear, however;
multiple factors could have caused this drop in conversion.
Hydrolysis of the maleimide moiety to the nonreactive
maleamic acid at pH > 8.5 has been reported in the literature,45
but at pH 6.5 where our reactions are carried out, this should be
minimized.46,47 This was conﬁrmed by MALDI-TOF MS where
intact DSPE-PEG2000-maleimide as well as unreacted TATE-SH
was observed. However, a minor amount of methoxy-
substituted maleimide was also observed by MALDI-TOF
MS indicating that the oxa-Michael addition is a competing side
Figure 3. Conjugation of DSPE-PEG2000 and TATE by the CuAAC
reaction. Reactions carried out in solution and directly on the liposome
surface. TATE-azide (1c) + DSPE-PEG2000-alkyne (2a) in solution
(○), TATE-azide (1c) + DSPE-PEG2000-alkyne (2a) on liposomes
(□), TATE-alkyne (1d) + DSPE-PEG2000-azide (2d) in solution (◊),
TATE-alkyne (1d) + DSPE-PEG2000-azide (2d) on liposomes (Δ). All
values are means ± SEM (n = 3).
Figure 4. Conjugation of DSPE-PEG2000 and TATE by strain-
promoted Click reaction. Reactions were carried out in solution and
directly on the liposome surface. TATE-azide (1c) + DSPE-PEG2000-
cyclooctyne (2b) in solution (○), TATE-azide (1c) + DSPE-PEG2000-
cyclooctyne (2b) on liposomes (□). All values are means ± SEM (n =
3).
Figure 5. Conjugation of DSPE-PEG2000 and TATE by Michael
addition. Reactions carried out in solution and directly on the
liposome surface. TATE-maleimide (1a) + DSPE-PEG2000-SH (3) in
solution (○), TATE-maleimide (1a) + DSPE-PEG2000-SH (3) on
liposomes (□), TATE-thiol (1b) + DSPE-PEG2000-maleimide (4) in
solution (◊), TATE-thiol (1b) + DSPE-PEG2000-maleimide (4) on
liposomes (Δ). All values are means ± SEM (n = 3).
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reaction.48 As poor conversion was observed for the reaction
carried out in solution as well as on the surface, we speculated
that the TATE-thiol (1b) peptide was the limiting factor in this
reaction. TATE-thiol (1b) is highly prone to oxidation resulting
in nonreactive TATE-dimers; however, dimerization was not
observed by HPLC or by MALDI-TOF MS. As a positive
control of the reactivity of the commercial DSPE-PEG2000-
maleimide (4), a test reaction using 2-mercaptoethanol was
conducted. Using this small and highly reactive thiol, complete
product formation was observed within two hours as conﬁrmed
by MALDI-TOF MS, conﬁrming excellent reactivity of DSPE-
PEG2000-maleimide (4). Hence, the reason for the low coupling
eﬃciency between DSPE-PEG2000-maleimide (4) and TATE-
SH (1b) is not clear.
■ CONCLUSION
In conclusion, a novel highly eﬀective method to functionalize
liposomes by postfunctionalization as well as under solution
conditions has been introduced in the form of an oxime bond
formation between an aldehyde and a hydroxylamine. This
conjugation is chemoselective and bioorthogonal to functional
groups in most naturally occurring relevant ligands, and based
on our investigations, it could serve as an excellent alternative
to existing liposome postfunctionalization methods.
In addition, a systematic study has been conducted to
elucidate the optimal postfunctionalization chemistry with
focus on the relative position of the reactive functionalities.
In general, the reactions carried out directly on the surface of
the functionalized liposomes were slower than the solution-
phase counterpart, except for the strain-promoted Click
reaction, which surprisingly showed the opposite trend. Despite
of possible heterogeneities of liposomal formulations, surface
conjugation reactions were, in general, highly reproducible. The
relative position of the reactive functionalities was found to
have a signiﬁcant impact on the degree of conversion for the
Michael addition and the CuAAC reaction. The Michael
addition was found to be most eﬀective when the nucleophilic
thiol was present at the distal end of the PEG polymer
compared to the N-terminal of TATE. A similar observation
was observed for the CuAAC reaction. The relative positions of
the azide and the alkyne did not inﬂuence the degree of
conversion in solution; however, once performed on the
liposome surface it had a decisive impact. Having the alkyne
functionality present at the liposome surface resulted in 75%
conversion, whereas the azide functionalized liposomes only
resulted in 43% product formation.
The ﬁndings described above will be useful for future
postfunctionalization designs and clearly illustrate that care
should be taken to select the most appropriate chemistry for
the desired chemical manipulation. Furthermore, it is also
evident that postfunctionalized nanoparticles in general should
always be analyzed in order to ensure the desired composition
of the nanoparticle constructs.
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Abstract Our ability to engineer nanomaterials for biological and medical
applications is continuously increasing, and nanomaterial designs are becoming
more and more complex. One very good example of this is the drug delivery ﬁeld
where nanoparticle systems can be used to deliver drugs speciﬁcally to diseased
tissue. In the early days, the design of the nanoparticles was relatively simple, but
today we can surface functionalize and manipulate material properties to target
diseased tissue and build highly complex drug release mechanisms into our
designs. One of the most promising strategies in drug delivery is to use ligands that
target overexpressed or selectively expressed receptors on the surface of diseased
cells. To utilize this approach, it is necessary to control the chemistry involved in
surface functionalization of nanoparticles and construct highly speciﬁc function-
alities that can be used as attachment points for a diverse range of targeting ligands
such as antibodies, peptides, carbohydrates and vitamins. In this review we provide
an overview and a critical evaluation of the many strategies that have been
developed for surface functionalization of nanoparticles and furthermore provide
an overview of how these methods have been used in drug delivery systems.
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1 Introduction
The pharmaceutical industry has successfully developed numerous drugs for the
treatment of cancer, but it remains one of the world’s most devastating diseases
with more than 10 million new incidences every year [105]. One of the major
obstacles to current treatments is inadequate delivery of the therapeutics to the
tumor site, which leads to severe side effects [8]. There is therefore increasing
demand for delivery systems that transport the drug speciﬁcally to the diseased
tissue and improve the therapeutic index of the encapsulated drug. Nanoparticle
systems have been investigated as drug delivery systems for several decades, and
strategies are becoming increasingly complex to fulﬁll the growing requirement
for treating diseases. The nanoparticle drug delivery systems offer new treatment
regimes for a large variety of different diseases; however, due to the relatively high
costs of many of the utilized materials, they have mainly found applications for
treatment of cancer. Of the many classes of nanocarrier systems that are currently
under investigation, liposomes remain one of the most successful. Liposomes were
ﬁrst proposed as drug delivery vehicles by Gregoriadis et al. [54] in 1974. Early
liposomal formulations suffered from rapid clearance by phagocytic cells of the
reticuloendothelial system (RES). This issue was solved by coating the liposomes
with polymers, particularly poly(ethylene glycol) (PEG), which suppress protein
absorption and opsonization of the liposomes [139]. These Stealth or sterically
stabilized liposomes were found to accumulate in tumors and inﬂammatory tissue
by passive diffusion because of the leaky vasculature and the lack of an effective
lymphatic drainage present in such tissues [82, 87]. This phenomenon is com-
monly referred to as the enhanced permeation and retention effect (EPR effect).
Despite the enhanced accumulation in cancerous or inﬂammatory tissue as a result
of the EPR effect, there is strong motivation for improving the accumulation by
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coating the outer liposomal membrane with ligands targeted towards overex-
pressed or selectively expressed receptors on diseased cells. Active targeting with
ligands, such as peptides, carbohydrates, glycoproteins, antibodies or fragments
thereof, has been utilized to selectively deliver drugs to the desired site of action
by increasing the nanocarrier accumulation. Targeted liposomes/nanoparticles are
superior compared to drug immunoconjugates since only few targeting ligands are
needed to deliver several thousands drug molecules. Furthermore, liposomes are
highly biocompatible and can protect encapsulated drugs from premature degra-
dation in the blood stream. However, surface functionalization of liposomes or
nanoparticles with targeting ligands are not trivial even though multiple reports
have already utilized the targeting strategy. One of the largely overlooked prob-
lems when attaching targeting ligands is that reactions that normally work well in
solution may proceed very slowly on a surface, and care should be taken to select
the chemistry that is suitable for the desired synthetic manipulation. In particular,
in many studies there is no evaluation of the success of the functionalization,
which is highly problematic as many of the utilized chemistries are far from
quantitative.
The aim of this review is to summarize the recent advances in the ﬁeld of
nanoparticle functionalization. The focus is on surface functionalization of lipo-
somes, but the discussed chemistry is equally relevant for other nanoparticle
constructs. We will discuss the many new and highly speciﬁc conjugation methods
that have been developed in recent years to functionalize liposomes and give
examples of how different classes of targeting ligands have been attached to
liposomes and used to target diseased tissue. We will furthermore brieﬂy discuss
the membrane anchors that are employed, which is an overlooked problem in
many studies.
2 Surface Functionalization of Liposomes
Three methods are commonly used to functionalize liposomes with targeting
ligands. Small targeting ligands, such as vitamins [44, 77, 117], saccharides [25,
33, 122, 149] and small peptides [37, 39], are often covalently attached to a
hydrophobic anchor (e.g., a lipid) in organic solvent and puriﬁed. The function-
alized lipid can thereafter be mixed with natural lipids and hydrated to form
liposomes. This approach is only possible when working with smaller ligands and
is particularly useful when the ligand comes in relatively large quantities (due to
the puriﬁcation step). A major advantage of the approach is the complete control of
the amount of ligands per liposome since the initially added amount can be varied
in a controlled manner. However, approximately 50% of the added functionalized
lipids will be oriented towards the interior of the liposome, thus, not interacting
with the outer environment.
Another way to introduce speciﬁc ligands at the outer liposomal membrane is
the post-insertion approach [62], which is useful for expensive ligands. In this
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approach the ligands are typically covalently coupled to preformed lipid–PEG
micelles (e.g., DSPE–PEG), which have functionality in the distal end of the PEG
that allows coupling to the ligand. Alternatively, synthesized and puriﬁed ligand–
lipid moieties made by the strategy discussed above can also be used. Succeeding,
incubation of the micelles with preformed liposomes allows the DSPE–PEG–
ligand conjugates to transfer from the micelles into the outer liposomal membrane
in a temperature- and time-dependent manner, if the process is thermodynamically
favored. This approach has been used to functionalize liposomes with antibodies
[6, 13, 36, 61, 62, 100], peptides [95, 114, 135] and proteins [24]. A major
advantage of this approach is that the loading of the liposomes is decoupled from
the insertion of the ligands, which allows for optimization of both parameters.
Targeting liposomes prepared by the post-insertion approach have been shown to
have the same in vitro drug leakage rates, cell association proﬁles and therapeutic
efﬁcacies compared to liposomes made by other approaches [6, 61, 95]. However,
the amount of ligands inserted into the liposome membrane must be quantiﬁed
when using this approach.
Functionalization of liposomes with targeting ligands can also be carried out by
post-functionalization, e.g., performing the conjugation directly on the preformed
liposomes with anchors exposing speciﬁc functionalities in their respective head
groups. This method is primarily used with larger and complex ligands, such as
proteins and antibodies or fragments thereof. One should realize that the reactions
often do not go to completion, and the degree of functionality should always be
quantiﬁed. A large number of different anchors, e.g., fatty acids, phospholipids and
sterols, have been used. The effect and the properties of these anchors will be
discussed in the end of this review.
Ideally, surface coupling reactions should be simple, fast, efﬁcient, reproducible
and result in bonds that are non-toxic and non-immunogenic. Furthermore, reac-
tion conditions for surface functionalization should be mild in order to retain the
biological activity of the targeting ligands. A wide range of coupling methods has
successfully been developed during the last 25 years, resulting in a broad variety
of possible methods to functionalize liposomes. Early coupling methods are
generally characterized by unspeciﬁc surface functionalization resulting in mod-
erate yields, whereas the modern approaches enable site-speciﬁc functionalization
in high yields. Each coupling reaction used to covalently attach ligands to the
liposome surface will be described separately in order to highlight the advantages
and disadvantages of the various methods. To limit the scope of this review, only
surface functionalization of liposomes is discussed; however, the surface chem-
istry applies for the majority of other nanoparticle-based drug delivery systems.
2.1 Coupling of Ligands to Amine-Modiﬁed Liposomes
One of the earliest developed methods to covalently couple ligands to the liposome
surface is based on amine functionalized liposomes. Torchilin et al. [124, 125]
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described the use of two homobifunctional crosslinkers (Fig. 1a), glutaraldehyde
(1) and dimethyl suberimidate (2) (Fig. 2), for amine–amine crosslinking. Addi-
tion of either 1 or 2 to DPPE-containing liposomes resulted in up to 70% imine or
amidine formation, respectively, at the liposome surface. Incubation of these
liposomes with rabbit anticanine cardiac myosin antibodies at 4C in aqueous
buffer resulted in 60% conversion [125] without loss of the binding capacity of the
antigen.
The major advantage of this surface functionalization approach is the fact that it
is based on naturally occurring lipids, which can be used without prior derivati-
zation. However, the use of homobifunctional crosslinkers can result in uncon-
trollable homopolymerization of ligands or liposomes during the crosslinking
reaction, which can lead to liposome aggregation. Furthermore, since multiple
amine functionalities are usually present in antibodies, a random attachment can be
Fig. 1 Schematic illustration of the various coupling methods that have been developed in order
to post-functionalize liposomes. a Amine functionalization, b carboxylic acid functionalization,
c aldehyde functionalization, d hydrazine functionalization, e maleimide functionalization, f thiol
functionalization, g thiol functionalization (disulﬁde bond formation), h bromoacetyl function-
alization, i cysteine functionalization, j cyanur functionalization, kp-nitrophenylcarbonyl
functionalization, l alkyne functionalization, m triphosphine functionalization
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expected. This may interfere with the binding of the antibody to its receptor and
thus alter the binding afﬁnity.
2.2 Coupling of Ligands to Carboxylic Acid-Modiﬁed Liposomes
Covalent coupling of ligands to carboxylic acid-modiﬁed liposomes (Fig. 1b) is a
widely used approach to functionalize liposomes [14, 16, 63, 74, 86, 99, 143]. The
method was ﬁrst introduced by Kung and Redemann [74], who introduced the
carboxylic acid functionality by reacting PE-lipids with a wide range of anhydrides
in presence of triethylamine. Liposomes, exposing the carboxylic acid function-
ality, were activated in situ by the addition of water soluble 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC). The activated ester was found to react
readily with primary amines present on mouse IgG resulting in a stable amide
bond. The achieved coupling efﬁciencies ranged from 1 to 58%, depending on the
length of the spacer between the liposome surface and the carboxylic acid
functionality.
The effect of the spacer becomes negligible when the ligand is introduced at the
PEG terminus, as described by Maruyama et al. [86], who prepared monoclonal
IgG 273-34A-modiﬁed liposomes by the above-described approach. These im-
munoliposomes were found to have prolonged circulation times and a higher
degree of target cell recognition compared to liposomes exposing antibodies
directly on the liposome surface.
The major advantage of using carboxylic acid-modiﬁed liposomes for surface
modiﬁcation purposes is that no prior ligand modiﬁcation is required, thus
reducing the risk of denaturation. On the other hand, since multiple amine func-
tionalities are present in antibodies, a random attachment can be expected, which
could alter the binding afﬁnity towards the targeted receptor.
2.3 Coupling of Ligands to Aldehyde-Modiﬁed Liposomes
Coupling of hydrazino-derivatized ligands to aldehyde functionalized liposomes
by hydrazone formation (Fig. 1c) has been described by Bonnet et al. [20], who
Fig. 2 Chemical structure of glutaraldehyde (1) and dimethyl suberimidate (2) utilized for
amine–amine crosslinking by Torchilin et al. [124, 125]
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introduced the aldehyde functionalized ether lipid di-O-hexadecyl-rac-glyceral-
dehyde into the liposomal membrane. Incubation with a hydrazino-derivatized
dodecapeptide from the cytoplasmic domain of lysosome-associated membrane
protein (LAMP) in aqueous buffer resulted in quantitative conversion within 5 h.
The method described by Bonnet et al. [20] offers an effective approach to
conjugate synthetic peptides prepared by solid-phase peptide synthesis (SPPS) to
liposomes. The hydrazino functionality is easily introduced to the synthetic pep-
tide on resin by the use of N,N,N-tri(tert-butyloxycarbonyl)-hydrazino acetic acid,
which is fully compatible with SPPS synthesis [18, 19]. Furthermore, hydrazone
formation occurs spontaneously without the need of a catalyst. Thus, this method
is one of the most effective for the functionalization of liposomes with targeting
ligands when it is possible to introduce a hydrazino group into the ligand. How-
ever, this is unfortunately problematic for antibodies and other complex ligands.
2.4 Coupling of Ligands to Hydrazide-Modiﬁed Liposomes
A more widely adapted approach, compared to the one described above, is to
invert the position of the functional groups, i.e., introducing the aldehyde to the
ligand and the hydrazine functionality to the liposome surface (Fig. 1d) [26, 56,
57, 72, 91, 145, 146]. Initially, the hydrazine functionality was introduced by
incorporation of lauric acid hydrazide [26] into the liposome membrane (it should
be noted that this is a poor anchor). Later, a method to introduce the hydrazine
functionality to the distal end of the PEG chain of DSPE–PEG has been described
by Zalipsky [145]. Having the hydrazine functionality exposed on the liposomal
membranes offers a unique advantage for coupling of antibodies to the liposomal
membrane. Mild oxidation of the carbohydrate groups on the constant region of
the heavy chain of the immuoglobulin with either galactose oxidase [26] or sodium
periodate [26, 56, 57, 72, 91] results in the formation of an aldehyde, which can be
chemoselectively attached to the hydrazine-functionalized liposomes through
hydrazone bond formation. By utilizing the carbohydrate groups from the Fc
region, the antibodies are correctly oriented once attached onto the surface of the
liposomes, because only the Fc region is involved in the coupling reaction, leaving
the antigen-binding site available for receptor interactions. Comparative studies
have indicated that this method results in low coupling efﬁciencies (17%) [56], yet
positive in vitro results have been obtained using this methodology with liposomes
targeted towards rat colon carcinoma CC531 cells [72].
2.5 Coupling of Ligands to Maleimide-Modiﬁed Liposomes
The most often used approach to functionalize liposomes with targeting ligands is
based on the formation of a thioether bond between maleimide-functionalized
liposomes and thiol-derivatized ligands [13, 29, 34, 40, 42, 49, 64, 70, 85, 98, 101,
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119] by Michael Addition (Fig. 1e). For direct surface functionalization, N-(4-(p-
Maleimidophenyl)butyryl)-phosphatidylethanolamine has been used as the func-
tionalized anchor, whereas DSPE–PEG–maleimide is used for attachment on the
distal end of the PEG polymer. Garnier et al. [49] recently used this approach to
covalently attach the Annexin-A5 protein, known to target membranes containing
negatively charged phospholipids, to DSPE–PEG–maleimide functionalized lipo-
somes. A mutant of the natural Annexin-A5 protein (35 kDa), exposing a cysteine
residue at a highly accessible loop on the concave face of the protein, was
developed. Addition of this protein to liposomes exposing the maleimide func-
tionality in HBS buffer at pH 6.3 for 4 h resulted in a coupling efﬁciency of
approximately 80%. The Annexin-A5-functionalized liposomes were found to
bind to solid supported lipid membranes composed of DOPC/DOPS in a Ca2+
depending manner, as monitored by quartz crystal microbalance (QCM). Michael
addition of thiolated OX26 MAb Fab0 fragments to DSPE–PEG–maleimide
functionalized liposomes has recently been described by Béduneau et al. [13].
Despite optimizing the coupling conditions, the coupling yield was constantly
approximately 25%. However, it is noteworthy to mention that quantitative cou-
pling efﬁciencies have been reported with small thiolated pentameric cRGD
peptides using a similar coupling protocol [64].
An interesting study performed by Fleiner et al. [40] concerning the inﬂuence of
the spacer length between the liposome surface and the reactive maleimido group
and its polarity revealed that longer polar spacers resulted in higher coupling
efﬁciencies. Surprisingly, comparison of the reactivity of liposome functionalized
with either m- or p-maleimido benzoic acid esters revealed that the less reactive
(less electrophilic) m-maleimido benzoic acid ester resulted in a higher coupling
efﬁciency (46 ± 7%) compared to the more electrophilic p-maleimido benzoic acid
analogue (30 ± 5%). This could be explained by the increasing susceptibility to
competing nucleophiles, such as water, of the maleimide group with higher
electrophilicity.
Surface conjugation to maleimide-functionalized liposomes is a straightforward
and reliable method to attach ligands without prior activation or addition of cat-
alysts to promote the reaction. The reaction proceeds at ambient temperature, close
to neutral pH and within a short period of time. Conjugation of smaller ligands
often results in quantitative yields, whereas more moderate yields can be expected
for larger molecules. Despite the popularity of this conjugation method, maleimide
derivatives have been shown to be immunogenic [17, 106].
2.6 Coupling of Ligands to Thiol-Modiﬁed Liposomes
Thiol-functionalized liposomes have often been used for the attachment of ligands
to the outer liposomal membrane. Normally, the reactive thiol is introduced to the
membrane as the disulﬁde protected derivate N-(30-(pyridyldithio)propionoyla-
mino–PEG–DSPE (DSPE–PEG–PDP), which is activated in situ by reduction with
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dithiothreitol (DTT), as described by Allen et al. [5]. Attachment of maleimide-
derivatized antibodies (Fig. 1f) was achieved by overnight incubation in yields
ranging from 13 to 88%, depending on the liposome composition and amount of
maleimide-derivatized antibodies added. Quantitative conjugation yields with
maleimide-derivatized My10 antibodies have been reported when the reactive thiol
is introduced at the distal end of longer PEG chains than the ones otherwise
present in the liposome [92].
Surface conjugation to thiol-modiﬁed liposomes can also be achieved by
disulﬁde formation (Fig. 1g). This approach was adopted by Muñoz et al. [96],
who introduced the hepatitis A VP3 (101–121) peptide to DSPE–PEG–PDP
containing liposomes. Overnight incubation in borate buffer at pH 8 resulted in
approximately 50% conjugation yield. A disadvantage of this approach is that free
thiols may react among themselves to produce intermolecular disulﬁde bonds,
leading to crosslinking of the reactive ligands or liposomes.
2.7 Coupling of Ligands to Bromoacetyl-Modiﬁed Liposomes
Conjugation of cysteine-containing peptides to bromoacetyl-modiﬁed liposomes
(Fig. 1h) has been described by Frisch et al. [42]. The bromoacetyl functionality
was introduced by acylation of DPPE with 2-[2-[2-[(2-bromoacetyl)amino]eth-
oxy]ethoxy]ethoxy acetic acid (3) (Fig. 3) in the presence of N,N0-dicyclohexyl-
carbodiimide (DCC). An octapeptide derivatized from the C-terminal of the
histone H3 peptide was added to liposomes, exposing the bromoacetyl function-
ality at pH 9.0 resulting in quantitative conversion within 1 h. At lower pH, the
reaction was found to be less pronounced. This phenomenon was utilized by
Schelté et al. [119], who formulated liposomes exposing both the maleimide- and
the bromoacetyl functionality at the outer membrane. This study showed that
important kinetic discrimination can be achieved between the maleimide and
bromoacetyl functionalities when the reactions with thiols are performed at pH 6.5.
Reaction with cysteine-containing peptides was found to be three orders of mag-
nitude faster with the maleimide functionality than with the bromoacetyl deriva-
tive, resulting in a high degree of chemoselectivity. These ﬁndings enabled the
coupling of two different cysteine peptides sequentially. The ﬁrst coupling was
carried out on the maleimide derivative at pH 6.5, followed by a coupling to the
bromoacetyl derivative at pH 9.0 under experimental conditions, which were found
Fig. 3 Chemical structure of 2-[2-[2-[(2-bromoacetyl)amino]ethoxy]ethoxy]ethoxy acetic acid
(3) used to introduce the acetyl bromo functionality to DPPE, as described by Frisch et al. [42]
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not to alter the integrity of the liposomes. Furthermore, neither the bromoacetyl
nor the maleimide functionality was found to react with other nucleophiles such as
a- and e-amino groups or imidazole, which could also be present in peptides.
2.8 Coupling of Ligands to Cysteine-Modiﬁed Liposomes
Conjugation of recombinant proteins to the liposome surfaces through native
chemical ligation (Fig. 1i) has recently been described by Reulen et al. [109].
Native chemical ligation was ﬁrst reported by Dawson et al. [32] as a unique
method to ligate two unprotected peptide fragments and form an amide bond,
thereby facilitating the synthesis of large proteins. Native chemical ligation is a
chemoselective reaction, which occurs spontaneously between a thioester and an
N-terminal cysteine under aqueous conditions at neutral pH, which makes it ide-
ally suited for liposome conjugation purposes. Reulen et al. [109] introduced the
cysteine functionality to the distal end of DSPE–PEG–NH2 by reacting it with
succinimidyl-activated trityl-protected cysteine, followed by deprotection of the
trityl protection groups with dilute triﬂuoroacetic acid (TFA). The C-terminal of
the collagen-binding protein domain (CNA35) from the bacterial adhesion protein
of Staphylococcus aureus was modiﬁed with sodium 2-mercaptoethanesulfonate
(4) (MESNA) (Fig. 4) to form a thioester suitable for native chemical ligation.
Cysteine-functionalized liposomes were incubated with MESNA-CNA35 protein
in HBS buffer at pH 8 for 48 h in the presence of thiophenol, benzyl mercaptan or
MESNA to catalyze the reaction. In the presence of either thiophenol or benzyl
mercaptan, approximately 30% conversion was observed, whereas only 10%
conversion was achieved with MESNA. However, the poorly water soluble and
toxic thiophenol and benzyl mercaptan were found to accumulate in the
phospholipid bilayer, making them difﬁcult to remove after ligation. This was not
the case with the water-soluble MESNA, which was easily removed by centrifu-
gation. The CNA35-functionalized liposomes were tested in a collagen-binding
assay and were found to have a 150-fold increase in afﬁnity compared to the free
protein.
Surface conjugation through native chemical ligation is an attractive method to
directly conjugate thioester-modiﬁed ligands to the liposome surface. The method
enables site-speciﬁc conjugation, since only a single site in the ligand is available
for conjugation. The low coupling yield is an obstacle that needs to be addressed.
Fig. 4 Chemical structure of sodium 2-mercaptoethanesulfonate (4) (MESNA) used to catalyze
the native chemical ligation on the liposome surface, as described by Reulen et al. [109]
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2.9 Coupling of Ligands to Cyanur-Modiﬁed Liposomes
A method for attaching antibodies directly to the PEG terminus of liposomes
without prior derivatization has been described by Brendas et al. [21]. Introduction
of the cyanur functionality to the PEG terminus of DPPE–PEG–OH was achieved
under basic conditions by adding cyanuric chloride (5) (Fig. 5). Anti E-selectin
monoclonal antibodies were coupled to cyanuric-modiﬁed liposomes (Fig. 1j) at
pH 8.8 by nucleophilic substitution resulting in immunoliposomes having a high
degree of in vitro binding to Chinese hamster ovary cells expressing E-selectins
receptors. The nucleophilic substitution between the anti-E-selectin monoclonal
antibodies and the cyanur-modiﬁed liposomes was found to be very sensitive
towards the pH of the buffer. No surface functionalization was observed at neutral
pH, whereas a more alkaline environment resulted in hydrolytic degradation of the
cyanuric chloride.
This methodology offers a straightforward approach for attaching antibodies to
the PEG terminus of liposomes without previous derivatization. However, cyan-
uric chloride is known to react with a wide range of nucleophilic functionalities,
such as alcohols, amines and thiols, which means that a random attachment of the
antibodies can be expected. This may interfere with the binding of the antibody to
its receptor, thus altering the binding afﬁnity. In addition to this, cyanuric chloride
is regarded as a sensory respiratory irritant [113], but has not shown any sign of
acute, chronic or genotoxicity [140].
2.10 Coupling of Ligands to p-Nitrophenylcarbonyl-Modiﬁed
Liposomes
An additional method to directly conjugate antibodies to the PEG terminus of
liposomes without prior derivatization has been described by Torchilin et al. [128].
The amphiphilic derivate p-nitrophenylcarbonyl–PEG–1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (pNP–PEG–DOPE), which was obtained in a single step
from DOPE and bis(p-nitrophenylcarbonyl)-PEG, forms stable and non-toxic
carbamate bonds with ligands containing primary amines (Fig. 1k). However, one
drawback is the utilization of the bis-functionalized bis(p-nitrophenylcarbonyl)-
PEG, which may result in dimerization, although this side product is easily
Fig. 5 Chemical structure of cyanur chloride (5) used to introduce the cyanur functionality into
liposomes by acylation of DPPE–PEG–OH, as described by Brendas et al. [21]
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separated from the product. Torchilin et al. demonstrated this approach with
several proteins, such as concanavalin A (ConA), wheat germ agglutinin (WGA),
avidin, monoclonal antimyosin antibody 2G4 (mon2G4) and monoclonal antinu-
cleosome antibody 2C5 (mon2C5), and observed almost quantitative surface
functionalization yields at pH 8.0. Despite the fact that this method does not enable
site-speciﬁc conjugation, the speciﬁc activities of the surface bound proteins were
retained after conjugation.
2.11 Coupling of Ligands to Alkyne-Modiﬁed Liposomes
One of the more elegant coupling methods to functionalize liposomes is based on
the work of Meldal and co-workers [129, 130] and Sharpless and co-workers
[111], who reported the use of Cu(I) to catalyze the azide/alkyne Huisgen 1,3-
dipolar cycloaddition, commonly referred to as the click reaction. This reaction
offers unique ﬂexibility because of the high level of orthogonality to other
chemical functionalities and generally proceeds rapidly in high yields. This
approach to functionalize liposomes was ﬁrst described by Hassane et al. [58], who
introduced the alkyne functionality to the liposome surface by incorporating the
synthetic ether lipid N-[2-(2-(2-(2-(2,3-bis(hexadecyloxy)propoxy)ethoxy)eth-
oxy)-ethoxy)ethyl]hex-5-ynamide (6) (Fig. 6) into the liposomal membrane
(Fig. 1l). Addition of an azido-modiﬁed mannose ligand in the presence of CuSO4
and sodium ascorbate to generate Cu(I) in situ resulted in approximately 25% yield
within 24 h. However, by adding the water-soluble Cu(I)-stabilizing ligand
bathophenanthroline disulfonic acid [78] to the reaction mixture, complete con-
version was observed within 6 h. These reaction conditions did not alter the size of
the liposomes or provoke leakage from liposomes loaded with self-quenching
concentrations of 5,6-carboxyﬂuoroscein. Furthermore, the mannose residue was
found to be readily accessible to concanavalin A, which upon addition to the
liposomes caused instant aggregation.
The click reaction approach has also been adopted by Cavalli et al. [23], who
introduced the alkyne functionality by derivatization of DOPE with proliolic acid.
Full conversion was in this case achieved within 20 h with a small azido-NBD
derivative without the use of bathophenanthroline disulfonic acid.
The Cu(I) catalyzed azide/alkyne Huisgen 1,3-dipolar cycloaddition is a very
powerful conjugation reaction for surface modiﬁcation of liposomes. The
Fig. 6 Chemical structure of N-[2-(2-(2-(2-(2,3-bis(hexadecyloxy)propoxy)ethoxy)ethoxy)-eth-
oxy)ethyl]hex-5-ynamide (6) used to introduce the alkyne functionality into the liposome
membrane as described by Hassane et al. [58]
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unreactive nature of both alkynes and azides towards the other functionalities
present in biomolecules makes site-speciﬁc conjugation possible. Furthermore, the
formed triazole ring is both thermal and hydrolytically stable, and the reaction can
occur efﬁciently in aqueous media at room temperature. However, the mandatory
use of copper catalyst represents a limitation. Copper is considered toxic and
complete removal prior to in vitro or in vivo use is necessary. In addition to this,
unsaturated phospholipids are known to be oxidized by copper ions in the presence
of oxygen [46, 75], which could cause degradation of the liposomal membrane.
Alternative methods to promote triazole formation between azides and alkynes,
without Cu(I), have been described recently. Strain-promoted [3] or electron-
deﬁcient alkynes [79] have been reported to react with azides in absence of Cu(I),
but these methods have not yet been applied to the liposome ﬁeld.
2.12 Coupling of Ligands to Triphosphine-Modiﬁed Liposomes
The latest member of the wide range of possible surface conjugation reactions
described is based on the Staudinger ligation [118], in which an azide and a
triphosphine selectively react to form an amide bond (Fig. 1m). This approach was
adopted by Zhang et al. [148], who introduced the triphosphine functionality by
acylation of DPPE with 3-diphenylphosphino-4-methoxycarbonylbenzoic acid (7)
(Fig. 7). Triphosphine-functionalized liposomes were incubated with an unpro-
tected lactosyl derivate carrying an ethyl spacer functionalized with an azide group
in PBS buffer, which resulted in 80% surface functionalization within 6 h. The
surface conjugation reaction was not found to alter the size or provoke leakage of
the liposomes. The surface-conjugated lactose residues were shown to be easily
accessible to b-galactose-binding lectin, which, upon addition, caused aggregation
of the liposomes.
The methodology described by Zhang et al. [148] offers an efﬁcient and
chemoselective conjugation method for liposome surface functionalization. The
reaction beneﬁts from being performed under mild conditions without the need of
a catalyst. Furthermore, methods to engineer bacteria and yeast enabling them to
incorporate azido functionalities into proteins have been developed [53]. This
enables direct attachment to the triphosphine-functionalized liposome without
prior derivatization of the protein.
3 Targeting Strategies: Active Targeting of Tumor Vasculature
and Tumor Cells
Ligand-modiﬁed liposomes can be designed to target receptors expressed by cells
in the tumor vasculature or on the tumor cells. When targeting tumor cells directly,
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a number of obstacles have to be overcome as the drug delivery system has to
cross the vasculature and travel through the interstitium in the tumor tissue before
being able to deliver the drug at the desired site of action. Vascular targeting is
generally considered to be advantageous over tumor cell targeting as endothelial
cells are genetically stable and the risk of developing drug resistance is minimized
[1]. Proliferating endothelial cells in solid tumors share similar characteristics in a
variety of tumor types and a number of these can be utilized. In addition, endo-
thelial cells lining the blood vessels in tumors are more accessible for binding by
circulating drug delivery systems that are administered intravenously [1]. A
strategy that targets both the tumor vasculature and the tumor cells has been
envisioned as more effective than targeting the two tissues individually, and
Koning et al. have provided proof-of-principle for this hypothesis [73]. These
strategies have been investigated using a range of targeting molecules including
antibodies, peptides, carbohydrates and vitamin analogs, and an overview of these
different targeting moieties is discussed below.
3.1 Immunoliposomes
Antibodies represent one of the most versatile ligands that can be attached to
liposomes. However, the antibody functionalization of liposomes is generally
challenging, where region speciﬁcity and degree of conversion are the main
problems, even though a number of good methods exist. One of the main reasons
for this is that antibodies can only be attached to liposomes by post-functionali-
zation, i.e., the lipsomes are formed prior to attachment, and the chemistry
therefore has to work well in aqueous buffer. Early attempts to attach these
molecules for the speciﬁc targeting of diseased tissue were originally communi-
cated in the 1970s [136] where antibodies were coupled to the surface of non-
PEGylated liposomes. Today, it is commonly known that non-PEGylated (or non-
polymer) liposomes have little treatment beneﬁt because of fast clearance from the
blood stream. Coupling of the targeting ligands to the distal end of PEG is
therefore the method-of-choice today to maximize liposome accumulation at the
target site [56, 116]. Antibodies can be attached as whole monoclonal antibodies or
as a fragment thereof (Fig. 8). Full antibodies have stability advantages over small
Fig. 7 Chemical structure of 3-diphenylphosphino-4-methoxycarbonylbenzoic acid (7) used to
introduce the triphosphine functionality into liposomes by acylation of DPPE as described by
Zhang et al. [148]
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fragments such as Fab0 and scFv, but can trigger complement [94] and induce
antibody-dependent cell-mediated cytotoxicity [115]. Furthermore, the Fc frag-
ment is known to accelerate clearance of the immunoliposome by uptake of cir-
culating liver and spleen macrophages possibly through opsonization, and thus
decreases the circulation time of the liposomes [5]. By attaching fragments of the
antibody such as Fab0 or Fv, this undesired clearance can be minimized [12].
The most commonly used antibody-targeting moieties belong to the immuno-
globulins of the IgG class [126], which have been coupled to the distal end of PEG
using a hydrazido-PEG–DSPE construct [57]. The oligosaccharide moiety of the
antibody molecule was oxidized using sodium periodate, creating an aldehyde
functionality that reacts with the hydrazido-group on the PEG–DSPE to form a
stable hydrazone linkage. Immunoglobulins consist of 82–96% polypeptide and
4–18% carbohydrates [10, 11], and the carbohydrate moieties are mainly situated
on the heavy chain in the Fc portion of the antibody. As this region is not involved
in the binding to the receptor, a modiﬁcation in this part should not inﬂuence
antigen-binding efﬁcacy [52]. However, one potential problem with the oxidation
of the carbohydrates is the risk of oxidizing amino acids situated in the antigen-
binding Fab0 region. Amino acids most prone to oxidation with sodium periodate
are cysteine, methionine, tryptophan, tyrosine and histidine, as well as serine and
threonine if they occur as terminal residues [28].
Antibodies against the human epidermal growth factor receptor 2 (HER2) have
been widely used in combination with liposomal drug delivery systems. This
antigen is frequently overexpressed on various types of cancer cells and is only
weakly expressed in normal tissues. One of the ﬁrst studies of investigating Fab0
Fig. 8 Schematic
representation of various
antibody constructs:
Monoclonal antibody (mAb);
F(ab0)2 generated by pepsin
digestion of the Fc domain of
mAb; Fab0 from reduction of
the disulﬁde bond in the
hinge region of F(ab0)2; scFv
of recombinant VL and VH
regions linked by a short
peptide sequence
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and scFv targeting of HER2 was reported by [85]. They utilized PEGylated lip-
osomes that were functionalized with a maleimide functionality in the distal end of
PEG. Fab0 was conjugated to the liposomes through a thioether linkage using the
free thiol group in the Fab0 hinge region at pH above 7 to deprotonate the thiol.
This site is located distant from the antigen-binding site and should not interfere
with its function. The thioether bond formed between Fab0 and the maleimide
functionalized liposome was stable and not prone to reduction in a reductive
environment, e.g., serum [84]. ScFv fragments contain immunoglobulin heavy-
and light-chain variables linked by a [-(Gly)4-Ser-]3 motif. At the C-terminal end
of the recombinantly produced scFv, a cysteine can be introduced that can be
exploited in the covalent attachment to maleimide-activated PEG–DSPE. Two
internal disulﬁde bonds are present in the scFv fragment; however, these have
proven to be rather stable to reduction [4]. An analogous approach has been
developed with the use of a PDP–PEG–DSPE liposome composition. After
reduction with DTT, the liposome was incubated with an anti-HER2 male-
imidophenylbutyrate functionalized Fab0 fragment, resulting in the immunolipo-
some [47]. For targeting the transferrin receptor (TfR), its antibodies or Fab0
fragments have been coupled to maleimide-modiﬁed PEG–DSPE liposomes. The
TfR expression is elevated in many types of cancerous tissues and correlates with
the proliferation rate and aggressiveness of the cancer. Hence, the TfR is a
valuable potential target for drug delivery in cancer therapy [13, 141].
For the targeting of endothelial cells in malignant tissues, different forms of
adhesion molecules such as endothelial-leukocyte adhesion molecule-1 (ELAM),
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1) have been applied. These have been coupled to DOPE-N-dodecanoyl
lipids by the use of EDC/N-hydroxysuccinimide (NHS) chemistry [55]. However,
as there are several amine groups in anti-ELAM and anti-ICAM, this strategy leads
to a non-speciﬁc crosslinking between the liposome and the antibody. This can be
avoided by applying the maleimide method described above where the antibody is
coupled via a thioether bond to the surface of PEGylated liposomes. However, an
additional step is required to introduce a thiol functionality on the cell adhesion
molecule. This is readily done using N-succinimidyl-S-acetylthioacetate [35].
Related to this strategy, immunoliposomes have been prepared using maleimide–
DPPE through a reaction with thiolated F(ab0)2 fragments of the monoclonal
antibody GAH [131]. GAH recognizes surface molecules especially in stomach
cancer, and a PEGylated immunoliposome formulation using GAH targeting has
been shown to have better efﬁcacy than non-targeting liposomes in Phase I clinical
trials [59, 88].
A signiﬁcant number of monoclonal antibodies have been identiﬁed and can be
engineered as Fab0 or scFv fragments as well as chimeric or humanized antibodies.
Highly effective and reproducible methods of coupling whole antibodies or their
fragments to the surface of plain liposomes or PEGylated liposomes exist, and in
general immunoliposomes show an enhanced recognition of target cells, as well as
a better internalization and intracellular drug delivery over non-targeted liposomes
[71, 102].
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3.2 Folate-Modiﬁed Liposomes
Liposomes functionalized with the vitamin, folic acid, have attracted much
attention as the folate receptor is highly overexpressed in a number of cancers, and
it can retain its high afﬁnity binding to the folate receptors even after being
covalently linked to a variety of macromolecules [144]. The vitamin is internalized
to a large extent in proliferating cells as folic acid is essential in the biosynthesis of
nucleotides; consequently, cancerous cells overexpress the folate receptor as the
fast-dividing malignant cells are in great need of this nutrient. Normally, the folate
receptor is expressed at the apical side of epithelial cells and is not accessible to
blood-borne drugs. However, when the epithelial cells become malignant, the
membrane loses its polarity and the folate receptor can be located at the basal
surface of the membrane as well, taking up therapeutics from the plasma [81].
There is no evidence that normal healthy cells are expressing the folate receptor to
a signiﬁcant extent, and healthy tissue should therefore not be affected by the
delivery of folate-targeted drugs [103, 138]. The ﬁrst report of using folate-tar-
geted liposome to transport drugs into tumor cells was published in the 1990s by
Lee and Low [76]. They conjugated the NHS-ester of folic acid to the distal end of
a NH2-PEGylated liposomes forming a stable amide bond. Gabizon et al. applied a
similar approach simply using a DCC-mediated coupling procedure linking the
terminal free c-carboxylic acid on folate and the free PEG amine functionality
[44]. Folate contains both an a- and c-carboxylic acid moiety, but as the gamma
position has a higher reactivity, this is the main coupling product observed [68].
After endocytotic uptake [9] of the liposome complex by the folate receptor-
expressing cell, release of the liposome content has been accomplished taking
advantage of the endosomal acidic environment, either by introducing pH-sensi-
tive fusogenic peptides to promote uptake into the endosome [134] or adding pH-
sensitive lipids to the liposome to increase liposome permeability and accelerate
unloading of the content in the acidic endosome [112]. The folate molecule can
form dimers, trimers and even higher self-assembling constructs. An increasing
level of folate attached to the liposome surface was found not to increase the level
of folate–liposome-complex binding to the folate receptor, as this receptor can
only bind one folate and will not respond to multiple folates [27, 107]. One of the
advantages with folate targeting is that the lipid–PEG–folate conjugates can be
synthesized in organic solvent and puriﬁed. This allows for a precise control of the
amount of targeting ligands that are present in the liposome, and there is no need
for post-functionalization.
3.3 Saccharides
A large number of mammalian cells express sugar-binding proteins known as
lectins. These have been found to be overexpressed on malignant cells and are
believed to be involved in metastasis formation [31, 43]; they can thus serve as a
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target for drug delivery systems. Liposomes functionalized with carbohydrates are
biodegradable, low in toxicity and have a protein-shielding ability that makes them
able to minimize liposome clearance from circulation. For instance, monosialo-
ganglioside have been shown to enhance the circulation time similar to that
observed for PEGylated liposomes [8, 90]. A number of different carbohydrates
have been conjugated to the surface of liposomes. Hassane et al. [58] used click
chemistry to couple an unprotected a-D-mannosyl derivative carrying a PEG spacer
functionalized terminally with a reactive azide moiety. However, selective pro-
tection of the mannose alcohol groups is naturally required during functionalization
with the PEG chain to avoid multiple substitutions [58]. Surface functionalization
of liposomes using lactose, galactose and a diverse array of polysaccharides as the
carbohydrate components have been synthesized using Staudinger ligation [148],
thioglycoside-mediated attachment [147] and EDC couplings between the head-
group amine on the lipid, and an activated NHS-ester of the saccharide moiety [123,
142]. The employed methods have both involved post-functionalization and com-
plete synthesis of the targeting lipid–ligand conjugate in organic solvent, allowing
isolation of the target compound. The latter method is possible with all carbohy-
drate targeting ligands and should be the method-of-choice.
3.4 Peptides
The use of peptide-targeted liposomes as therapeutics has become highly inter-
esting with the increasing knowledge of speciﬁc peptide sequences of proteins
involved in cell–cell interactions as well as the improvements in synthesis or
expression of synthetic peptides that closely resemble the human ones. For
attachment of peptide moieties to the liposome surface, the typically reactive
amino acids used are lysine, serine, cysteine, histidine, arginine, aspartic acid,
glutamic acid, threonine, tyrosine, the N-terminal amino group and C-terminal
carboxylic acid. The primarily used method is to react one of these reactive
functionalities with an activated PEG component situated on the surface of the
liposome. As lysine is one of the most prevalent amino acids in proteins, this has
been a favored linking site; however, upon reaction of a nucleophilic amine group
with an electrophilic activated PEG, multiple substitutions are often observed due
to the the presence of multiple lysines in the peptide. Amine linkage to PEG has
been achieved in multiple ways including the use of PEG dichlorotriazine [2] and
PEG tresylate [41]. Many PEG conjugates have furthermore been synthesized
using activated carbonate derivatives, such as succinimidyl carbonate, trichlor-
ophenyl carbonate and p-nitrophenyl carbonate [93, 132]. Liposomes have been
modiﬁed with cell-penetrating peptides such as TAT using a p-nitrophenyl car-
bonate-functionalized PEG under slightly basic conditions to form the non-toxic
carbamate linkage. TAT and other cell-penetrating peptides such as penetratin and
synthetic polyarginines have been conjugated to the surfaces of liposomes to
improve liposome uptake by cells [127]. In general, lower reactivity of the
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carbonate reagents provides higher selectivity; however, carbonate linkage with
several amino acids such as lysine, histidine and tyrosine have been observed
[110]. When a highly selective conjugation is required, a PEG–propionaldehyde
can be prepared. This functionality will, if pH is controlled, react selectively with
the N-terminal a-amine because of the lower pKa value of this amine compared to
other possible nucleophiles in the sequence [69]. Another possibility is to make
the activated ester of PEG carboxylic acids, such as NHS–PEG, which will react
with primary amines to form stable amides. This method has been applied for the
modiﬁcation of liposomes with the vasoactive intestinal peptide (VIP) to target
VIP receptors in breast cancer [30]. The receptor for this 28-amino acid neuro-
peptide is found to be overexpressed and homogenously distributed in all parts of
the breast tumor and thus serves as a potential tumor-targeting functionality [108].
Other active targeting carriers are based on delivery systems that mimic local
bioadhesion. Integrins and in particular the a5b1 integrin have attracted much
attention as this and its ligand, ﬁbronectin, are found to be upregulated in blood
vessels in tumor biopsies. There is strong evidence that peptides that mimic the
cell adhesion domain of ﬁbronectin and contain the peptide sequence RGD
(arginine-glycine-aspartic acid) are potent inhibitors of tumor-growth, tumor
metastasis and tumor-induced angiogenesis [89]. The RGD sequence has been
prepared as a cyclic constrained 5-mer modiﬁed with a C-terminal thioacetyl
group for linkage to the liposome. Deprotection of the acetyl group and incubation
with a maleimide-PEGylated functionalized liposome resulted in a thioester
linkage between the peptide and liposome [120]. A similar approach was used for
the attachment of the linear ATWLPPR (alanine-threonine-tryptophan-leucine-
proline-proline-arginine) sequence, found to have afﬁnity for the vascular endo-
thelial growth factor receptor (VEGF), a receptor overexpressed in the surface of
angiogenic endothelial cells [15]. Utilization of cysteine residues is the main
approach for site-speciﬁc modiﬁcation due to high speciﬁcity and ease of modi-
ﬁcation of a sequence that lacks a cysteine residue. In addition, few free cysteines
are present on the surface of proteins compared to, e.g., lysine. An additional
synthetic peptide sequence often applied in blocking cancer cell adhesion is
YIGSR (tyrosine-isoleucine-glycine-serine-arginine)—a sequence shown to be
important in laminin receptor binding. Conjugation of the peptide moiety to the
liposomal surface can be achieved by mild periodate oxidation of the threonine
residue in the hexapeptide TYIGSR, leading to a reactive glyoxylyl functionality
in the N-terminal end of the peptide followed by attachment to a hydrazide
functionalized PEG lipid [146]. The oxidation of carbohydrate residues or N-
terminal serine or threonine creates the possibility for site-directed PEGylation
using hydrazides. The glyoxylyl functionality formed by the oxidation of N-
terminal serine or threonine reacts site-speciﬁcally with PEG-hydrazide deriva-
tives [45], and the PEGylated peptide can be puriﬁed before use. A similar site-
speciﬁc N-terminal modiﬁcation of peptides has been described by Geoghegan
and Stroh [50]. In general, the peptides discussed above can be achieved in several
ways and can both be inserted by post-functionalization and by synthetic proce-
dures in organic solvent. The former is an advantage for larger peptides ([30
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amino acids) that are relatively expensive as the puriﬁcation step utilized in the
latter procedure results in loss of compound. However, a synthetic approach that
involves puriﬁcation should always be employed when possible to remove
side products and reagents. A number of reports furthermore utilize SPPS of
lipopeptide conjugates, and this is a highly efﬁcient method for smaller
peptides [66].
4 Membrane Anchors
In relation to liposomes and other self-organized materials, an important consid-
eration when choosing the chemical structure of the targeting conjugate is that
membrane afﬁnity for the speciﬁc lipid membrane has to be sufﬁciently high to
secure stability during blood circulation and binding to the target receptor. The
easiest strategy is of course to choose the same lipid anchor for the targeting
conjugate as the majority of the lipids used in the formulation; however, this may
not always be possible, and for large hydrophilic targeting conjugates it may not
always be sufﬁcient. Depending on the targeting conjugate and the concentration
used, the packing parameter of the molecule should also be considered [83]. The
ﬂexibility of the functional group as well as the crowding from other molecules on
the membrane surface will inﬂuence the conformation of the anchored group, e.g.,
brush-like versus mushroom-like structures of PEG [48]. Two of the most
important factors in choosing an anchoring molecule are the critical aggregation
concentration (CAC) of the targeting conjugate and how compatible it is with the
lipid membrane in terms of membrane thickness and ﬂuidity, e.g., saturated versus
unsaturated hydrocarbon chains. It should be noted that using poly-unsaturated
hydrocarbon chains might induce a stability challenge, since these are prone to
oxidation [133]. A simple example of the importance of ﬂuidity is that rhodamine-
labeled DOPE in a DSPC liposome membrane migrates in cell culture to the cell
membrane, whereas rhodamine-labeled DSPC remains bound to the liposomes. It
is therefore highly important to evaluate the physico-chemical properties of the
targeting conjugate and measure the formulation stability with appropriate bio-
physical methods.
A large variety of lipids has been used to anchor different targeting ligand
conjugates in liposomal membranes. Among the most widely used are phospho-
lipids (PL) [137], cholesterol [22], ether lipids [38], acyl chains [60], glycophos-
phatidylinositol (GPI) [121] and molecular rods [51]. Each anchor type has
several subtypes where small modiﬁcations can have a signiﬁcant inﬂuence on
how well the anchor of the functionalized group associates with the membrane.
The choice of anchor depends on the physico-chemical properties of the conju-
gated group.
Phospholipids are the most widely used anchors since most liposome-based
drug delivery systems are composed of commercially available PLs. PE and
PE–PEG–NH2 are the most utilized when synthesizing targeting moieties by
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standard chemistry in organic solvent. The linkage chemistry of choice is often
activated carbonates, and ‘‘click’’ chemistry is utilized more and more often due to
the high level of functional group orthogonality. However, hydrazines should also
be considered for reaction with aldehydes as this chemistry works very well and is
highly orthogonal to other chemistries. For post-functionalization, Michael addi-
tion to maleimides with thiols is by far the most often used approach as this
chemistry is fully compatible with the aqueous environment. ‘‘Click’’ chemistry
can also be considered, but it is more difﬁcult to achieve high coupling efﬁciency
between sterically hindered moieties in comparison to the maleimide chemistries.
A special case of PLs is the sphingolipids, which have three major subclasses: (1)
ceramides, (2) sphingomyelins and (3) glycosphingolipids, where the latter is
mainly used to anchor large proteins. One drawback of using glycerophospholipids
as anchors is that enzymes that hydrolyze the lipids giving free fatty acid
and lysophospholipids can be overexpressed in diseased tissue, e.g., phosholi-
pase A2 (PLA2) [7, 65]. The enzyme hydrolysis will eventually disrupt the
lipid membrane, and the liposome thereby loses its targeting capacity. To cir-
cumvent problems with enzymatic hydrolysis or chemical degradation of the ester
bonds (which are the weakest chemical bond in the usual phospholipid conju-
gates), ether lipids can be used. The chemistry of conjugation is the same as for the
normal diacyl-glycerophospholipids, but the cost of manufacturing represents a
limitation.
Cholesterol and derivatives like thio-cholesterol are also among the frequently
used anchors for functional groups on the surface of liposomes. Like PLs, cho-
lesterols are widely used in liposomal drug delivery systems and are also highly
present in natural membranes, making cholesterol anchors highly compatible with
most membranes. Cholesterol is typically coupled to a functional group via an
ester bond, carbamate ester or ether bond using the same type of chemistry as for
PLs. Cholesterol will usually serve as a strong anchoring molecule to relatively
large targeting conjugates with a low CAC value.
Acyl chains are also commonly used as anchors due to the easy coupling to
primary amines and alcohols. The stability of the amide bond makes this approach
suitable for solid phase synthesis and usually involves only one acyl chain, but in
some cases it involves two or three [80].
The use of only one acyl chain has been seen in multiple studies, but does not
generally serve as a sufﬁcient anchor in vivo (or even in vitro) as the water
solubility is too high and fast migration to, e.g., cell membranes will be observed.
If mono-acylation is used, particular attention should always be given to verifying
the anchoring stability.
Molecular rods are a relatively new form of anchors for lipid membranes with
functional groups attached to each end. They are designed to ﬁt into membranes
spanning the entire bilayer, unlike most other lipid anchors, and can be synthesized
with various lengths and desired rigidity needed for the individual target mem-
brane [97]. The principle of lipids spanning the entire membrane is known from
archaebacterial membranes, and mimics of the natural occurring lipids have been
synthesized [104]. Both molecular rods and tetraether lipids have the advantage of
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spanning the entire membrane, making it several orders of magnitude more stable
compared to conventional lipids.
5 Future Directions and Conclusion
The chemistry for functionalizing liposomes with targeting ligands is diverse and
has been developed over the last 3 decades. Even so, a number of challenges
remain as there is a growing need for reactions that are highly regioselective and
efﬁcient. ‘‘Click’’ chemistry is a very good example of the type of chemistry that is
required as it provides a very high degree of orthogonality to naturally occurring
functional groups. However, the reaction suffers from use of copper as catalyst,
and it is not a highly efﬁcient reaction on the surface of liposomes. Another
important requirement is that the reactions should be relatively cost efﬁcient where
the most important factor is that it proceeds in high yield. Lastly, for post-func-
tionalization, the reactions should ideally not give any need for successive puri-
ﬁcation. Good examples of reactions that fulﬁll this requirement are the Michael
addition to maleimides with thiol-containing ligands and hydrazine condensation
with aldehydes that do not require puriﬁcation if all ligands react. Another
important step forward will furthermore be to develop chemistries that are easily
evaluated for efﬁciency as it is not always a trivial task to evaluate reaction
progression depending on the ligand being used. This can be envisaged in a number
of ways, and it is certain that the coming years will provide much better func-
tionalization chemistries giving high coupling efﬁciencies, high regio-selectivity
and methods for fast evaluation of reaction progression. This is not only for use in
drug delivery applications, but also to meet the growing needs in the development
of new diagnostic tools where nanoparticles are in increasing demand.
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Understanding Detergent Effects on Lipid Membranes: A Model Study
of Lysolipids
Jonas R. Henriksen,† Thomas L. Andresen,† Lise N. Feldborg,† Lars Duelund,‡ and John H. Ipsen‡*
†DTU-Nanotech, The Technical University of Denmark, Roskilde, Denmark; and ‡MEMPHYS-Center of Biomembrane Physics, Department of
Physics and Chemistry, University of Southern Denmark, Odense, Denmark
ABSTRACT Lysolipids and fatty acids are the natural products formed by the hydrolysis of phospholipids. Lysolipids and fatty
acids form micelles in solution and acts as detergents in the presence of lipid membranes. In this study, we investigate the deter-
gent strength of a homologous series of lyso-phosphatidylcholine lipids (LPCs) on 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphati-
dylcholine (POPC) lipid membranes by use of isothermal titration calorimetry and vesicle ﬂuctuation analysis. The membrane
partition coefﬁcient (K) and critical micelle concentration (cmc) are determined by isothermal titration calorimetry and found to
obey an inverse proportionality relation (cmc$K ~ 0.05–0.3). The partition coefﬁcient and critical micelle concentration are
used for the analysis of the effect of LPCs on the membrane bending rigidity. The dependency of the bending rigidity on LPC
membrane coverage has been analyzed in terms of a phenomenological model based on continuum elastic theory, which yields
information about the curvature-inducing properties of the LPC molecule. The results reveal: 1), an increase in the partition coef-
ﬁcient with increasing LPC acyl-chain length; and 2), that the degree of acyl-chain mismatch between LPC and POPC deter-
mines the magnitude of the membrane mechanical perturbation per LPC molecule in the membrane. Finally, the three-stage
model describing detergent membrane interaction has been extended by a parameterDMCI, which governs the membrane curva-
ture stability in the detergent concentration range below the cmc-value of the LPC molecule.
INTRODUCTION
The effect of detergents and surfactants on ﬂuid interfaces
is a well-explored ﬁeld in colloidal chemistry. A classical
experiment is to demonstrate the dramatic decrease of the
surface tension, g, of an aqueous interface in the presence
of detergents described by the Gibbs adsorption relation.
For a freely suspended lipid membrane, the interfacial
tension is vanishing, and the mesoscopic and macroscopic
conformational properties are determined by the bending
elasticity governed by the Helfrich (1) energy functional:
Hbend ¼ gA þ k
2
Z
A
dAð2H  2H0Þ2: (1)
The membrane is characterized by the area, A, the mean
curvature, H, and the resistance to bending is governed by
the bending rigidity, k. The spontaneous curvature, H0,
reﬂects the preferred mean curvature of the membrane,
caused by asymmetry arising from 1), differences in the lipid
composition of the two membrane leaﬂets; or 2), differences
in solvent composition to which the two membrane leaﬂets
are exposed. The main distinction between the amphiphile
constituting the membrane and the detergent is that the latter
can partition into both the membrane and the solvent. The
effect of detergentlike molecules on k has only been sub-
jected to minor investigations, e.g., the emulsifying effect
of cosurfactants in microemulsions (2). However, it is well
established that lipid bilayer membranes are mechanically
destabilized by the presence of detergents (3,4). A classical
model of surfactant destabilization of lipid membranes is
the three-stage model (5), in which 1), surfactants partition
into the membrane at low concentrations; 2), mixed micelles
coexist with bilayer membranes enriched in detergent
above a threshold concentration; and 3), above a second
threshold in the detergent concentration, only micelles
persist. A more quantitative extension of the three-stage
model is based on the partitioning properties of monomeric
surfactants in membranes and micelles (6), where the ﬁrst
threshold composition of the membrane (deﬁning the onset
of membrane solubilization) can be approximated by the
product of the membrane partition coefﬁcient, K, and the
critical micelle concentration, cmc. In this study, we show
that although these models are able to describe important
properties of surfactant lipid systems, they cannot account
for the capacity of surfactants to destabilize membranes
mechanically. An increased understanding of the interaction
between detergentlike compounds and membranes has many
applications in membrane biophysics, e.g., the effect of
bile salts (7) and antimicrobial peptides (8) on biomem-
branes, isolation of membrane proteins (9), identiﬁcation
of insoluble membrane fragments (rafts) (10) and further-
more in the development of tumor target drug delivery
systems (11). So far, few studies have been focused on the
partitioning of lysolipids into membranes (12). Lysolipids
have been shown to increase the ion permeability (13), cause
changes in the bilayer hydration properties (14), modify
membrane channel function (15), and reduce the lysis
tension (16).
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In this study, we investigate the surfactant properties of
a homologous series of Lyso-phosphatidylcholine lipids
(LPCX,whereX¼ 12, 14, 16 represents the number of hydro-
carbons along the saturated acyl-chain) on 1-palmitoyl-2-
oleyl-sn-glycero-3-phosphatidylcholine (POPC)membranes.
The interaction of LPCs and POPC lipid membranes is quan-
tiﬁed by isothermal titration calorimetry (ITC) and vesicle
ﬂuctuation analysis (VFA) to determine the partition coefﬁ-
cient (K) and themembrane bending rigidity (k), respectively.
The critical micelle concentration of each lysolipid was, in
addition, determined by ITC. The study is conducted in the
dilute, excess water regime at 25C, which is far above the
main phase transition of POPC. The information obtained
from the membrane partitioning and destabilizing capacity
of the LPCs allows us to make a detailed analysis of the effect
of the LPCs on the membrane stability. The results are inter-
preted in terms of a phenomenological model, andwe propose
a simple criterion for the membrane destabilizing potency of
a surfactant.
MATERIALS AND METHODS
Experimental
Materials
1-Palmitoyl-2-oleyl-sn-glycerol-3-phosphatidylcholine (POPC; purity>98%),
1-dodecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC12), 1-tetradeca-
noyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC14), and 1-hexadecanoyl-
2-hydroxy-sn-glycero-3-phosphocholine (LPC16) were obtained from Avanti
Polar Lipids (Alabaster, AL). Organic solvents and sugars were obtained
from Sigma-Aldrich (St. Louis, MO). All materials were used without further
puriﬁcation.
Giant unilamellar vesicle preparation
Twenty microliters of POPC lipid in chloroform (0.2 mM) was deposited on
platinum wire electrodes using a Hamilton syringe. The solvent was subse-
quently evaporated overnight in a vacuum chamber. Giant unilamellar vesi-
cles (GUVs) were formed by electroformation (17,18) in a 75 mOsm sucrose
solution containing LPCs at the desired concentration. All GUV preparations
were conducted at 25C. The vesicles were then resuspended in a 75 mOsm
glucose solution containing LPCs at the desired concentration and subse-
quently thermostated in an observation chamber. Solution osmolarities
were regulated using a freezing-point osmometer (Model 3D3; Advanced
Instruments, Norwood,MA) andMilliQwater was used throughout the prep-
aration (Millipore, Bedford, MA).
Large unilamellar vesicle preparation
One-hundred-nanometer large unilamellar vesicles (LUVs) were prepared
from POPC lipid ﬁlms, whichwere rehydrated in a 75mOsm glucose solution
for 60 min followed by extrusion with an Avanti Polar Lipids mini-extruder.
The size distribution of the LUVs was checked by dynamic light scattering
(Zetasizer Nano; Malvern Instruments, Malvern, UK) and the effective lipid
concentrationwasdeterminedby ICP-AES(VistaAX;Varian,PaloAlto,CA).
Data analysis
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) measurements were performed on an
iTC200 (Microcal, Northampton, MA) with a cell volume of 204 mL. Small
aliquots of 100 nm POPC LUVs were injected into a 75 mM glucose solu-
tion containing LPC. Data analysis was performed using custom-made soft-
ware, which includes an improved baseline estimation and ﬁtting of the
partition model described below to the data by c2-minimization. The base-
line is determined by linear regression of the heat transfer data from the last
20% of the time interval between two injections. The obtained regression
lines are then interpolated by line segments. The measured standard devia-
tion of data from the regression line is used to estimate the errors si on
the integrated heat transfer DQi for each injection. In Fig. 1 a, the full
heat transfer curve is shown.
The data is interpreted in terms of a simple partition model,
Cp
CL
¼ KCf ; K ¼ 1
Cw
exp
 DGmemw =RT; (2)
where Cp is the concentration of lysolipids partitioned into the membrane,
CL is the total lipid concentration, Cf is the free lysolipid concentration in
bulk solution,K is the partition coefﬁcient,Cw¼ 55.5M is the molar concen-
tration of water, and DGmemw is the free energy of partitioning. The amount of
lysolipid is conserved during the titration experiment and is given by the ITC
cell concentration C0 ¼ Cp þ Cf. Enforcing this constraint on the lysolipid
-0.04
-0.02
0.00
 0.02
 0.04
 0.06
 0.08
 0.10
 0.12
 0.14
 0  500  1000  1500  2000  2500
P 
[μ
C
al
/s
]
Time [s]
a
-1.0
-0.5
 
0.0
 0.5
 1.0
 1.5
 2.0
 2.5
 0  2  4  6  8  10  12  14  16  18  20
Inj. nr.
Q
 [μ
C
al
]
Peak integral
Data fit
b
FIGURE 1 Isothermal titration calorimetry injecting POPC LUVs into
LPC12 at 25C. (a) Heat-spikes from 2 mL 65.4 mM POPC LUVs injected
into a 200 mM LPC12 solution containing 75-mM glucose. (b) Peak inte-
grals of the heat-spikes shown in panel a as a function of injection number.
The peak integrals are ﬁtted using Eqs. 3–5 yielding the partition coefﬁcient,
K, the molar enthalpy of partitioning,DHmemw , and the heat of dilution, qdil, as
ﬁtting parameters.
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concentration, in combinationwith Eq. 2, yields an expression for the amount
of partitioned lysolipid Cp¼ KCLC0/(1þ KCL). According to Heerklotz and
Seelig (6), the cumulant heat, Qi, is assumed proportional to the amount of
compound partitioned into the membrane plus a contribution from heat of
dilution. The heat of ith injection is thus modeled as
DQi ¼ DHmemw VcellDCip þ qdil;
DCip ¼
KCiLC
i
0
1 þ KCiL
 KC
i1
L C
i1
0
1 þ KCi1L
;
(3)
where Ci0 and C
i
L are the lysolipid and lipid concentration in the cell after
the ith injection, respectively,Vcell is the ITC cell volume,DH
mem
w is the molar
enthalpy of partitioning, and qdil is the heat of dilution, which is assumed to be
constant. According to Tellinghuisen (19), if instant mixing upon injection is
assumed, the lysolipid and lipid concentrations are given by
Ci0 ¼ C0

1 exp
V iadd
Vcell

;
CiL ¼ CLexp
V iadd
Vcell

;
(4)
where
V iadd ¼
Xi
0
Vi
is the cumulant volume injected into the cell upon the ith injection. As C0,
CL, Vcell, and Vi are given by the experimental setup, the remaining unknown
parameters K, DHmemw , and qdil, are determined as ﬁtting variables by mini-
mization of
c2

K;DHmemw ; qdil
 ¼ X
i

DQexpi  DQi
si
2
; (5)
where DQi
exp is the experimentally measured heat from each injection
(shown in Fig. 2 b) and DQi is given by Eq. 3. The experimental error asso-
ciated with the heat of injection, si, is estimated from the ITC thermogram as
described previously. The results are compiled in Table 1 and are averages of
3–6 independent ITC experiments.
Bending rigidity measurements
Large unilamellar vesicleswere cultivated by electroformation of POPCﬁlms
hydrated in a 75 mM sucrose solution containing LPC. Suspending the vesi-
cles in a 75 mM glucose solution ensures both improved phase contrast and
sedimentation of the GUVs at the bottom of the observation chamber. Prep-
aration of GUVs with the partitioning agent present in the hydration solution
ensures that 1), the LPCs are distributed evenly between the two monolayer
leaﬂets of the bilayer; and 2), the lysolipid reservoir is large and the concen-
tration can therefore be considered as constant. The free (bulk) concentration
of lysolipid in the GUV sample can, as a consequence, be estimated by the
LPC concentration in the hydration solution because only a small fraction
of lysolipid has partitioned into the lipid membrane (K x 102 – 104 M1
and CGUVL x 10
7 M, which results in Cp/C0x KCL< 10
3). In a tempera-
ture-controlled chamber (25C), undulating vesicles are visualized using
phase contrast microscopy (Axiovert S100; Carl Zeiss, Oberkochen,
Germany). The chamber is sealed to prevent evaporation from the solution
and possible changes of concentrations during the experiment. For each
measurement, a set of 4000–6000 GUV contours is collected as described
in earlier work (20). Each estimate of the bending rigidity is an average ob-
tained from measurements of ~20 individual vesicles. The data analysis for
determination of k is performed by custom-made software (20). In general,
the VFA technique is well suited for measuring the bending rigidity of
membranes perturbed by partitioning agents, because themeasuring principle
is noninvasive and the measuring chamber prevents evaporation.
RESULTS AND DISCUSSION
ITC
The titration of POPC LUVs into LPC solutions were all per-
formed at LPC concentrations at which demicellization is
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FIGURE 2 Plot of the effective bending rigidity as a function of (a) the
LPC bulk concentration given in units of the LPC cmc-value and (b) the
LPC membrane molar fraction, xp, given by xpxCLPCp =CLip ¼ KCLPC for
CLPC < cmc. Lines representing the ﬁt of Eq. 7 are shown in panel a and
guidelines emphasizing the differences in LPC inﬂuence on keff as a function
of xb are shown in panel b.
TABLE 1 Parameter values derived from ITC and VFA at 25 C
LPC12 LPC14 LPC16
K [M1] 460 5 50 17505 94 125005 3900
DGmemw [kJ/mol] 25.15 0.3 28.15 0.1 33.35 0.7
DHmemw [kJ/mol] 1.3 5 0.1 3.0 5 0.1 3.05 0.5
cmc [mM] 640 5 10 455 2 4*
K$cmc 0.295 0.03 0.0805 0.006 0.0505 0.003
DMCI 2.9 0.6 0.3
l[A˚] 1.8 1.6 1.5
Compilation of the thermodynamic data obtained by ITC at 25C and
mechanical stability parameters assessed by VFA.
*The cmc-value of LPC16 was adopted from the literature (12,21), which we
veriﬁed by ﬂuorescence anisotropy measurements.
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neglectable, and partitioning of monomeric LPC into the
membrane is thus assumed to be the main contribution of
the heat transfer. The cmc-values for LPC12 and LPC14
were determined by ITC (data not shown) and the cmc of
LPC16 was adopted from literature (12,21). Fig. 1 a shows
heat-spikes from injecting POPC LUVs into LPC12. The
heat per injections and the best ﬁt of Eq. 5 to the data is given
in Fig. 1 b. The obtained values for the partition coefﬁcients
and molar enthalpies of partitioning of LPCs into the
membrane are given in Table 1. The partition coefﬁcient
increases strongly with LPC acyl-chain length with an
approximative linear relationship between the free energy
of partitioning and the chain length,
DGmemw =RT ¼ lnð55:5M$KÞx 0:14 0:83X;
in agreement with earlier reports (12). The free energy of
LPC monomer partitioning into micelles similarly exhibits
a linear relationship with X,
DGmicw =RT ¼ ln ð55:5M=cmcÞx3:83 1:27X:
For the three different LPCs, K$cmc ~ 0.05  0.3, showing
that the free energy of transferring a monomer from micelle
to membrane (DGmemmic ¼  RT ln(K$cmc) > 0) is positive
and that the process does not occur spontaneously. In work
of Heerklotz and Seelig (6), the product, K$cmc, was
suggested as a measure of a surfactant’s capacity to
solubilize a membrane. In their classiﬁcation of surfactants,
K$cmc% 1 (DGmemmic R 0) infers a strong detergent whereas
K$cmcR 1 (DGmemmic % 0) is a weak detergent. By this deﬁ-
nition of detergent strength, the LPCs investigated in this
study are all strong detergents and follow the sequence:
LPC16 > LPC14 > LPC12.
Bending rigidity
The measurements of membrane bending rigidity were per-
formed over a wide range of LPC concentrations at 25C.
In the case of LPC16, GUVs could be studied at concentra-
tions ranging from zero to values above the cmc value of
LPC16. For LPC12, GUV formation was only possible in
a limited concentration-range below cmc, whereas for studies
of LPC14 the GUVs lost their optical contrast near the cmc-
value of LPC14. The overall trend is a dramatic decrease in
the observed bending rigidity with increasing LPC concen-
trations, except at the lowest LPC concentrations where
minor increases in the bending rigidity are observed (Fig. 2).
In Fig. 2 the bending rigidity is plotted as a function of 1),
the bulk/free LPC concentration scaled with respect to the
LPC cmc-value; and 2), as a function of the LPC membrane
molar fraction xp x Cp/Clip. The magnitude of the LPCs’
effect on the membrane bending rigidity depends on whether
it is measured relative to the bulk or membrane concentration
which is evident in Fig. 2. The decrease in k, when measured
as a function of xp or the cmc-scaled bulk concentration, is
more pronounced as the acyl-chain length of the lysolipids
is reduced. Despite the larger partition coefﬁcient of
LPC16, the effect on k per LPC molecule in the membrane
is less than for its shorter homologs. For LPC16, a saturation
of k is observed at high concentrations (Fig. 2 a), which
correlates with the formation of micelles above the cmc-
value. Above cmc, the LPC16 monomer concentration in
the solution is approximately constant and no further parti-
tioning of LPC monomers into the membrane occurs. Below
cmc, the monomer concentration in the solution is well
approximated by total lysolipid concentration. From Fig. 2 b,
it is evident that the LPC molecules reduce the effective
bending rigidity in a common range of xp; however, there
are differences in the degree of the perturbation caused by
the individual LPC molecules depending on acyl-chain
length. This effect is evident by the change in keff as a func-
tion of xp, as indicated by the slope of the guidelines shown
in Fig. 2 b.
Phenomenological model
The dramatic reduction in the effective bending rigidity at
low lysolipid concentration can be interpreted in terms of
a simple phenomenological model, which includes the
local effect of the LPCs on the membrane mean curvature.
The Helfrich (1) free energy (see also Eq. 1), for the case
H0 ¼ 0, is extended by adding a free energy contribution
arising from the lateral distribution of lysolipids,
Hint ¼ k0l
R
dAðrþ  rÞ2H
þ kBT
R
dA

rln

alysor
 þ rþ lnalysorþ ; (6)
where r5 is the local lateral density of lysolipids in the upper
and lower monolayer leaﬂets and alyso is the cross-sectional
area per lysolipid in the membrane. The bending rigidity of
the detergent free lipid membrane is given by k0. In a ﬁrst
approximation, alyso can be set equal to alipid ¼ 70 A˚2
(22). The second term in Eq. 6 represents the gas approxima-
tion of the free energy for the lateral distribution of lysolipids
in the membrane monolayers, while the ﬁrst term models the
coupling between the local lysolipid density difference
(rþ  r) and the mean curvature (H). The coupling strength
of (rþ  r) and H is governed by the parameter l, which
has dimension of length. The term l/2 (rþ  r) can be iden-
tiﬁed as the local spontaneous curvature. Stability analysis of
the total free energy, H ¼ Hint þHint, show that the
coupling term ðHintÞ in general leads to a reduction of the
effective bending rigidity of the membrane (23,24),
keff  k0
k0
¼ 4l2r0
k0
kBT
¼  4l
2
alipid
k0
kBT
ðKcmcÞ cf
cmc
; (7)
where r0 is the average lateral density of lysolipid in the
membrane. A ﬁt of Eq. 7 to the data shown in Fig. 2 a
provides an estimate of l for each of the three lysolipids,
which are given in Table 1. The data shown in Fig. 2 and
the predictions of the phenomenological model (Eq. 7),
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keff/ 0 for
4l2
alipid
k0
kBT
ðKcmcÞ cf
cmc
> 1;
suggest an extension of Heerklotz and Seelig’s (6) measure
of detergent potency by introducing a membrane curvature
instability (MCI) parameter:
DMCI ¼ 4l
2
alipid
k0
kBT
ðKcmcÞ: (8)
In this study, the ﬁt of Eq. 7 to the data shown in Fig. 2 a yield
equal values of k0 for all three LPCs, while K$cmc and
l decreases with the LPC acyl-chain length leading to sig-
niﬁcant changes in DMCI (see Table 1). In general, both the
extent of partitioning and the local membrane perturbing
effect is important for the overall mechanical stability of
the membrane subject to the partitioning agents. Both of
these effects are incorporated into the parameter DMCI.
Within the framework of the presented phenomenological
model, the detergent strength is thus deﬁned as strong when
DMCI > 1 and weak for DMCI < 1. The value DMCI < 1
corresponds to the classical model of membrane destabiliza-
tion (5). According to this, micelles and membranes may
coexist at concentration levels above cmc, and even the small-
est lipid-uptake by the micelles will eventually lead to the
disappearance of the bilayer membranes with increasing
surfactant concentration. In the case DMCI < 1, the phase-
line separating the region of mixed micelles and of intact
membranes is given by CsatD ¼ (1 þ KCL)cmc, where CsatD is
the detergent concentration at which the membrane is satu-
rated (6,25). For the case DMCI > 1, the vesicles collapse at
a concentration CMCID below cmc of the surfactant due to
membrane curvature stress. Above this concentration, lipid-
surfactant aggregates are characterized by a higher curvature
(1/R) and a considerable increase in the partition coefﬁcient
of ~exp(k/kBT l/R ralyso) is expected (due to the ﬁrst term
of Eq. 6). The structure of these lipid-surfactant aggregates
will depend on the particular system, but tubular membranes
of high curvature or tubular micelles are obvious candidates
and have been observed in some lipid surfactant systems
(26). Furthermore, for DMCI > 1, the phase-line separating
the region of intactmembranes and the collapsed state is given
by CMCID ¼ (1þ KCL)cmc/DMCI, where CMCID is the detergent
concentration at which the membrane collapses. The param-
eter DMCI can be determined via the previous equation if
K$cmc and the phase line has been determined experimen-
tally, e.g., by ITC. According to this deﬁnition of detergent
strength, only LPC12 is a strong detergent and the LPCs
investigated follow the sequence: LPC12>LPC14>LPC16.
Interpretation of l
The incorporation of LPCs into lipid bilayers is expected to
organize with their polar PC-headgroups close to the bilayer
interface and their hydrocarbon chain buried into the hydro-
phobic core of the membrane, as shown in Fig. 3. A single
lysolipid in one of the monolayers will perturb the packing
properties of the surrounding lipids in a radius characterized
by the lateral correlation length x (27). For temperatures well
above the main phase transition of the lipid membrane, this
correlation length is short, at xx 1–2 nm. A possible calcu-
lation procedure is to consider a membrane square patch
(length of 2x with zero tension) with a lysolipid incorporated
into one of the monolayers and calculate l by (28)
k0
l
alyso
¼
Zd
d
PðzÞzdz; (9)
where P(z) is the lateral pressure proﬁle through the
membrane of thickness 2d. This can be done by self-consis-
tent ﬁeld theory (29,30), molecular dynamics, or coarse-
grained simulations of the membrane.
A simpler approach is to make a rough estimate of l from
dimensional analysis by assuming that the lateral effects
from a local membrane perturbation, e.g., insertion of a lyso-
lipid, vanish over the length x. A simple packing consider-
ation leads to
lx
alyso
l

1 þ Dn
nLip

1
Nx
; (10)
where nLip ¼ ðnsn1 þ nsn2Þ=2 is the average lipid hydro-
carbon chain length and Dn ¼ nLip  X is a measure of the
chain length difference between lipid and lysolipid. Here
2l corresponds to the hydrophobic thickness of the lipid
bilayer and Nx is the number of lipids within a lateral coher-
ence patch. Assuming alyso¼ 70 A˚2, lmax¼ 1 nm, nLip ¼ 17,
and Nx ¼ 7 leads to l(LPC16) ¼ 1.1 A˚, l(LPC14) ¼ 1.2 A˚,
LP
C1
6
LP
C1
2
LP
C1
4
K1/cmc
ΔGwΔGw
memmic
FIGURE 3 Illustration of the LPC equilibria in the pres-
ence of a lipid membrane. The partitioning of LPC is given
by the partition coefﬁcient, K, and the free energy of parti-
tioning, DGmemw . The micelle formation equilibrium is
described by the cmc-value and the free energy of transfer-
ring a detergent monomer from bulk to micelle, DGmicw . The
incorporation of LPC molecules in the membrane bilayer is
illustrated, showing increased degree of acyl-chain
mismatch going from LPC16 to LPC12.
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and l(LPC12) ¼ 1.3 A˚, which is a reasonable estimate of the
size and trend of l when compared to the values in Table 1.
Comparison with antimicrobial peptides
The above results have strong similarity with ﬁndings on
themembrane perturbation of antimicrobial peptides. Antimi-
crobial peptides are typically small helical peptides that parti-
tion into the bilayer leaﬂets and perturb the membrane by
inducing curvature stress. Membrane softening and destabi-
lizing behavior has also been observed with this class of
peptides. Gramicidin (31) and Magainin (20,23) are speciﬁc
examples where a saturation in the bending rigidity is
observed with increasing bulk concentration. However, there
are no indications of aggregation in the bulk solution to
explain this behavior and interaction and aggregation of
peptides in the membrane must thus be taken into account.
For Gramicidin, the trans-membrane dimerization, and for
Magainin, the transient membrane pore formation, serve to
couple peptides between the monolayers. Consequently, the
membrane destabilization parameter,DMCI, must bemodiﬁed
so that cmc is replaced by the bulk concentration at which
some aggregation of peptides in the membrane takes place.
It is interesting to note that the lytic activity of amphiphatic
peptides has been observed to increase with both the peptide
partitioning into themembrane and the hydrophobic moment,
a measure of the capability of a peptide to perturb a bilayer
interface (32). Indications of bilayer softening in the presence
of cationic surfactants can be inferred from observations of
extensive swelling of the lamella phase (33,34). Because
high salt concentration (100mMNaCl) excludes long-ranged
electrostatic repulsion as a possible mechanism, the Helfrich
(1) steric entropic repulsion due to reduced membrane
bending rigidity is the most plausible explanation. Further-
more, deuterium nuclear-magnetic-resonance studies (35)
suggest that lipid bilayers are softened by a range of antimi-
crobial peptides.
CONCLUSIONS
In this article, the interaction of LPC molecules with POPC
lipid membranes was investigated using ITC and VFA tech-
niques. The obtained results for the membrane partition
properties of the LPCs and the inﬂuence on the membrane
bending rigidity revealed signiﬁcant differences in the action
of LPCs on the membrane, depending on the LPC acyl-chain
length. The longest acyl-chain LPC16 (displaying the small-
est acyl-chain mismatch to POPC) gave the weakest pertur-
bation per LPC molecule associated with the membrane,
while the LPC12, with the shortest acyl-chain (displaying
the largest acyl-chain mismatch) displayed the largest pertur-
bation. Furthermore, GUVs were formed well above the cmc
of LPC16, whereas studies of LPC12 were only possible at
concentrations CMCID < 0.4$cmc(LPC14)— i.e., well below
the cmc-value. These results point to the conclusion that
some detergents are strong in the sense that they mechani-
cally destabilize the membrane through curvature stress,
resulting in curvature-induced instability of the GUV, and
others are strong detergents in the sense that they form
micelles in which the membrane can dissolve. In extension
of the three-stage model, a parameter DMCI was proposed
that captures the curvature instability induced by a deter-
gent. The MCI parameter revealed that LPC12 is a strong
(DMCI > 1) and LPC14 and LPC16 are weak (DMCI < 1)
detergents of POPC membranes. From phenomenological
modeling, we found that the parameter DMCI can be
expressed by the bending rigidity, cmc$K, and the local
mean curvature coupling-parameter l, which is related to
the packing properties of LPCs in the bilayer. The criterion
of a strong detergent by the model of Heerklotz and Seelig
(6) (K$cmc< 1) is not always sufﬁcient, and the introduction
of the DMCI parameter may provide an alternative determina-
tion of detergent strength.
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Appendix II 
Materials and methods for Chapter 2 
Materials 
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-(polyethylene glycol)2000 (DSPE-PEG2000), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000-
NH2), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)2000] (DSPE-PEG2000-Mal), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[PDP(polyethylene glycol)2000] (DSPE-PEG2000-PDP) were purchased from Avanti 
Polar Lipids Inc. (Alabaster, USA). Dithiothreitol (DTT), 5-azidopentanoic acid, 4-formyl 
benzoic acid, 4-pentynoic acid, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC·HCl), thallium(III) trifluoroacetate, trifluoroacetic acid (TFA), and 
triisopropylsilane (TIS) were purchased from Sigma Aldrich (Schnelldorf, Germany). The 
coupling reagent O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HATU), Wang Resin and all Fmoc protected amino acids used for 
the solid phase peptide synthesis were purchased from GL Biochem (Shanghai, China). 
All chemicals and reagents were of analytical grade and used without further purification. 
 
Instrumentation 
FT-IR was recorded on a Perkin Elmer Spectrum 100 FT-IR Spectrometer. Dynamic light 
scattering and zeta-potential measurements were performed on a Brookhaven Instruments 
Corporation Zeta PALS zeta potential analyzer. Analytical reversed-phase high-
performance liquid chromatography (RP-HPLC) was carried out on a Shimadzu LC-2010 
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analytical HPLC by employing a Waters XTerra® C8 5 µm (4.6 x 150 mm) column. Semi-
preparative HPLC was performed on a Waters Semi-preparative HPLC equipped with a 
Waters 600 Pump & Controller and a Waters 2489 UV/Visible Detector using a a Waters 
XTerra® C8 5µm (19 x 150 mm) column. HPLC Eluent A consisted of a 5% MeCN 
aqueous solution with 0.1% TFA; HPLC Eluent B consisted of 0.1% TFA in MeCN. 
HPLC analysis was monitored using dual channel UV detection at 254 nm and 280 nm. 
Pre-packed Strata C8 solid phase extraction (SPE) (55 µm, 70 Å) Giga Tubes from 
Phenomenex (Torrance, USA) were used for the purification of functionalized 
phospholipids. Mass spectra were recorded using a Bruker Daltonics Reflex IV MALDI-
TOF Spectrometer using 2,5-dihydroxybenzoic acid (DHB) spiked with sodium 
trifluoroacetate in MeOH as matrix. NMR spectra were recorded either on a Bruker 
Avance DPS 250 MHz or a Varian Mercury 300 MHz Spectrometer using the solvent 
peak as an internal reference. 
 
Synthesis of functionalized TATE peptides 
General SPPS protocol: The linear TATE octapeptide NH2-D-Phe-Cys(Acm)-Tyr(tBu)-
D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu)-Resin was synthesized manually by 
SPPS on a Wang Resin preloaded with NH2-Thr(tBu)-OH (0.50 g, 0.50 mmol/g) by 
standard Fmoc methodology. Each coupling was performed by 4.0 equiv. Fmoc protected 
amino acid, 3.95 equiv. HATU and 8.0 equiv. 2,4,6-collidine in DMF (5.0 mL). Cleavage 
of the Fmoc group was carried out using piperidine in DMF (1:4) for 2 x 5 minutes. 
Completion of each coupling and deprotection step were monitored by the Kaiser test. 
Removal of the Acm protection groups on the two cysteines and simultaneous disulfide 
bond formation was achieved by addition of Tl(CF3COO)3 (0.27 g, 0.50 mmol, 2.0 
equiv.) in DMF (5.0 mL) for 75 min.. The resin containing the cyclized peptide was 
extensively washed with DMF (10 × 5.0 mL) and subsequently divided into five SPPS 
reaction vials (5 × 0.10 g) in which the N-terminal was acylated with the desired 
functionality as described below. 
 
TATE-maleimide (1a). 4-Maleimidobutyric acid (38 mg, 0.20 mmol, 4.0 equiv.), HATU 
(75 mg, 0.198 mmol, 3.95 equiv.) and 2,4,6-colidine (53 uL, 0.40 mmol, 8.0 equiv.) in 
DMF (2.0 mL) were added to the resin immobilized cyclic octapeptide for 2 hours at 
room temperature followed by washing with DMF (4 × 5.0 mL). The peptide was cleaved 
from the solid support by addition of TFA/H2O/TIS (95:2.5:2.5) for 2 hours. Final 
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purification was achieved by semi-preparative HPLC employing a Waters Xterra® C8 
5µm (19 x 150 mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA 
in CH3CN. Gradient profile; linear gradient from 0% B to 100% B over 15 min. Flow 
rate; 15 mL/min. Maleimido-TATE (1a) was isolated as a homogenous peak with 
retention time of 7.99 min. The solvent was removed in vacuo and the product lyophilized 
from a mixture of water and acetonitrile to give a white fluffy powder (27 mg, 45%). The 
purity of the product was monitored by analytical HPLC, using the same gradient profile 
and solvent mixtures as above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) 
column, flow rate 1 mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. 
For C57H71N11O15S2 (M+Na)+ 1236.45. Found: 1236.39. 
 
TATE-SH (1b). 3-(tritylthio)-propionoic acid (70 mg, 0.20 mmol, 4.0 equiv.), HATU (75 
mg, 0.198 mmol, 3.95 equiv.) and 2,4,6-colidine (53 μL, 0.40 mmol, 8.0 equiv.) in DMF 
(2.0 mL) were added to the resin immobilized cyclic octapeptide for 2 hours at room 
temperature followed by washing with DMF (4 × 5.0 mL). The peptide was cleaved from 
the solid support by addition of TFA/H2O/TIS (95:2.5:2.5) for 2 hours. Final purification 
was achieved by semi-preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 
mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. 
Gradient profile; linear gradient from 0% B to 40% B over 15 min. Flow rate; 15 mL/min. 
TATE-thiol (1b) was isolated as a homogenous peak with retention time of 13.83 min. 
The solvent was removed in vacuo and the product lyophilized from a mixture of water 
and acetonitrile to give a white fluffy powder (2.8 mg, 6.0%). The purity of the product 
was monitored by analytical HPLC using the same gradient profile and solvent mixtures 
as above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 
mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For C52H68N10O13S3 
(M+Na)+ 1159.33. Found: 1159.57. 
 
TATE-azide (1c). 5-azidopentonoic acid (29 mg, 0.20 mmol, 4.0 equiv.), HATU (75 mg, 
0.198 mmol, 3.95 equiv.) and 2,4,6-colidine (53 μL, 0.40 mmol, 8.0 equiv.) in DMF (2.0 
mL) were added to the resin immobilized cyclic octapeptide for 2 hours at room 
temperature followed by washing with DMF (4 × 5.0 mL). The peptide was cleaved from 
the solid support by addition of TFA/H2O/TIS (95:2.5:2.5) for 2 hours. Final purification 
was achieved by semi-preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 
mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. 
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Gradient profile; linear gradient from 0% B to 40% B over 15 min. Flow rate; 15 mL/min. 
TATE-azide (16b) was isolated as a homogenous peak with retention time of 16.22 min. 
The solvent was removed in vacuo and the product lyophilized from a mixture of water 
and acetonitrile to give a white fluffy powder (9.6 mg, 17%). The purity of the product 
was monitored by analytical HPLC using the same gradient profile and solvent mixtures 
as above but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. 
Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For C54H71N13O13S2 (M+Na)+ 
1196.33. Found: 1236.39. 
 
TATE-alkyne (1d). 4-pentynoic acid (20 mg, 0.20 mmol, 4.0 equiv.), HATU (75 mg, 
0.198 mmol, 3.95 equiv.) and 2,4,6-colidine (53 μL, 0.40 mmol, 8.0 equiv.) in DMF (2.0 
mL) were added to the resin immobilized cyclic octapeptide for 2 hours at room 
temperature followed by washing with DMF (4 × 5.0 mL). The peptide was cleaved from 
the solid support by addition of TFA/H2O/TIS (95:2.5:2.5) for 2 hours. Final purification 
was achieved by semi-preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 
mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. 
Gradient profile; linear gradient from 0% B to 30% B over 15 min. Flow rate; 15 mL/min. 
TATE-alkyne (16c) was isolated as a homogenous peak with retention time of 18.32 min. 
The solvent was removed in vacuo and the product lyophilized from a mixture of water 
and acetonitrile to give a white fluffy powder (7.2 mg, 13%). The purity of the product 
was monitored by analytical HPLC using the same gradient profile and solvent mixtures 
as above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 
mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For C54H68N10O13S2 
(M+Na)+ 1151.29. Found: 1151.51.  
 
TATE-hydroxylamine (1e). Bis-Boc-amino-oxyacetic acid (47 mg, 0.15 mmol, 3 
equiv.), HATU (56 mg, 0.146 mmol, 2.95 equiv.) and 2,4,6-colidine (41 μL, 0.30 mmol, 
6.0 equiv.) in DMF (2.0 mL) were added to the resin immobilized cyclic octapeptide for 2 
hours at room temperature, followed by washing with DMF (4 × 5.0 mL). The peptide 
was cleaved from the solid support by addition of TFA/H2O/TIS (95:2.5:2.5) for 2 hours. 
Final purification was achieved by semi-preparative HPLC employing a Waters Xterra® 
C8 5µm (19 x 150 mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% 
TFA in CH3CN. Gradient profile; linear gradient from 0% B to 30% B over 15 min. Flow 
rate; 15 mL/min. TATE-hydroxylamine (16d) was isolated as a homogenous peak with 
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retention time of 14.17 min. The solvent was removed in vacuo and the product 
lyophilized from a mixture of water and acetonitrile to give a white fluffy powder (15 mg, 
27%). The purity of the product was monitored by analytical HPLC using the same 
gradient profile and solvent mixtures as above, but with a Waters XTerra® C8 5μm (4.6 x 
150 mm) column, flow rate 1 mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): 
Calcd. For C51H67N11O14S2 (M+Na)+ 1144.25. Found: 1144.41. 
 
Synthesis of functionalized DSPE-PEG2000 phospholipids 
DSPE-PEG2000-alkyne (2a). DSPE-PEG2000-NH2 (40 mg, 14 µmol, 1.0 equiv.) was 
dissolved in dry CH2Cl2 (5.0 mL) in a pre-dried flask under a nitrogen atmosphere. A 
mixture of 4-pentynoic acid (6.4 mg, 66 µmol, 4.7 equiv.) , EDC·HCl (12.2 mg, 64 µmol, 
4.6 equiv.) and DMAP (16.2 mg, 0.13 mmol, 9.3 equiv.) in dry CH2Cl2 (1.0 mL) were 
added and the reaction stirred overnight under nitrogen at room temperature. The solvent 
was removed in vacuo and the product purified on a Strata-C8 SPE column using a 10% 
stepwise gradient from 0-100% MeOH in water. Fractions with the desired compound 
was combined, reduced in vacuo and lyophilized from a mixture of water and acetonitrile 
to give the title compound as a white powder (25 mg, 61%). 1H-NMR (250MHz, CDCl3): 
δ 8.20 (bs, 1H), 6.57 (bs, 1H), 5.87 (bs, 1H), 5.27-5.18 (m, 1H), 4.36 (dd, J = 11.7, 3.4Hz, 
1H), 4.25-3.90 (m, 7H), 3.64 (bs, 164H), 2.35-2.25 (m, 8H), 2.02 (t, J = 2.5Hz, 2H), 1.67-
1.51 (m, 4H), 1.25 (bs, 56H), 0.88 (t, J = 6.6Hz). MALDI-TOF MS (m/z) (DHB+Na): 
2807.1 ± n×44.0. IR (KBr): ν(cm-1) 3435.9, 2918.3, 2851.4, 1697.5, 1112.9. 
 
DSPE-PEG2000-cyclooctyne (2b). DSPE-PEG2000-NH2 (75 mg, 27 µmol, 1.0 equiv.) was 
dissolved in dry DMF (3.0 mL) in a pre-dried flask under a nitrogen atmosphere. A 
mixture of 1-fluorocyclooct-2-ynecarboxylic acid (Schultz, 2010) (9.2 mg, 54 µmol, 2.0 
equiv.), Et3N (7.5 µL, 54 µmol, 2 equiv.) and HATU (20 mg, 53 µmol, 1.96 equiv.) in dry 
DMF (3.0 mL) were added and the reaction stirred overnight under nitrogen at room 
temperature. The solvent was removed in vacuo and the product purified on a Strata-C8 
SPE column using a 10% stepwise gradient from 0-100% MeOH in water. Fractions with 
the desired compound was combined, reduced in vacuo and lyophilized from a mixture of 
water and acetonitrile to give the title compound as a white powder (56 mg, 71%). 1H-
NMR (250MHz, CDCl3): δ 6.89 (bs, 1H), 5.83 (bs, 1H), 5.25-5.19 (m, 1H) , 4.40-4.04 
(m, 10H), 3.95-3.89 (m, 2H), 3.64 (bs, 164H), 3.53-3.33 (m, 6H), 2.37-2.29 (m, 6H), 
1.67-1.55 (m, 6H), 1.25 (bs, 56H), 0.88 (t, J = 6.6 Hz, 6H). MALDI-TOF MS (m/z) 
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(DHB+Na): 2968.3 ± n×44.0. IR (KBr): ν(cm-1) 3445.3, 2918.2, 2851.4, 1741.6, 1648.9, 
1104.6. 
 
DSPE-PEG2000-benzaldehyde (2c). DSPE-PEG2000-NH2 (100 mg, 36 µmol, 1.0 equiv.) 
was dissolved in dry DMF (1.0 mL) in a pre-dried flask under a nitrogen atmosphere. A 
mixture of 4-formyl benzoic acid (22 mg, 0.14 mmol, 4.0 equiv.), Et3N (40 µL, 0.29 
mmol, 8 equiv.) and HATU (54 mg, 0.14 mmol, 3.95 equiv.), in dry DMF (0.40 mL) 
were added and the reaction was stirred under nitrogen over night at room temperature. 
The solvent was removed in vacuo and the product purified on a Strata-C8 SPE column 
using a 10% stepwise gradient from 50-100% MeOH in water. Fractions with the desired 
compound was combined, reduced in vacuo and lyophilized from a mixture of water and 
acetonitrile to give the title compound as a white powder ( 62 mg, 59%). 1H-NMR 
(300MHz, CDCl3): δ 10.08 (s, 1H), 8.01 (d, J = 8.4Hz, 2H), 7.94 (d, J = 8.4Hz, 2H), 6.00 
(bs, 1H), 5.21 (bs, 1H), 4.37-3.31 (m, 1H), 4.22-4.03 (m, 10H), 3.89-3.85 (m, 2H), 3.64 
(bs, 164H), 3.51-3.39 (m, 4H), 2.37-2.29 (m, 6H), 1.67-1.55 (m, 6H), 1.25 (bs, 56H), 0.88 
(t, J = 6.6 Hz, 6H). MALDI-TOF MS (m/z) (DHB+Na): 2904.6 ± n×44.0. IR (neat): 
ν(cm-1) 2917.0, 2850.8, 1744.5, 1702.1, 1466.5, 1343.5, 1102.5. 
 
DSPE-PEG2000-azide (2d). DSPE-PEG2000-NH2 (100 mg, 36 µmol, 1.0 equiv.) was 
dissolved in dry DMF (1.0 mL) in a pre-dried flask. A mixture of 5-azidopentanoic acid 
(21 mg, 0.14 mmol, 4.0 equiv.), Et3N (40 µL, 0.29 mmol, 8.0 equiv.) and HATU (54 mg, 
0.14 mmol, 3.95 equiv.) in dry DMF (0.50 mL) were added and the reaction stirred 
overnight under nitrogen at room temperature. The solvent was removed in vacuo and the 
product purified on a Strata-C8 SPE column using a 10% stepwise gradient from 50-100% 
MeOH in water. Fractions with the desired compound was combined, reduced in vacuo 
and lyophilized from a mixture of water and acetonitrile to give the title compound as a 
white powder (79 mg, 79%). 1H-NMR (300MHz, CDCl3): δ 6.37 (bs, 1H), 5.20 (bs, 1H), 
5.83 (bs, 1H), 4.38-4.32 (m, 1H) , 4.23-3.99 (m, 8H), 3.89-3.84 (m, 4H), 3.64 (bs, 164H), 
3.54-3.27 (m, 4H), 2.33-2.16 (m, 8H), 1.75-1.55 (m, 8H), 1.25 (bs, 58H), 0.88 (t, J = 6.6 
Hz, 6H). MALDI-TOF MS (m/z) (DHB+Na): 2898.4 ± n×44.0. IR (neat): ν(cm-1) 2917.2, 
2851.0, 2097.7, 1739.3, 1343.2, 1102.3. 
 
DSPE-PEG2000-SH (3). DTT (10 mg, 66 µmol, 3.9 equiv.) was added to a pre-dried flask 
under a nitrogen atmosphere containing DSPE-PEG2000-PDP (50 mg, 17 µmol, 1.0 equiv.) 
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in dry MeOH (1.0 mL). The reaction was stirred under nitrogen over night at room 
temperature after which the solvent was removed and the product purified on a Strata-C8 
SPE column, using a 10% stepwise gradient from 50-100% MeOH in water. Fractions 
with the desired compound were combined, reduced in vacuo and lyophilized from a 
mixture of water and acetonitrile to give a white fluffy powder (34 mg, 71%). 1H-NMR 
(300MHz, CDCl3): δ 6.99 (bs, 1H), 6.59 (bs, 1H), 5.20 (bs, 1H), 4.39-4.34 (m, 1H) , 4.23-
4.13 (m, 4H), 4.08-3.99 (m, 4H), 3.89-3.85 (m, 2H), 3.64 (bs, 166H), 3.57-3.38 (m, 4H), 
2.81 (dt, J = 8.3, 6.8 Hz, 2H), 2.51 (t, J = 6.8 Hz, 2H), 2.33-2.26 (m, 4H), 2.07 (s, 1H), 
1.67-1.56 (m, 6H), 1.25 (bs, 56H), 0.88 (t, J = 6.6 Hz, 6H). MALDI-TOF MS (m/z) 
(DHB+Na): 2904.4 ± n×44.0. IR (neat): ν(cm-1) 2917.1, 2850.9, 1739.0, 1466.6, 1343.0, 
1101.6. 
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Appendix III 
Materials and methods for Chapter 3 
Materials 
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-(polyethylene glycol)2000 (DSPE-PEG2000), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000-
NH2), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-
4-yl) (DSPE-NBD), cholesterol were purchased from Avanti Polar Lipids Inc. (Alabaster, 
USA). 5-azidopentanoic acid, trifluoroacetic acid (TFA), and triisopropylsilane (TIS) 
were purchased from Sigma Aldrich (Schnelldorf, Germany). 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was purchased from Macrocyclics 
(Dallas, USA). The coupling reagent O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HATU), 2-chlorotrityl chloride Resin and all 
Fmoc protected amino acids used for the solid phase peptide synthesis were purchased 
from GL Biochem (Shanghai, China). Amicon Ultra-15 centrifugal filter units were 
purchased from Millipore (Denmark). TLC-plates Silica gel 60 F254 (ref. no. 
1.05549.001) were purchased from Merck (Darmstadt, Germany). All chemicals and 
reagents were of analytical grade and used without further purification. 
 
Instrumentation 
Dynamic light scattering and zeta-potential measurements were performed on a 
Brookhaven Instruments Corporation Zeta PALS zeta potential analyzer. FT-IR was 
recorded on a Perkin Elmer Spectrum 100 FT-IR Spectrometer. UV spectra were 
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recorded using a Shimadzu UV-visible Spectrophotometer. Analytical reversed-phase 
high-performance liquid chromatography (RP-HPLC) was carried out on a Shimadzu LC-
2010 analytical HPLC by employing a Waters XTerra® C18 5 µm (4.6 x 150 mm) column 
or a Waters XTerra® C8 5 µm (4.6 x 150 mm) column. Semi-preparative HPLC was 
performed on a Waters Semi-preparative HPLC equipped with a Waters 600 Pump & 
Controller and a Waters 2489 UV/Visible Detector using a a Waters XTerra® C18 5µm 
(19 x 150 mm) column or a Waters XTerra® C8 5µm (19 x 150 mm) column. HPLC 
Eluent A consisted of a 5% MeCN aqueous solution with 0.1% TFA; HPLC Eluent B 
consisted of 0.1% TFA in MeCN. HPLC analysis was monitored using dual channel UV 
detection at 206 nm and 254 nm. Pre-packed Strata C8 solid phase extraction (SPE) (55 
µm, 70 Å) Giga Tubes from Phenomenex (Torrance, USA) were used for the purification 
of functionalized phospholipids. Mass spectra were recorded using a Bruker Daltonics 
Reflex IV MALDI-TOF Spectrometer using 2,5-dihydroxybenzoic acid (DHB) spiked 
with sodium trifluoroacetate in MeOH as matrix. Flow cytometry was carried out on a 
Gallios flow cytometer (Beckman Coulter, Denmark). NBD-fluorescent cells were 
measured by the blue laser (488 nm) for excitation and fluorescence emission was 
measured in FL2 (band pass filter 525 ± 10 nm). Confocal imaging was performed on a 
Leica TCS SP5 AOBS with a 63x water-immersed objective (Leica Microsystems, 
Germany). 
 
DSPE-PEG2000-azide (2d). DSPE-PEG2000-NH2 (200 mg, 72 µmol, 1.0 equiv.) was 
dissolved in dry DMF (2.0 mL) in a pre-dried flask. A mixture of 5-azidopentanoic acid 
(41 mg, 0.29 mmol, 4.0 equiv.), Et3N (80 µL, 0.57 mmol, 8.0 equiv.) and HATU (108 
mg, 0.28 mmol, 3.95 equiv.) in dry DMF (0.50 mL) were added and the reaction stirred 
overnight under nitrogen at room temperature. The solvent was removed in vacuo and the 
product purified on a Strata-C8 SPE column using a 10% stepwise gradient from 50-100% 
methanol in water. Fractions with the desired compound was combined, reduced in vacuo 
and lyophilized from a mixture of water and acetonitrile to give the title compound as a 
white powder (185 mg, 88%). MALDI-TOF MS (m/z) (DHB+Na): 2898.4 ± n×44.0. IR 
(neat): ν(cm-1) 2914, 2885, 2850, 2097, 1739, 1343, 1100. 
 
cRGDfPropargyl (5). The linear RGDfPropargyl pentapeptide NH2-Asp(OtBu)-D-Phe-
Propargyl-Arg(Pbf)-Gly-Resin was synthesized manually by SPPS on a 2-chlorotrityl 
chloride Resin (0.40 g, 0.20 mmol/g) by standard Fmoc methodology. Fmoc 
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quantification was used to determine the precise loading (λ = 290 nm, ε = 5253 M-1cm-1). 
Each coupling was performed by 4.0 equiv. Fmoc protected amino acid, 3.95 equiv. 
HATU (119 mg, 0.31 mmol, 3.95 equiv.) and 8.0 equiv. 2,4,6-collidine (83 µL, 0.64 
mmol, 8.0 equiv.) in DMF (4.0 mL). Cleavage of the Fmoc group was carried out using 
piperidine in DMF (1:4) for 2 x 2 minutes. Completion of each coupling and deprotection 
step were monitored by the Kaiser test. The peptide was cleaved from the solid support by 
addition of AcOH:TFE:CH2Cl2 (10:20:70) for 2 x 20 minutes. Cyclization was performed 
in solution (15 mL DMF) between the N-terminal of the aspartic acid and the free 
carboxylic acid on glycine using diphenyl phosphoryl azide (257 mg, 0.80 mmol, 3.0 
equiv.) and sodium hydrogencarbonate (336 mg, 4.0 mmol, 15 equiv.). The reaction was 
moitored by MALDI-TOF MS and was complete within 3 hours. The cyclized peptide 
was extracted using ethyl acetate, the organic phase combined and washed with a 
saturated solution of ammonium chloride, followed by brine and dried over anhydrous 
magnesium sulphate. Solvent was removed in vacuo and the crude peptide dissolved in 
TFA:H2O:TIS (95:2.5:2.5). Deprotection was complete within 24 hours. The TFA 
mixture was removed in vacuo and the crude peptide re-dissolved in acetonitrile:water 
(1:3) and purified by semi-preparative HPLC employing a Waters Xterra® C18 5µm (19 x 
150 mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in 
CH3CN. Gradient profile; linear gradient from 0% B to 100% B over 20 min. Flow rate; 
14 mL/min. cRGDfPropargyl was isolated as a homogenous peak with retention time of 7 
min. The solvent was removed in vacuo and the product lyophilized from a mixture of 
water and acetonitrile to give a white fluffy powder (31 mg, 69%). The purity of the 
product was monitored by analytical HPLC, using the same gradient profile and solvent 
mixtures as above, but with a Waters XTerra® C18 5μm (4.6 x 150 mm) column, flow rate 
1 mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For C26H34N8O7 
(M+Na)+ 570.25. Found: 570.43. 
 
cGRDfPropargyl (6). The linear GRDfPropargyl pentapeptide NH2-Asp(OtBu)-D-Phe-
Propargyl-Gly-Arg(Pbf)-Resin was synthesized manually by SPPS on a 2-chlorotrityl 
chloride Resin (0.40 g, 0.40 mmol/g) by standard Fmoc methodology. Fmoc 
quantification was used to determine the precise loading (λ = 290 nm, ε = 5253 M-1cm-1). 
Each coupling was performed by 4.0 equiv. Fmoc protected amino acid, 3.95 equiv. 
HATU (239 mg, 0.63 mmol, 3.95 equiv.) and 8.0 equiv. 2,4,6-collidine (167 µL, 1.3 
 158 
 
mmol, 8.0 equiv.) in DMF (4.0 mL). Cleavage of the Fmoc group was carried out using 
piperidine in DMF (1:4) for 2 x 2 minutes. Completion of each coupling and deprotection 
step were monitored by the Kaiser test. The peptide was cleaved from the solid support by 
addition of AcOH:TFE:CH2Cl2 (10:20:70) for 2 x 20 minutes. Cyclization was performed 
in solution (15 mL DMF) between the N-terminal of the aspartic acid and the free 
carboxylic acid on arginine using diphenyl phosphoryl azide (129 mg, 0.47 mmol, 3.0 
equiv.) and sodium hydrogencarbonate (197 mg, 2.3 mmol, 15 equiv.). The reaction was 
moitored by MALDI-TOF MS and was complete within 24 hours. The cyclized peptide 
was extracted using ethyl acetate, the organic phase combined and washed with a 
saturated solution of ammonium chloride, followed by brine and dried over anhydrous 
magnesium sulphate. Solvent was removed in vacuo and the crude peptide dissolved in 
TFA:H2O:TIS (95:2.5:2.5). Deprotection was complete within 24 hours. The peptide in 
TFA was precipitated into icecold diethyl ether, solid collected by centrifugation, 
resuspended in water and acetonitrile from which it was lyophilized giving a white fluffy 
powder (28 mg, 62%). The purity of the product was monitored by analytical HPLC, 
using the same gradient profile, solvent mixtures, column, and flow rate as above 
(cRGDfPropargyl (5)). Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For 
C26H34N8O7 (M+Na)+ 570.25. Found: 570.59. 
 
DSPE-PEG2000-cRGD (7). cRGDfPropargyl (5) (19 mg, 34 µmol, 2.0 equiv.) and DSPE-
PEG2000-N3 (2d) (47 mg, 16 µmol, 1.0 equiv.) were dissolved in methanol (1.0 mL). 
Copper(II) sulphate pentahydrate (8.0 mg, 32 µmol, 2.0 equiv.) and sodium ascorbate (13 
mg, 65 µmol, 4.0 equiv.) were dissolved in water (1.0 mL) and added to the above 
mixture. The reaction was stirred overnight. The solution was extracted with chloroform, 
the organic phases combined, washed with water and dried over anhydrous sodium 
sulphate. The solvent was removed in vacuo and the product purified by semi-preparative 
HPLC employing a Waters Xterra® C8 5µm (19 x 150 mm) column. Eluent: (A) 5% 
CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; linear gradient 
from 50% B to 100% B over 20 min. Flow rate; 14 mL/min. DSPE-PEG2000-cRGD (7) 
was isolated as a homogenous peak with retention time of 10 min. The solvent was 
removed in vacuo and the product lyophilized from a mixture of water and acetonitrile to 
give a white fluffy powder (29 mg, 52%). The purity of the product was monitored by 
analytical HPLC, using the same gradient profile and solvent mixtures as above, but with 
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a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. Purity >98%. 
MALDI-TOF MS (m/z) (DHB+Na): 3468.9 ± n×44.0. 
 
DSPE-PEG2000-cGRD (8). cGRDfPropargyl (6) (4.7 mg, 8.2 µmol, 2.0 equiv.) and 
DSPE-PEG2000-N3 (2d) (12 mg, 4.1 µmol, 1.0 equiv.) were dissolved in methanol (1.0 
mL). Copper(II) sulphate pentahydrate (2.0 mg, 8.2 µmol, 2.0 equiv.) and sodium 
ascorbate (3.2 mg, 16 µmol, 4.0 equiv.) were dissolved in water (1 mL) and added to the 
above mixture. The reaction was stirred overnight. The solution was extracted with 
chloroform, the organic phases combined, washed with water and dried over anhydrous 
sodium sulphate. The solvent was removed in vacuo and the product purified by semi-
preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 mm) column. Eluent: 
(A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; linear 
gradient from 50% B to 100% B over 20 min. Flow rate; 14 mL/min. DSPE-PEG2000-
cGRD (8) was isolated as a homogenous peak with retention time of 10 min. The solvent 
was removed in vacuo and the product lyophilized from a mixture of water and 
acetonitrile to give a white fluffy powder (7.6 mg, 53%). The purity of the product was 
monitored by analytical HPLC, using the same gradient profile and solvent mixtures as 
above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. 
Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): 3469.0 ± n×44.0. 
 
Liposomes for in vitro applications. Small unilamellar vesicles were prepared as 
described by Bangham et al. Lipids were dissolved in methanol:chloroform (1:9) and 
mixed in the desired ratios. For functionalized liposomes this ratio was DSPC:DSPE-
NBD:DSPE-PEG2000:DSPE-PEG2000-R (R being either cRGD or cGRD) (94.5:0.5:4:1) 
and for control PEG-liposomes the ratio was DSPC:DSPE-NBD:DSPE-PEG2000 
(94.5:0.5:5). The organic solvent was removed under a gentle strem of nitrogen and fully 
removed in vacuo overnight. The lipid film were hydrated in a phosphate buffered saline 
(PBS) at 65 °C for 1 hour, followed by freeze-thaw cycles and extrusion at 65 °C through 
100 nm polycarbonate filters using an Avanti Polar Lipids mini-extruder. The small 
unilamellar liposomes were analyzed by dynamic light scattering and zeta potential 
measurements (Zeta PALS, Brookhaven Instruments). 
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Liposomes for in vivo applications. Small unilamellar vesicles were prepared as 
described by Bangham et al. Lipids were dissolved in methanol:chloroform (1:9) and 
mixed in the desired ratios. For functionalized liposomes this ratio was 
DSPC:cholesterol:DSPE-PEG2000:DSPE-PEG2000-R (R being either cRGD or cGRD) 
(55:40:4:1) and for control PEG-liposomes the ratio was DSPC:cholesterol:DSPE-
PEG2000 (55:40:5). The organic solvent was removed under a gentle stream of nitrogen 
and fully removed in vacuo overnight generating a lipid film. The lipid film were 
hydrated in an aqueous HEPES buffer (10 mM, 150 mM NaCl, pH 7.4), containing 
DOTA (CDOTA = 10 mM) adjusted to pH 7.4 and 375 mOsm/l using NaOH and/or HCl. 
The lipid film was hydrated at 65 °C for 1 hour, followed by extrusion at 65 °C through 
100 nm polycarbonate filters using an Avanti Polar Lipids mini-extruder. Un-
encapsulated DOTA were removed by filtration through Amicon Ultra-15 centrifugal 
filter units exchanging the external buffer with a HEPES buffer (10 mM, 150 mM NaCl, 
pH 7.4, 295 mOsm/l). The formed liposomes were characterized by DLS and zeta 
potential measurements (Zeta PALS, Brookhaven Instruments). 
 
Flow cytometry. The internalization of cRGD-, cGRD-, and PEG-liposomes were 
analyzed using flow cytometry (Gallios, Beckman Coulter). The human glioblastoma 
U87MG cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (Sigma-Aldrich) and 100 UI/mL penicillin and streptomycin (Lonza). Cells were 
incubated in a 5% CO2 humidified incubator at 37 °C. The day before used the cells were 
plated in 12-well dishes (50,000 cells per well). The medium was replaced with fresh and 
liposomes were added. The cells were incubated 5 hours at 37 °C. The cells were washed 
with PBS, trypsinized and placed into a FACS tube containing 3 mL of PBS using 1 mL 
of medium. The cells were centrifuged for 3 min at 850 rpm, supernatant removed and the 
cells resuspended in 300-500 µL PBS. The NBD-fluorescent cells were measured with a 
blue laser (488 nm) for excitation and emission was measured in FL2 with a band pass 
filter of 525 ± 10 nm. 10,000 events were collected for each sample and non-treated cells 
were used as reference and the gates adjusted from those. 
 
Inhibition study. The human glioblastoma U87MG cells were grown in RPMI 1640 
medium supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 100 UI/mL 
penicillin and streptomycin (Lonza). Cells were incubated in a 5% CO2 humidified 
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incubator at 37 °C. The cells were plated in 12-well dishes and used when 50,000 cells 
per well were present. The medium was replaced with fresh and free peptide dissolved in 
20% DMSO in PBS in concentrations ranging from 2.3 mM to 2.3 µM was added (20 µL 
per 1 mL media). The cells were incubated 15 minutes at 37 °C, before the addition of 
liposomes. The cells were incubated with the liposomes for 5 hours at 37 °C. Then 
washed with PBS, trypsinized and placed into a FACS tube containing 3 mL of PBS 
using 1 mL of medium. The cells were centrifuged for 3 min at 850 rpm, supernatant 
removed and the cells resuspended in 300-500 µL PBS. The NBD-fluorescent cells were 
measured using flow cytometry (Gallios, Beckman Coulter) with a blue laser (488 nm) 
for excitation and emission was measured in FL2 with a band pass filter of 525 ± 10 nm. 
10,000 events were collected for each sample and non-treated cells were used as reference 
and the gates adjusted from those. 
 
Confocal microscopy. The internalization of cRGD-, cGRD-, and PEG-liposomes were 
analyzed using confocal microscopy (Leica Microsystems). The human glioblastoma 
U87MG cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (Sigma-Aldrich) and 100 UI/mL penicillin and streptomycin (Lonza). Cells were 
incubated in a 5% CO2 humidified incubator at 37 °C. The day before used the cells were 
plated in 24-well plates (20,000 cells per well) ontop of small glasslides. The medium 
was replaced with fresh and liposomes were added. The cells were incubated 24 hours at 
37 °C. The cells were washed with PBS, heparin containing PBS and two times with PBS 
again. They were fixated in 4% paraformaldehyde in PBS for 3 minutes, followed by 
washing with PBS. The plate was allowed to dry, before being mounted on a microscope 
slide using Vectashield® HardSet Mounting Medium. The imaging was performed with a 
Leica confocal microscope using an excitation wavelength of λ = 476 nm and an emission 
bandwidth range of 485-600 nm.  
 
64Cu-liposomes. 64Cu was produced on a PETtrace cyclotron (GE Healthcare) equipped 
with a beamline [Petersen, 2011]. Radioactive 64CuCl2 was evaporated to dryness from 
aqueous hydrochloric acid and the DOTA containing liposomes were added. The mixture 
was incubated at 50-55 °C for 1 hour, before the loading efficiency was measured. This 
was done by separating un-encapsulated 64Cu-DOTA from 64Cu-liposomes by size 
exclusion chromatography (SEC) using a Sephadex G-25 column (1 x 25 cm) eluted with 
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a HEPES buffer (10 mM, 150 mM NaCl, pH 7.4). The fraction of un-encapsulated free 
64Cu i the liposome containing solution was quantified by radio-thin layer 
chromatography (radio-TLC) eluting the plates in 10% ammonium acetate:methanol 
(50:50). The retention factor of 64Cu-DOTA was 0.3-0.4, while 64Cu stayed at the 
baseline. The loading efficiencies were < 95%. 
 
Animal xenograft model. Seven weeks old female NMRI nude mice purchased from 
Tarconic (Borup, Denmark) were inoculated in the right and left flank with 10E+07 
U87MG cells (LGC standards, Boras, Sweden) in a 1:1 mixture with matrixgel™ (BD 
Biosciences, Albertslund, Denmark). Tumors were allowed to grow for 4 weeks. The 
mice were divided in 3 groups; cRGD-liposomes (n = 4), cGRD-liposomes (n = 4) and 
untargeted control PEG-liposomes (n = 6). The animal experiments were approved by the 
Animal Research Committee of the Danish Ministry of Justice. 
 
Acquisition protocol for in vivo studies. 64Cu-liposome suspensions were administered 
intravenous (i.v.) for biodistribution imaging and quantification. The 64Cu-liposome 
formulations was intravenously injected in a lateral tail vein of anesthetized mice at a 
volume of 200 µL and a lipid concentration of 20 mg/kg. The average administered 
activity dose levels were 9.63 ± 0.60 MBq animal-1. The PET/CT scans were acquired on 
a dedicated small animal system (MicroPET Focus 120 & MicroCAT® II, Siemens 
Medical Solutions, Malvern, PA, USA) at 1h, 18h and 45h post injection (p.i.) with PET 
acquisition times of 10, 15 & 30 min. respectively. PET data were reconstructed with the 
2-dimentional ordered-subset expectation maximization (OSEM2D) reconstruction 
algorithm. PET and CT images were analyzed as fused images using the Inveon software 
(Siemens). CT settings were a tube voltage of 64 kVp, a tube current of 500 µA, 360 
rotation steps, an exposure time of 400 ms and a voxel size of 0.089 mm. Immediately 
following the last PET scan the mice were euthanized and blood as well as organs of 
interest collected and counted in a gamma counter (Perkin Elmer Life Sciences).  
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Appendix IV 
Materials and methods for Chapter 4 
Materials 
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-(polyethylene glycol)2000 (DSPE-PEG2000), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000-
NH2), cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (DOPE-RhoB), 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) were purchased from Avanti Polar Lipids Inc. (Alabaster, USA). Folic acid, 5-
azidopentanoic acid, 4-formyl benzoic acid, trifluoroacetic acid (TFA), and 
triisopropylsilane (TIS) were purchased from Sigma Aldrich (Schnelldorf, Germany). The 
coupling reagent O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HATU), TentaGEL PAP Resin was purchased from Rapp 
Polymere and NovoSyn TGR Resin from Novabiochem. 2-chlorotrityl chloride Resin, 
and all Fmoc protected amino acids used for the solid phase peptide synthesis were 
purchased from GL Biochem (Shanghai, China). All chemicals and reagents were of 
analytical grade and used without further purification. 
 
Instrumentation 
UV spectra were recorded using a Shimadzu UV-visible Spectrophotometer. Dynamic 
light scattering and zeta-potential measurements were performed on a Brookhaven 
Instruments Corporation Zeta PALS zeta potential analyzer. Analytical reversed-phase 
high-performance liquid chromatography (RP-HPLC) was carried out on a Shimadzu LC-
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2010 analytical HPLC by employing a Waters XTerra® C8 5 µm (4.6 x 150 mm) column 
or a Waters XTerra® C18 5 µm (4.6 x 150 mm) column. Semi-preparative HPLC was 
performed on a Waters Semi-preparative HPLC equipped with a Waters 600 Pump & 
Controller and a Waters 2489 UV/Visible Detector using a a Waters XTerra® C8 5µm (19 
x 150 mm) column or a Waters XTerra® C18 5µm (19 x 150 mm) column. HPLC Eluent 
A consisted of a 5% MeCN aqueous solution with 0.1% TFA; HPLC Eluent B consisted 
of 0.1% TFA in MeCN. HPLC analysis was monitored using dual channel UV detection 
at 254 nm and 280 nm. Pre-packed Strata C8 solid phase extraction (SPE) (55 µm, 70 Å) 
Giga Tubes from Phenomenex (Torrance, USA) were used for the purification of 
functionalized phospholipids. Mass spectra were recorded using a Bruker Daltonics 
Reflex IV MALDI-TOF Spectrometer using 2,5-dihydroxybenzoic acid (DHB) spiked 
with sodium trifluoroacetate in MeOH as matrix. 
 
DSPE-PEG2000-benzaldehyde (2c). DSPE-PEG2000-NH2 (100 mg, 36 µmol, 1.0 equiv.) 
was dissolved in dry DMF (1.0 mL) in a pre-dried flask under a nitrogen atmosphere. A 
mixture of 4-formyl benzoic acid (22 mg, 0.14 mmol, 4.0 equiv.), Et3N (40 µL, 0.29 
mmol, 8.0 equiv.) and HATU (54 mg, 0.14 mmol, 3.95 equiv.), in dry DMF (0.50 mL) 
were added and the reaction was stirred under nitrogen over night at room temperature. 
The solvent was removed in vacuo and the product purified by semi-preparative HPLC 
employing a Waters Xterra® C8 5µm (19 x 150 mm) column. Eluent: (A) 5% CH3CN + 
0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; linear gradient from 40% 
B to 100% B over 15 min. Flow rate; 14 mL/min. DSPE-PEG2000-benzaldehyde (2c) was 
isolated as a broad peak with retention time of 12.5 min. The solvent was removed in 
vacuo and the product lyophilized from a mixture of water and acetonitrile to give a white 
fluffy powder (98 mg, 96%). MALDI-TOF MS (m/z) (DHB+Na): 2860.9 ± n×44.0. 
 
DSPE-PEG2000-azide (2d). DSPE-PEG2000-NH2 (200 mg, 72 µmol, 1.0 equiv.) was 
dissolved in dry DMF (2.0 mL) in a pre-dried flask. A mixture of 5-azidopentanoic acid 
(41 mg, 0.29 mmol, 4.0 equiv.), Et3N (80 µL, 0.57 mmol, 8.0 equiv.) and HATU (108 
mg, 0.28 mmol, 3.95 equiv.) in dry DMF (0.50 mL) were added and the reaction stirred 
overnight under nitrogen at room temperature. The solvent was removed in vacuo and the 
product purified on a Strata-C8 SPE column using a 10% stepwise gradient from 50-100% 
methanol in water. Fractions with the desired compound was combined, reduced in vacuo 
and lyophilized from a mixture of water and acetonitrile to give the title compound as a 
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white powder (185 mg, 88%). MALDI-TOF MS (m/z) (DHB+Na): 2898.4 ± n×44.0. IR 
(neat): ν(cm-1) 2914, 2885, 2850, 2097, 1739, 1343, 1100. 
 
cRGDfPropargyl (5). The linear RGDfPropargyl pentapeptide NH2-Asp(OtBu)-D-Phe-
Propargyl-Arg(Pbf)-Gly-Resin was synthesized manually by SPPS on a 2-chlorotrityl 
chloride Resin (0.40 g, 0.20 mmol/g) by standard Fmoc methodology. Fmoc 
quantification was used to determine the precise loading (λ = 290 nm, ε = 5253 M-1cm-1). 
Each coupling was performed by 4.0 equiv. Fmoc protected amino acid, 3.95 equiv. 
HATU (119 mg, 0.31 mmol, 3.95 equiv.) and 8.0 equiv. 2,4,6-collidine (83 µL, 0.64 
mmol, 8.0 equiv.) in DMF (4.0 mL). Cleavage of the Fmoc group was carried out using 
piperidine in DMF (1:4) for 2 x 2 minutes. Completion of each coupling and deprotection 
step were monitored by the Kaiser test. The peptide was cleaved from the solid support by 
addition of AcOH:TFE:CH2Cl2 (10:20:70) for 2 x 20 minutes. Cyclization was performed 
in solution (15 mL DMF) between the N-terminal of the aspartic acid and the free 
carboxylic acid on glycine using diphenyl phosphoryl azide (257 mg, 0.80 mmol, 3.0 
equiv.) and sodium hydrogencarbonate (336 mg, 4.0 mmol, 15 equiv.). The reaction was 
moitored by MALDI-TOF MS and was complete within 3 hours. The cyclized peptide 
was extracted using ethyl acetate, the organic phase combined and washed with a 
saturated solution of ammonium chloride, followed by brine and dried over anhydrous 
magnesium sulphate. Solvent was removed in vacuo and the crude peptide dissolved in 
TFA:H2O:TIS (95:2.5:2.5). Deprotection was complete within 24 hours. The TFA 
mixture was removed in vacuo and the crude peptide re-dissolved in acetonitrile:water 
(1:3) and purified by semi-preparative HPLC employing a Waters Xterra® C18 5µm (19 x 
150 mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in 
CH3CN. Gradient profile; linear gradient from 0% B to 100% B over 20 min. Flow rate; 
14 mL/min. cRGDfPropargyl (5) was isolated as a homogenous peak with retention time 
of 7 min. The solvent was removed in vacuo and the product lyophilized from a mixture 
of water and acetonitrile to give a white fluffy powder (31 mg, 69%). The purity of the 
product was monitored by analytical HPLC, using the same gradient profile and solvent 
mixtures as above, but with a Waters XTerra® C18 5μm (4.6 x 150 mm) column, flow rate 
1 mL/min. Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): Calcd. For C26H34N8O7 
(M+Na)+ 570.25. Found: 570.43. 
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DSPE-PEG2000-cRGD (7). cRGDfPropargyl (5) (19 mg, 34 µmol, 2.0 equiv.) and DSPE-
PEG2000-N3 (2d) (47 mg, 16 µmol, 1.0 equiv.) were dissolved in methanol (1.0 mL). 
Copper(II) sulphate pentahydrate (8.0 mg, 32 µmol, 2.0 equiv.) and sodium ascorbate (13 
mg, 65 µmol, 4.0 equiv.) were dissolved in water (1.0 mL) and added to the above 
mixture. The reaction was stirred overnight. The solution was extracted with chloroform, 
the organic phases combined, washed with water and dried over anhydrous sodium 
sulphate. The solvent was removed in vacuo and the product purified by semi-preparative 
HPLC employing a Waters Xterra® C8 5µm (19 x 150 mm) column. Eluent: (A) 5% 
CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; linear gradient 
from 50% B to 100% B over 20 min. Flow rate; 14 mL/min. DSPE-PEG2000-cRGD (7) 
was isolated as a homogenous peak with retention time of 10 min. The solvent was 
removed in vacuo and the product lyophilized from a mixture of water and acetonitrile to 
give a white fluffy powder (29 mg, 52%). The purity of the product was monitored by 
analytical HPLC, using the same gradient profile and solvent mixtures as above, but with 
a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. Purity >98%. 
MALDI-TOF MS (m/z) (DHB+Na): 3468.9 ± n×44.0. 
 
DP-MCP-PEG (9). The linear peptide dipalmitoyl-Dap-Trp(Boc)-Ile-Pro-Val-Ser(tBu)-
Leu-Arg(Pbf)-Ser(tBu)-Gly-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-PEG2000-Resin 
was synthesized manually by SPPS on a TentaGEL PAP Resin (0.89 g, 0.34 mmol/g) by 
standard Fmoc methodology. Each coupling was performed by 4.0 equiv. Fmoc protected 
amino acid, 3.95 equiv. HATU (451 mg, 1.19 mmol, 3.95 equiv.) and 8.0 equiv. 2,4,6-
collidine (320 µL, 2.4 mmol, 8.0 equiv.) in DMF (9.0 mL). Cleavage of the Fmoc group 
was carried out using piperidine in DMF (1:4) for 2 x 2 minutes. Completion of each 
coupling and deprotection step were monitored by the Kaiser test. The peptide was 
cleaved from the solid support by addition of TFA:H20:TIS (95:2.5:2.5) for 3 hours. The 
TFA mixture was removed in vacuo and the crude peptide re-dissolved in dimethyl 
sulfoxide:water (1:1) and purified by semi-preparative HPLC employing a Waters 
Xterra® C8 5µm (19 x 150 mm) column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 
0.1% TFA in CH3CN. Gradient profile; linear gradient from 20% B to 100% B over 15 
min. Flow rate; 14 mL/min. DP-MCP-PEG (9) was isolated as a broad peak with 
retention time of 10.3 min. The solvent was removed in vacuo and the product lyophilized 
from a mixture of water and acetonitrile to give a white fluffy powder (328 mg, 26%). 
The purity of the product was monitored by analytical HPLC, using the same gradient 
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profile and solvent mixtures as above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) 
column, flow rate 1 mL/min. Purity >95%. MALDI-TOF MS (m/z) (DHB+Na): 4119.2 ± 
n×44.0. 
 
DSPE-PEG2000-Folate (10). DSPE-PEG2000-NH2 (10 mg, 3.6 µmol, 1.0 equiv.) was 
dissolved in dry DMF (0.50 mL) in a pre-dried flask. A mixture of folic acid (3.2 mg, 7.2 
µmol, 2.0 equiv.), Et3N (1.0 µL, 7.2 µmol, 2.0 equiv.) and HATU (1.4 mg, 3.6 µmol, 1.01 
equiv.) in dry DMF (0.50 mL) were added and the reaction stirred overnight under 
nitrogen at room temperature. The solvent was removed in vacuo and the product purified 
purified by semi-preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 mm) 
column. Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient 
profile; linear gradient from 50% B to 100% B over 20 min. Flow rate; 14 mL/min. 
DSPE-PEG2000-Folate (10) was isolated as a broad peak with retention time of 14.2 min. 
The solvent was removed in vacuo and the product lyophilized from a mixture of water 
and acetonitrile to give a yellow powder (3.1 mg, 27%). The purity of the product was 
monitored by analytical HPLC, using the same gradient profile and solvent mixtures as 
above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. 
Purity >89%. MALDI-TOF MS (m/z) (DHB+Na): 3230.2 ± n×44.0. 
 
Octaarginine-hydroxylamine (11). The linear peptide Bis-Boc-amino-oxyacetic acid-
[Arg(Pbf)]8-Resin was synthesized manually by SPPS on a NovaSyn tentagel (0.72 g, 
0.25 mmol/g) by standard Fmoc methodology. Each coupling was performed by 4.0 
equiv. Fmoc protected amino acid, 3.95 equiv. HATU (267 mg, 0.71 mmol, 3.95 equiv.) 
and 8.0 equiv. 2,4,6-collidine (186 µL, 1.4 mmol, 8.0 equiv.) in DMF (8.0 mL). Cleavage 
of the Fmoc group was carried out using piperidine in DMF (1:4) for 2 x 2 minutes. 
Completion of each coupling and deprotection step were monitored by the Kaiser test. 
The peptide was cleaved from the solid support by addition of TFA:H20:TIS (95:2.5:2.5) 
for 4 hours. The solvent was removed in vacuo and the product purified purified by semi-
preparative HPLC employing a Knauer Eurospher 100 C18 5µm (20 x 250 mm) column. 
Eluent: (A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; 
linear gradient from 0% B to 50% B over 15 min. Flow rate; 14 mL/min. Octaarginine-
hydroxylamine (10) was isolated as a homogenous peak with retention time of 7 min. The 
solvent was removed in vacuo and the product lyophilized from a mixture of water and 
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acetonitrile to give a white powder (65 mg, 27%). MALDI-TOF MS (m/z) (DHB+Na): 
Calcd. For C50H102N34O10 (M+Na)+ 1338.85. Found: 1339.43. 
 
DSPE-PEG2000-Octaarginine (12). DSPE-PEG2000-aldehyde (2c) (94 mg, 33 µmol, 1.0 
equiv.) was dissolved in methanol (3.0 mL) and mixed with Octaarginine-hydroxylamine 
(10) (64 mg, 48 µmol, 1.4 equiv.) dissolved in water (3.0 mL). The reaction was stirred 
overnight. The product was purified directly from the methanol:water mixture by semi-
preparative HPLC employing a Waters Xterra® C8 5µm (19 x 150 mm) column. Eluent: 
(A) 5% CH3CN + 0.1% TFA in H2O, (B) 0.1% TFA in CH3CN. Gradient profile; linear 
gradient from 0% B to 100% B over 15 min. Flow rate; 14 mL/min. DSPE-PEG2000-
Octaarginine (12) was isolated as a broad peak with retention time of 11 min. The solvent 
was removed in vacuo and the product lyophilized from a mixture of water and 
acetonitrile to give a white sticky powder (95 mg, 69%). The purity of the product was 
monitored by analytical HPLC, using the same gradient profile and solvent mixtures as 
above, but with a Waters XTerra® C8 5μm (4.6 x 150 mm) column, flow rate 1 mL/min. 
Purity >98%. MALDI-TOF MS (m/z) (DHB+Na): 4181 ± n×44.0. 
 
Preparation of liposomes for uptake studies. Small unilamellar vesicles were prepared 
as described by Bangham et al. Lipids were dissolved in methanol:chloroform (1:9) and 
mixed in the desired ratio. Generally, the liposomes consisted of DSPC, DOPE-RhoB, 
cholesterol and total of 5% DSPE-PEG2000 lipid - either as pure DSPE-PEG2000 
phospholipid or as a mixture with functionalized DSPE-PEG2000 phospholipid. DOTAP 
was excluded or used in an amount of 7.5%. Hence, liposomes composed without 
DOTAP would have the formulation of DSPC/DOPE-RhoB/cholesterol/DSPE-PEG2000 
(54.5:0.5:40:5), while liposomes containing DOTAP would be of the formulation 
DSPC/DOPE-RhoB/cholesterol/DSPE-PEG2000/DOTAP (47:0.5:40:5:7.5). The organic 
solvent was removed under a gentle strem of nitrogen and fully removed in vacuo 
overnight. The lipid films were hydrated in a HEPES/sucrose buffer (10 mM HEPES, 
10%w/v sucrose, pH 7.4) at at 65 °C for 1 hour, followed by freeze-thaw cycles and 
extrusion at 65 °C through 100 nm polycarbonate filters using an Avanti Polar Lipids 
mini-extruder. The small unilamellar liposomes were analyzed by dynamic light 
scattering and zeta potential measurements (Zeta PALS, Brookhaven Instruments). 
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Preparation of Oxaliplation loaded liposomes. Small unilamellar vesicles were 
prepared as described by Bangham et al. Lipids were dissolved in methanol:chloroform 
(1:9) and mixed in the desired ratio. The ratio of phospholipids were identical with the 
formulations described above only excluding the fluorescence DOPE-RhoB phospholipid. 
The organic solvent was removed under a gentle strem of nitrogen and fully removed in 
vacuo overnight. The lipid films were hydrated in a HEPES/sucrose buffer (10 mM 
HEPES, 10%w/v sucrose, pH 7.4) containing oxaliplatin (~15 mg/mL) at 70 °C for 1 hour 
followed by freeze-thaw cycles and extrusion at 70 °C through 100 nm polycarbonate 
filters using an Avanti Polar Lipids mini-extruder. To remove un-encapsulated oxaliplatin 
from the outside of the liposomes, they were transferred to dialysis cassettes (Slide-A-
lyzer Dialysis Cassette, Thermo Scientific, USA, MWCO 10 kDa) and dialyzed 3 days, 
exchanging the external oxaliplatin containing buffer with a HEPES/sucrose buffer. The 
encapsulation efficiency of oxaliplatin and leakiness of the liposomes were measured by 
ICP-AES. 
 
Flow cytometry. The internalization of fluorescent liposomes was analyzed using flow 
cytometry (Gallios, Beckman Coulter). The human glioblastoma U87MG were grown in 
RPMI 1640 medium, the human fibrosarcoma HT1080 were grown in DMEM medium, 
and the human nasopharyngeal epidermal carcinoma cell line KB were grown in RPMI 
1640 medium depleted of folic acid. All medium were supplemented with 10% fetal 
bovine serum (Sigma-Aldrich) and 100 UI/mL penicillin and streptomycin (Lonza). Cells 
were incubated in a 5% CO2 humidified incubator at 37 °C. The day before used the cells 
were plated in 12-well dishes (50,000 cells per well). The medium was replaced with 
fresh and liposomes were added. The cells were incubated 2 hours for KB and HT1080 
cells and 5 hours for U87MG and HT1080 cells at 37 °C. The cells were washed with 
PBS, trypsinized and placed into a FACS tube containing 3 mL of PBS using 1 mL of 
medium. The cells were centrifuged for 3 min at 850 rpm, supernatant removed and the 
cells resuspended in 300-500 µL PBS. The RhoB-fluorescent cells were measured with a 
blue laser (488 nm) for excitation and emission was measured in FL2 with a band pass 
filter of 575 ± 10 nm. 10,000 events were collected for each sample and non-treated cells 
were used as reference and the gates adjusted from those. 
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Inhibition study. The human nasopharyngeal epidermal carcinoma cell line KB were 
grown in RPMI 1640 medium depleted of folic acid. The media was supplemented with 
10% fetal bovine serum (Sigma-Aldrich) and 100 UI/mL penicillin and streptomycin 
(Lonza). Cells were incubated in a 5% CO2 humidified incubator at 37 °C. The day before 
used the cells were plated in 12-well dishes (50,000 cells per well). The medium was 
replaced with fresh and free peptide dissolved in 20% DMSO in PBS in concentrations 
ranging from 10 mM to 0.1 µM was added (20 µL per 1 mL media). The cells were 
incubated 15 minutes at 37 °C, before the addition of liposomes. The cells were incubated 
with the liposomes for 2 hours at 37 °C. Then washed with PBS, trypsinized and placed 
into a FACS tube containing 3 mL of PBS using 1 mL of medium. The cells were 
centrifuged for 3 min at 850 rpm, supernatant removed and the cells resuspended in 300-
500 µL PBS. The RhoB-fluorescent cells were measured using flow cytometry (Gallios, 
Beckman Coulter) with a blue laser (488 nm) for excitation and emission was measured 
in FL2 with a band pass filter of 575 ± 10 nm. 10,000 events were collected for each 
sample and non-treated cells were used as reference and the gates adjusted from those. 
 
Confocal microscopy. The internalization of fluorescent liposomes were analyzed using 
confocal microscopy (Leica Microsystems). The human glioblastoma U87MG were 
grown in RPMI 1640 medium; the human fibrosarcoma HT1080 were grown in DMEM 
medium, and the human nasopharyngeal epidermal carcinoma cell line KB were grown in 
RPMI 1640 medium depleted of folic acid. All medium were supplemented with 10% 
fetal bovine serum (Sigma-Aldrich) and 100 UI/mL penicillin and streptomycin (Lonza). 
Cells were incubated in a 5% CO2 humidified incubator at 37 °C. The day before used the 
cells were plated in 24-well plates (20,000 cells per well) ontop of small glasslides. The 
medium was replaced with fresh and liposomes were added. The cells were incubated 24 
hours at 37 °C. The cells were washed with PBS, heparin containing PBS and two times 
with PBS again. They were fixated in 4% paraformaldehyde in PBS for 3 minutes, 
followed by washing with PBS. The plate was allowed to dry, before being mounted on a 
microscope slide using Vectashield® HardSet Mounting Medium. The imaging was 
performed with a Leica confocal microscope using an excitation wavelength of λ = 561 
nm and an emission bandwidth range of 568-711 nm.  
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Cytotoxicity assay. The cytotoxicity of oxaliplatin loaded liposomes was evaluated using 
a colorimetric method for determining the number of viable cells. Cells were seeded in 
96-wells (3,000 cells per well) the day before use. Oxaliplatin loaded liposomes were 
added in concentrations from 0.3 µM to 50 µM and the cells incubated 24 hours before 
replacement of the oxaliplatin containing medium with fresh. The cells were incubated 
another 72 hours, before replacement of the medium with a MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt) / PMS 
(phenazine methosulphate) containing medium. The plates were incubated 2 hours before 
the absorbance of the formazan product was measured at λ = 490 nm using a micro plate 
reader (Perkin Elmer). 
 
Incubation with Thermolysin. DP-MCP-PEG containing liposomes (20 µL) were 
diluted into 20 µL HBS-1 buffer (100 mM NaCl, 50 mM HEPES, 1 mM CaCl2, 2 µM 
ZnCl2, pH 7.4). Thermolysin stock (0.4 mg/mL) (5 µL) was added and the mixture 
incubated overnight at 37 °C. The following day zeta potential was measured using 40 µL 
of the incubated mixture and 1460 µL HEPES/sucrose buffer (10 mM HEPES, 10%w/v 
sucrose, pH 7.4). The last 5 µL was mixed with matrix (DHB, Na) for MALDI-TOF MS 
analysis. 
